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Background:  Successful strategies for addressing inequalities in cancer care are greatly needed 
as critical racial/ethnic and socioeconomic cancer burden disparities persist in the United States.   
Patient navigation programs are a promising approach to reducing cancer care disparities.   
Methods:  A mixed-methods evaluation was conducted to systematically collect, analyze and 
share information about the context, activities, and early impacts of the University of Pittsburgh 
Medical Center (UPMC) Cancer Centers’ Minority Outreach Pilot Program (MOPP), a newly 
implemented cancer patient navigator intervention.    The dissertation applies and integrates two 
evaluation frameworks:  1) the Centers for Disease Control and Prevention (CDC) Framework 
for Program Evaluation, which provides an organizing structure and standards for conducting 
sound public health program evaluation, and 2) the RE-AIM framework, which helps to focus 
the evaluation on issues that are both relevant to stakeholders and critical to assessing the public 
health impact and generalizability of interventions.  The evaluation employs a case study design 
that includes qualitative (e.g., program document review and informal and semi-structured 
interviews) and quantitative (e.g., descriptive statistical analysis of program database) methods to 
examine MOPP development and implementation.   
Results:  The MOPP evaluation provided valuable qualitative and quantitative data related to 
program implementation achievements and challenges.  Additionally, the evaluation produced 
useful products (e.g., logic model and data reporting templates) and led to immediate small-scale 
enhancements (e.g., database modifications).  Results from the program evaluation suggest that 
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MOPP is generally being implemented as planned. However, findings also called attention to key 
issues that should be monitored closely within the MOPP program, and, perhaps, within the 
larger patient navigation movement.  These key issues include:  the challenges of effectively 
navigating patients with substance abuse and the need to address the emotional burden of patient 
navigator work.   
Conclusion:  The public health significance of the evaluation lies in its potential to strengthen 
MOPP’s impact on reducing cancer care disparities in the UPMC patient population.  In addition, 
publication of the evaluation research will contribute to the growing evidence base for cancer 
patient navigator interventions and address the need to develop the literature on patient 
navigation. 
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1.0  INTRODUCTION AND BACKGROUND 
A mixed-methods evaluation (i.e., an evaluation that combines qualitative and quantitative 
methods) was conducted to systematically collect, analyze and interpret, synthesize and share 
information about the context, activities, and early impacts of the University of Pittsburgh 
Medical Center (UPMC) Cancer Centers’ Minority Outreach Pilot Program (MOPP).  MOPP is a 
patient navigator program that works to ensure access to the latest innovations in cancer 
treatment, regardless of financial means, for newly diagnosed African American cancer patients 
seeking care at one of four UPMC medical centers.  Patient navigation in cancer care refers to 
individualized support offered to patients in accessing the cancer care system and overcoming 
barriers to quality care (United States Department of Health and Human Services, National 
Institutes of Health, National Cancer Institute [NCI], 2004).  MOPP is one of UPMC Cancer 
Centers’ strategies for reducing racial and ethnic disparities in cancer care and cancer clinical 
trial participation.  The evaluation process has led to enhancements in Minority Pilot Outreach 
Program monitoring.  Evaluation findings will be used to support improvements in program 
implementation and to help plan for program expansion and future evaluation activities.  
Additionally, planned publication of evaluation findings will help develop the literature on 
cancer patient navigator programs.  
 The MOPP evaluation applies the Centers for Disease Control and Prevention (CDC) 
Framework for Program Evaluation, which provides an organizing structure and standards for 
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conducting sound public health program evaluation.  In addition, the evaluation pays special 
attention to the underling principles of the RE-AIM evaluation framework—namely that 
evaluation should focus on issues that are both relevant to stakeholders and critical to assessing 
the intervention’s public health impact and generalizability.  Detailed descriptions of these 
evaluation frameworks are provided in Section 1.5.3.  The MOPP evaluation employs a case 
study design that includes qualitative (e.g., program document review and informal and semi-
structured interviews) and quantitative (e.g., descriptive statistical analysis of the program 
database) methods to examine MOPP development and implementation.  
1.1 THE CANCER BURDEN AND DISPARITIES 
Patient navigation programs “provide a very promising approach to reducing disparities for 
cancer and other diseases” (Institute for Alternative Futures, 2007, p. 3).  Successful strategies 
for addressing inequalities in cancer care are needed because critical racial/ethnic and 
socioeconomic cancer burden disparities persist in the United States:  “In terms of disease stage 
at presentation and 5-year survival rates, a disproportionate burden of disease falls on members 
of racial and ethnic minority groups, those of lower SES [socioeconomic status], and recent 
immigrants—groups that, together, may be considered medically underserved or disadvantaged” 
(Dohan & Schrag, 2005, p. 848).  These disparities are examined more closely in the following 
section, which presents national, state, and county cancer statistics that are of particular 
relevance to the efforts of UPMC Cancer Centers’ Minority Outreach Pilot Program. 
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1.1.1 Incidence and mortality 
In the United States, African Americans are more likely than whites to be diagnosed at a later 
stage of cancer, possibly due to factors such as less knowledge about cancer symptoms and 
reduced access to cancer screening services.  Detection at a later stage, in turn, contributes to 
lower cure rates and shorter survival (ACS, 2005).  For all cancer sites combined, African 
Americans are more likely to develop and die from cancer than persons of any other racial or 
ethnic group. They are also at greater risk of dying of the four most common types of cancer 
(lung, breast, colon, and prostate cancer) than any other minority group (ACS, 2005).  Disparities 
in the cancer burden among racial/ethnic groups are often compounded by social ills.  Poverty, 
together with related social and cultural factors, influences the entire spectrum of cancer care 
from prevention, detection and treatment to quality of life and survival.  African Americans 
make up 13% of the US population, but comprise 24% of the nation’s poor (American Cancer 
Society [ACS], 2005).  An overlap of poverty and insurance coverage issues also contributes to 
disparities in cancer care.  Low-income men and women who have inadequate or no health 
insurance coverage are more likely to be diagnosed with cancer at later stages, when survival 
times are shorter (CDC, 2006/2007).  
 In Pennsylvania, age-adjusted incidence rates for all cancers among African Americans 
were consistently higher than the rates for Whites during the eleven-year period 1993-2003 
(Pennsylvania Department of Health [PA DOH], 2006).  The 2003 cancer incidence rate per 
100,000 among African American Pennsylvanians (523.3) was 7.1 percent higher than the rate 
for White Pennsylvanians (PA DOH, 2006).  Additionally, in 2003, the age-adjusted incidence 
rate for African Americans in Pennsylvania was nearly 5 percent higher than the rate (499.4) 
recorded for African Americans by the National Cancer Institute’s SEER Program (PA DOH, 
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2006).  During the three-year period of 2001-2003, cancers among African American 
Pennsylvanians were most commonly diagnosed at the local stage (37.2 percent). Compared to 
Whites, African Americans in Pennsylvania had a lower percentage of cancers diagnosed at early 
stages (43.5 vs. 50.4) and a higher percentage of cancers diagnosed at late stages (43.8 vs. 39.0).  
 In Allegheny County, home to the four UPMC sites that participate in the Minority 
Outreach Pilot Program, the 3-year (2003-2005) age-adjusted cancer incidence rate per 100,000 
(498.5) for all residents was significantly higher than the state rate (491.4) (Pennsylvania 
Department of Health [PA DOH], n.d.).  In addition, the 3-year (2003-2005) county cancer 
incidence rate for African Americans (556.9 per 100,000) was significantly higher than the rate 
(491.2) for Whites (PA DOH, n.d.). 
1.1.2 Clinical trials  
Participation in cancer clinical trials (CCT) helps researchers make significant advances in the 
fight against cancer and provides patients with access to state-of-the-art treatments (C-Change, 
n.d.).  An estimated 1.2 million Americans will receive a diagnosis of cancer this year, but only 
3-5% of these new cancer patients will participate in a cancer clinical trial (C-Change), and this 
participation rate is even lower among minority groups and women (Baquet, Commiskey, Daniel 
Mullins, & Mishra, 2006; Bolen et al., 2006; Ford et al., 2005; Sheppard et al., 2005).  Brawley 
(2004) asserts that racial/ethnic disparities in cancer clinical trial participation is also an issue of 
social justice.  Among all cancer patients in the United States, those of higher socioeconomic 
status have led the increases in CCT accrual over the past several years and, thus, are major 
beneficiaries of clinical trial participation (Sateren et al., 2002).  In addition, examination of the 
20% increase in admissions to National Cancer Institute trials since the mid-1990s reveals that 
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the number of Asian, African American, Hispanic and Native American patients entering trials 
has remained relatively stable while the enrollment of whites has increased (Christian & Trimble, 
2003). 
The literature identifies several barriers to and facilitators of participation in cancer 
clinical trials, including patient and provider knowledge, attitudes and beliefs; access; religious 
and cultural beliefs; and strict inclusion and exclusion eligibility criteria for trials (Bruner, Jones, 
Buchanan, & Russo, 2006; Christian & Trimble, 2003; Comis, Miller, Aldige, Krebs, & Stoval, 
2003; Ford et al., 2005).  Racial and ethnic disparities in cancer clinical trial participation are 
often assumed to be the result of minorities’ unwillingness to participate in health research; 
however, there is little evidence to support this claim (Wendler et al., 2006; Trauth et al., 2005).  
In fact, some studies suggest that the primary challenge with CCT recruitment and accrual is not 
the attitudes of patients or their unwillingness to participate, but rather the limited availability of 
appropriate trials and the disqualification of large numbers of patients due to comorbidities, 
insurance coverage issues, or even transportation barriers (Comis, Miller, Aldige, Krebs, & 
Stoval, 2003).  Reluctance of some physicians to engage in accrual (Comis et al., 2003), a 
reluctance that may be heightened by certain assumptions about patients’ willingness and 
financial ability to participate in CCTs (Michaels, n.d.), also partly explains low CCT 
participation rates.  These barriers speak to the importance of culturally appropriate strategies for 
CCT recruitment (Sheppard et al., 2005).  
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1.2 CANCER PATIENT NAVIGATION 
1.2.1 Origins and description 
Underserved populations face a number of barriers that impede timely quality cancer care, 
including:  being uninsured or underinsured; differing cultural orientations that may contribute to 
lack of trust in medical systems or difficulties in negotiating relationships with health care 
providers and organizations; and existing logistical barriers, such as lack of transportation or 
child care, inconvenient clinic schedules, rural residence and distance from health care centers 
(Dohan & Schrag, 2005; Fowler, Steakley, Garcia, Kwok. & Bennet, 2006).  Such barriers can 
be placed within a larger context of the “complex and overlapping interplay of poverty, culture, 
and social injustice” in the United States, which Freemen posits “underscore the challenge of 
reducing cancer disparities (2004, p. 44).  In an effort to help patients overcome financial, 
communication, medical system, and emotional or fear barriers to cancer screening, diagnosis 
and timely treatment, the nation’s first patient navigator program was implemented in 1990 by 
Freeman and colleagues at Harlem Hospital in New York City (Fowler et al., 2006; Freeman 
2006).   
The original patient navigator program model was established in response to key findings 
from the American Cancer Society’s 1989 hearings on cancer in poor populations, in which 
testimony was heard from patients, their medical care providers and other cancer experts 
(Freeman, Muth, & Kerner, 1995; Vargas, Ryan, Jackson, Rodriguez, & Freeman, 2008); 
analysis of mortality data for the Harlem community that revealed racial and ethnic disparities in 
excess mortality from cancer and other treatable diseases (Vargas et al.; 2008); and Dr. 
Freeman’s “personal experience in providing cancer care to poor black patients in Harlem” 
 20 
(Freeman, 2006, p. 139).  The nation’s first patient navigation program focused on reducing 
breast cancer care disparities among a predominantly poor and African American patient 
population (Freeman, 2006).   
Since the implementation of the first patient navigator program, the Harlem community 
served has experienced a decrease in the percentage of patients presenting with late stage breast 
cancer and an increase in the percentage of patients presenting with stage 0 or 1 breast cancer 
(Vargas et al., 2008).  While a causal association has not been established, the initial positive 
findings from the early navigator model, along with the significant need for interventions that are 
effective in reducing cancer care disparities, have led to widespread adoption, adaptation, and 
replication of the patient navigation model across the country (Vargas et. al, 2008).  Not only is 
patient navigation being applied across the broad spectrum of cancer care, it is also being used 
for a variety of diseases across the United States (Vargas et al., 2008; Freeman, 2007).    
Despite its popularity and widespread use, limited study of cancer patient navigation 
appears in the peer-reviewed literature (Vargas et al, 2008).  Moreover, variation exists in the 
model definitions and descriptions developed by prominent cancer care experts and 
organizations.  In a qualitative study designed to define the processes, structure and contextual 
influences of the first patient navigator programs, Vargas and colleagues (2008, electronic 
publication ahead of print) maintain that patient navigation is a “system as opposed to a 
person….  The processes of this intervention are largely defined by navigators removing barriers 
to care, documenting these barriers, and feeding back this information to directors to implement 
system level change, thus providing the opportunity to address individual and system level 
contributors to disparities”. 
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Vargas and colleagues describe the patient navigation system, which is broader in scope 
than both the action of patient navigation (i.e., supporting and guiding patients through the 
cancer care system) and the person, or navigator, who performs this action.  This system 
description is complemented by definitions from the National Cancer Institute and C-Change, 
which detail exactly what is included in patient navigation as an action.  According to the 
National Cancer Institute, patient navigation for cancer care “refers to support and guidance 
offered to persons with abnormal findings in accessing the cancer care system and overcoming 
barriers to quality, standard care.  Navigation spans the period from abnormal finding from 
cancer detection procedure through necessary cancer diagnostic tests to completion of cancer 
treatment” (NCI, 2004, p. 2).  C-Change, a national organization comprised of the nation’s key 
cancer leaders from government, business, and non-profit sectors, established a similar definition 
for patient navigation in cancer care: 
Patient navigation in cancer care refers to individualized assistance offered to 
patients, families, and caregivers to help overcome health care system barriers 
and facilitate timely access to quality medical and psychosocial care from pre-
diagnosis through all phases of the cancer experience. Navigation services and 
programs should be provided by culturally competent professional or non-
professional persons in a variety of medical, organizational, advocacy, or 
community settings. The type of navigation services will depend upon the 
particular type, severity, and/or complexity of the identified barriers (C-
Change, 2005).  
Clearly, the C-Change definition for cancer patient navigation promotes the context-
driven nature of the intervention and acknowledges that variability among programs exists 
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around navigator characteristics, program setting, and services provided.  In 2003, NCI’s Center 
to Reduce Cancer Health Disparities (CRCHD) surveyed 89 community-based cancer patient 
navigator programs (Garcia, 2005).  Among the 51 programs that responded, CRCHD found 
considerable variation in the services patient navigators provided, training of navigators, and the 
backgrounds and professional experience of navigators (Garcia, 2005).  Garcia reports that some 
programs have lay navigators, including cancer survivors and community members, while in 
other programs, navigators are nurses or social workers (2005).  With regard to navigator 
characteristics, Freeman (2006) explains that patient navigators are charged with identifying, 
anticipating, and helping to alleviate barriers to cancer care that patients encounter.  Thus, 
navigators should be sensitive, compassionate, and culturally attuned to the patients and 
community being served; knowledgeable about the healthcare system and environment; and 
connected with critical decision makers within the healthcare system, particularly with financial 
decision makers (Freeman, 2004, 2007).   
By design, patient navigation is a context-driven intervention—the services navigators 
provide are specific to the needs of their patients and the barriers they identify.  Consequently, 
navigator programs throughout the nation vary widely in the strategies they adopt and apply in 
order to reduce or eliminate cancer care barriers, but interventions often include: 
• Providing emotional support to cancer patients, as well as information on what to 
expect during their cancer care;  
• Helping patients understand their diagnoses; 
• Coordinating appointments with providers to ensure that patients with suspicious 
findings receive timely diagnosis and treatment; 
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• Helping to arrange transportation and/or child/elder care for visits to cancer 
treatments; 
• Helping to arrange language translation or interpretation services; 
• Helping patients and their families access support systems; and 
• Facilitating access to available financial support and assisting with related paperwork. 
(Dohan & Schrag, 2005; NCI, 2006).   
Navigator program activities may also include community outreach and screening 
services, efforts to improve access to cancer clinical trials, and partnership building with local 
organizations and groups to link patients to cancer support groups or needed social services 
(NCI, n.d.).  Patient navigators have some characteristics and roles that are commonly associated 
with those of community health workers and case managers, including working with populations 
that experience racial and ethnic disparities in care and coordinating care for a complex disease 
within a complex care system (Vargas et al., 2008).  However, Vargas and colleagues explain 
that community health workers operate primarily outside of a medical center, unlike navigators 
(2008).   Additionally, unlike navigators in the original intervention model, case managers are 
generally certified trained health care professionals and may not share a common community or 
cultural connection with patients served by the program (Vargas et al., 2008).  Fleisher maintains 
that “the purpose of navigation is not to replace or overlap existing roles, but to complement 
them by filling in gaps in services and proactively facilitating the delivery of care to all patients” 
(2008, p. 1). 
In addition to the high degree of variability in the services and structure of cancer patient 
navigator programs, the popular intervention is also noted as frequently informal and 
undocumented in health care (C-Change, n.d.): 
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…few tertiary hospitals including comprehensive cancer centers appear to 
have discrete cancer patient navigation programs. Instead, these specialty 
centers host a variety of services provided by social workers, nurses, and 
others designed specifically for their cancer patients on an as-needed basis. 
For cancers other than breast cancer, it is rare to find targeted patient 
navigation efforts, despite the many different approaches in the past 40 years 
initiated to help patients and families move through the cancer care system. 
(C-Change, p.15) 
Yet, health researchers, cancer experts, and national cancer organizations appropriately 
recognize patient navigation as a promising approach to improving the quality of patient care and 
reducing cancer disparities (Bowles, Tuzzio, Weise, Kirlin, Greene, Clauser, & Wagner, 2008; 
Fleisher, 2008; Institute for Alternative Futures, 2007).  A 2003 National Cancer Institute survey 
found that over 200 cancer care programs nationwide had some form of patient navigation—
many navigation activities and programs were funded by small grants from private foundations 
(Hede, 2006).   
1.2.2 Impact and research gaps 
The public health literature suggests that patient navigation is associated with improved rates of 
screening and follow-up, earlier diagnosis of disease, and higher levels of patient satisfaction 
(Dohan & Schrag, 2005).  Program descriptions and process evaluations further suggest that 
patient navigator services improve clinics’ ability to engage, track, and support patients and to 
develop and enhance communication and trust between clinic staff and patients from 
disadvantaged groups (Dohan & Schrag, 2005).  However, these inferences are merely 
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“suggestive of opportunities for future research” because “studies to date have not employed 
sufficiently rigorous research designs to allow any conclusions about the true effects of 
navigation programs”, and “published evidence from randomized trials demonstrating that 
navigation is effective in reducing health disparities does not exist”(Dohan & Schrag, 2005, p. 
853).  One of the only reviews of patient navigation effectiveness published by Dohan and 
Schrag asserts that “we have no definite knowledge of how or whether programs address barriers 
to care” (Dohan & Schrag, 2005, p. 853; Hede, 2006).  The researchers also argue that 
“systematic evaluations of navigation only recently have begun and have yet to appear in the 
literature…many navigation programs have been oriented toward local quality-improvement 
initiatives rather than scientific research, evaluation, and publication (Dohan & Schrag, 2005, p. 
849).  On patient navigator evidence to date, the National Cancer Institute summarizes:    
Training people within communities to guide and support patients who need 
assistance obtaining timely, quality standard cancer care, a concept known as 
patient navigation,  has already demonstrated potential.  Patient navigation has 
increased survival rates among African American breast cancer patients in 
Harlem, and educated the larger community about cancer prevention and 
treatment (NCI, 2006, p.2).  
The lack of definitive knowledge notwithstanding, Freeman (2004) maintains that 
“patient navigation is one community intervention that has great potential to save lives by 
eliminating economic and cultural barriers to the early diagnosis and treatment of cancer” and 
emphasizes that, in order to win the war on cancer, “we must apply what we know at any given 
time to all people, and we must also recognize and eliminate all barriers to quality cancer care” 
(p. 46).  In addition to noting the potential value of navigator programs for reducing barriers to 
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quality cancer care, the literature suggests that patient navigators can play an important role in 
promoting access to cancer clinical trials (Fowler et al., 2006).  Despite, the absence of sufficient 
rigorous research on the effectiveness of patient navigator programs, navigation is in demand by 
physicians and is “an appealing concept that many in the health care system are clamoring for” 
(Hede, 2006, p.159).   
Patient navigation is also receiving a great deal of attention at the federal government 
level, and efforts are underway to address the lack of sufficiently rigorous research on the true 
effects of navigator programs.  The Patient Navigator Outreach and Chronic Disease Act of 2005 
was enacted into public law in the United States in June 2005.  The Act authorized the Health 
Resources and Services Administration (HRSA) to administer a $25 million demonstration grant 
program in coordination with the Indian Health Service, the Office of Rural Health Policy, and 
the National Cancer Institute (Fowler et al., 2006).  NCI’s Center to Reduce Cancer Health 
Disparities (CRCHD) is currently conducting a pilot program in Portland, Oregon to evaluate the 
effectiveness of using patient navigators to help American Indians overcome the unique barriers 
to cancer care that they experience.  CRCHD has also collaborated with the NCI Radiation 
Research Program in using navigators to promote recruitment for clinical trials among medically 
underserved, low income, and minority communities (NCI, 2006, p.1).   
In 2005, the National Cancer Institute launched a multi-site Patient Navigator Research 
Program (PNRP), directed by the CRCHD, to test the navigator approach to increasing patient 
access to health care.  NCI recently awarded a total of 19.5 million in 5-year cooperative grants 
to eight academic research institutions to establish the PNRP; a ninth site was funded by the 
American Cancer Society (NCI, 2005).  PNRP participating institutions are charged with:  1) 
developing innovative patient navigator interventions to reduce or eliminate cancer health 
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disparities, and 2) testing the efficacy and cost-effectiveness of the interventions (NCI, 2006, 
p.1).  PNRP’s ultimate aim is to decrease the time between a cancer-related abnormal finding, 
definitive diagnosis, and delivery of quality standard care (NCI, 2006, p. 1), and PNRP projects 
are designed to address the following research questions: 
• How do patient navigation services assist patients in overcoming cancer care barriers 
(e.g., financial, language, transportation, health system)?  
• To what extent does type/degree of service reduce or eliminate patient barriers to 
accessing timely, quality standard cancer care?  
• Do navigated patients receive more timely cancer care diagnosis and treatment?  
• Does matching of patient and navigator demographics and primary spoken language 
affect standard-of-care adherence and perceived cancer care satisfaction?  
• Are patient navigation services cost-effective in reducing cancer health disparities? 
(NCI, n.d.)  
The federal funding of national pilot navigation programs reflects a major commitment to 
exploring the promise patient navigation holds for reducing cancer disparities, but the emphasis 
on building a base of rigorous evidence for patient navigation calls to mind current and ongoing 
debates in the public health field regarding valid forms of evidence (McQueen, 2001).   
 Indeed, the NCI PNRP and its academic institution grantees will address several 
important research questions regarding the impact of patient navigator programs by applying 
scientifically sound and rigorous practices and methods, including:  “a central data coordination 
and program evaluation contractor to conduct formal qualitative and quantitative evaluations”;  
“rigorous evaluation of navigation intervention effectiveness and cost-effectiveness”;  and 
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research designs that include both a continuous comparison group throughout the study period to 
“address history effects, system biases, community activities that may impact changes in cancer 
disparities, and other confounding factors” (NCI, 2004, p. 4).  However, results of the multi-site 
study, which are intended to “provide community-based patient navigator interventions that can 
be implemented in other communities across the nation”, will not be available to the public until 
2010 or later (NCI, 2004, p.4).   
 In the meantime in the world of public health practice, hundreds of patient navigator 
programs have already been established throughout the country as part of local cancer control 
efforts by cancer centers, community-based clinics and philanthropy (Dohan & Schrag, 2005; 
Hede, 2006).  Cancer care agencies, such as the UPMC Cancer Centers in Pittsburgh, will likely 
continue launching navigator services and programs to address identified disparities in the cancer 
burden, health care systems utilization, and quality of care in their local communities.  Existing 
navigator programs represent public health action in the absence of the best possible evidence 
regarding the effectiveness of patient navigation.   Arguably, timely and practical program 
evaluation is needed to guide, support and enhance practitioners’ effort to use the best available 
evidence to address cancer care needs and disparities in their communities: 
A continued dialogue will help us to further understand patient navigation and 
the various roles navigators can play to support patients through the cancer 
care continuum.  As the practice of patient navigation expands, there is a great 
deal to be learned about the process, political climate, and day-to-day 
challenges in planning and implementing a navigation program (Fleisher, 
2008, p.2). 
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1.3 UPMC CANCER CENTERS’ MINORITY OUTREACH PILOT PROGRAM 
1.3.1 Origins and description 
The Minority Outreach Pilot Program informs the study for the present dissertation.  The 
University of Pittsburgh Medical Center (UPMC) and UPMC Cancer Centers implemented the 
Minority Outreach Pilot Program in March 2006 with input from the African American Cancer 
Care Partnership (AACCP)—a task force of representatives from the Pittsburgh community, 
local health care centers, academic institutions, and community organizations working to 
facilitate collaboration among, and guide and coordinate the efforts of, various groups whose 
goals are to improve the health of African Americans.  Lyn Robertson, DrPH, RN, MSN led 
MOPP planning and development.  She received $750,000 in gap funds from UPMC and was 
charged with using the funds to address two issues identified by the medical center:  low levels 
of treatment compliance and cancer clinical trial participation among its African American 
patients.   
 The original goal of the Minority Outreach Program (MOPP) was to eliminate barriers to 
cancer care by ensuring that African American patients who were newly diagnosed with prostate, 
lung, breast, or colorectal cancer and who sought care at the Hillman Cancer Center, Magee-
Womens Hospital of UPMC, UPMC McKeesport, or UPMC Braddock had access to the latest 
innovations in cancer treatment, regardless of financial means.  However, shortly after MOPP 
initiation, managers realized that the program had the capacity to contact and serve African 
American patients at the four program sites who were newly diagnosed with any form of cancer.  
MOPP operates as a patient navigation system and includes culturally sensitive patient navigator 
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services, gap funds to cover care for patients on a clinical trial, individualized assessments of 
barriers to care, and identifying solutions to overcome those barriers.   
 MOPP’s program theory (i.e., the intended relationship between program inputs, 
activities, outputs, and intended outcomes) represents an adoption and tailoring of the original 
patient navigator model developed by Freeman in 1990 (Freeman, Muth & Kerner, 1995) and is 
graphically depicted in Appendix A.  The logic model presented in Appendix A was developed 
as part of the evaluation process presented in the dissertation.  It has and can continue to be used 
by the program to describe MOPP to administrators, stakeholders, and potential funders.  The 
logic model also helps to guide the evaluation activities that were completed for the dissertation 
and can help inform and direct ongoing program monitoring and future evaluations.   
 As depicted in the program model, the program is based on certain assumptions that are 
consistent with the Freeman patient navigation model.  Specifically, patient navigation operates 
as a process in which navigators provide social support to remove the barriers to care patients 
experience.  This social support includes emotional support, or expressions of empathy and 
caring; instrumental support, which is tangible aid and service; and informational support, or the 
provision of information, advice and suggestions that patients can use to address problems 
(Heaney & Israel, 2002).  The patient navigation process also includes the documentation of 
barriers, and the feeding back of barrier information to health care system management to 
support system level change.  The program also operates under the assumption that navigators 
need to be sensitive, compassionate, and culturally attuned to the patients and community being 
served; knowledgeable about the health care system & environment; and connected with critical 
decision makers within the health care system. 
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The program’s resources (including community partnerships, program staff and funding) 
support the delivery of navigation services, which include barrier assessments, financial 
counseling and assistance, and cancer clinical trial education and recruitment.  Over time, 
navigator services are intended to lead to change in cancer care knowledge, awareness and 
behavior among program participants and improvements in cancer care delivery systems.  Short-
term and intermediate outcomes include increasing patients’ knowledge of resources for 
overcoming barriers to care and increasing the health care centers’ knowledge of patient barriers 
to cancer care and cancer clinical trial participation.  Ultimately, the achievement of short-term 
and intermediate outcomes is expected to lead to the elimination of barriers to cancer care and 
increased survivorship for the program’s target patient population, as well as increased African 
American representation in cancer clinical trials across participating health care centers.  MOPP 
experiences in achievements in working toward these important long-term outcomes will help 
improve public health researchers and practitioners’ knowledge about improving CCT 
participation and reducing disparities among minority cancer patients.   
 Since its initiation in March 2006 through April 2008—the planned data collection end 
date for the dissertation research—a total of 249 patients have been referred to the Minority 
Outreach Pilot Program.  Of the 249 patients contacted and/or served by the program, 75 have 
accepted and utilized the program’s patient navigator services and 27 have enrolled in cancer 
clinical trials.  It is important to note that the 249 patients listed in the program database include 
14 patients for whom navigators were not available because the patients were not receiving care 
at one of the four participating MOPP sites.  However, as part of expanded program activities 
initiated in 2008, these 14 patients were contacted through MOPP to screen for their willingness 
and eligibility to participate in a cancer clinical trial (CCT).  None of these “CCT screen only” 
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patients enrolled in trials.  Excluding CCT screen only patients, about 32% of the target patient 
group touched by MOPP accepted and utilized patient navigation services.  Navigators and 
program staff communicate with patients both by phone and face-to-face.  Methods and 
frequency of communication, as well as services provided, are individualized according to each 
patient’s needs and preferences and therefore, may change throughout a patient’s cancer care 
experience. 
 Common barriers to cancer treatment identified and addressed through the Minority 
Outreach Pilot Program include: lack of transportation and no or limited health insurance.  
Program participants have also relayed housing-related, co-morbidity, and job-related concerns.  
These additional issues can pose barriers to care in the sense they may take priority over 
compliance with cancer detection and treatment appointments.  As presented in the following 
section, evaluation objectives and questions focused on describing program and patient 
characteristics through qualitative and quantitative research methods.  Hence, detailed summaries 
of program services and patient demographics are provided throughout the chapters of 
manuscript drafts and in Chapter 5. 
1.3.2 Evaluation needs 
The Minority Outreach Pilot Program was launched quickly in an effort to respond to real-time 
concerns about ensuring high quality cancer care for African American patients, particularly 
those who were new to the UPMC system, and increasing their participation in cancer clinical 
trials.  As MOPP is a fairly new program, evaluation needs primarily centered on the process of 
program development and initial years of implementation.  The Program Director and staff 
particularly valued the opportunity to:   
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? Clearly describe program context, activities, and planned impact to facilitate 
comparison with other cancer patient navigation interventions and MOPP expansion 
and possible replication; 
? Calculate the cost associated with MOPP development and implementation; 
? Identify achievements and challenges in carrying out planned program activities and in 
meeting short-term objectives; and  
? Explore opportunities for program improvement and identify key considerations for 
program maintenance and expansion. 
These stakeholder priorities helped to determine the focus of the evaluation, which is outlined in 
the following section.   
1.4 EVALUATION GOALS, OBJECTIVES AND QUESTIONS 
The mixed methods evaluation of the UPMC Cancer Centers’ Minority Outreach Pilot Program 
was designed to accomplish two broad goals:  1) to facilitate enhancements in Minority Outreach 
Pilot Program implementation, MOPP expansion, and ongoing MOPP monitoring and 
evaluation; and 2) to contribute to the growing national evidence base for cancer patient 
navigator programs by illuminating real-world contexts and experiences of patient navigator 
programs.  The following specific objective was developed to support the accomplishment of the 
two broad dissertation goals:  to systematically collect, analyze and interpret, synthesize and 
share information about the context, activities, outputs and early outcomes of the MOPP by May 
2008.   
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 MOPP evaluation questions, design and methods were guided by two evaluation 
frameworks, the Centers for Disease Control and Prevention (CDC) Framework for Program 
Evaluation in Public Health and RE-AIM framework; aligned with the priorities of key program 
stakeholders; and informed by key perspectives from public health evidence and translation 
debates, as well as by important principles for evaluating complex community interventions.  
The dissertation employed a case study research design, which included triangulation of data 
collection and analysis methods to answer the following questions about the Minority Outreach 
Pilot Program:   
• How many participants does the program serve, and what are the characteristics of the 
program participants? 
• What is the program’s reach into the target population? 
• To what extent is the program being implemented as planned? 
• Is the program making progress toward the achievement of short-term outcomes? 
• Are there unintended or unexpected program outcomes? 
• What are the costs associated with implementing the program? 
The evaluation appropriately focuses primarily on program implementation, or process, as 
MOPP is a newly implemented program. 
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1.5 GUIDING PERSPECTIVES, PRINCIPLES AND FRAMEWORKS 
1.5.1 Key perspectives from public health evidence and translation debates 
This dissertation research applies and encourages broad thinking with regard to what types of 
evidence are considered sufficiently sound and valid to support public health decision-making.  
The issue of how one defines evidence and categorizes it hierarchically—typically with study 
designs ranked according to the strength of their internal validity, with randomized control trials 
being the gold standard and descriptive case reports falling to the weaker end of the hierarchy 
(Petticrew & Roberts, 2003)—has been a topic of intense debate in the public health field since 
the 1990s (McQueen, 2002; Petticrew & Roberts, 2003).  The evidence-based public health 
movement grew out of the clinical evidence-based medicine model (McGuire, 2005), but over 
the years, public health researchers and practitioners have questioned the appropriateness and 
relevance of a clinical model for assessing the effectiveness of public health interventions 
(Goodman, 2001; Green, 2001; Green & Glasgow, 2006; McQueen, 2001). The public health 
evidence debate is multifaceted and reflects several related historic and ongoing tensions in the 
field.  An extensive review of these tensions and the history of the evidence debate are discussed 
in the third dissertation manuscript (Chapter 4).  A summary of the widely-debated evidence 
issues is provided in Table 1. 
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Table 1. Summary of Debated Evidence Issues in Public Health 
Tensions Arguments 
Paradigms 
There are historic differences between the ways in which 
“postivists/empirical realists and interpretivists/constructionists 
understand reality and causation” (McGuire, 2005, p.558). 
Sciences & Methods 
There is disagreement regarding the “relative value of evidence based 
on epidemiologic and probabilistic reasoning vs. that based on 
sociological methods” (Kemm, 2006, p.320). 
Areas of Study with 
Public Health 
There are differences “between concepts of what counts as evidence in 
biomedical public health versus health promotion practice” (Raphael, 
2000, p. 355). 
Units of Intervention 
“Taking communities rather than individuals as the unit of intervention 
and the importance of context means that frequently randomized 
controlled trials are not appropriate for the study of public health 
interventions” (Kemm, 2006, p.319; Raphael, 2000). 
Research vs. Practice 
“Differences in approach are sometimes found between practitioners 
and researchers.  Practitioners tend to emphasize the importance of 
providing services to people and the role of empathy and concern in 
the intervention process.  Researchers, on the other hand, may give 
more weight to the understanding provided by rigorous scientific 
analysis and objectivity. (Monette, Sullivan & DeJong, 1997, p. 320). 
 
“Significant tension exists between the imperatives of the university-
based research enterprise and the obligations of agencies and 
organizations responsible for addressing the health needs of 
populations” (Potter & Quill, 2006, p. 14). 
 
“Where did the field get the idea that evidence of an intervention’s 
efficacy from carefully controlled trials could be generalized as the 
best practice for widely varied populations and settings?” (Green, 
2001, p.167) 
 
“Much research fails to translate into practice because the programs 
and methods used fail to address contextual factors”—they “employ a 
limited and researcher-centric perspective as to what constitutes 
‘evidence’” (Glasgow & Emmons, 2007, p. 417). 
  
 McQueen provides an insightful summary of the evidence debate as it relates to 
intervention research and evaluation in communities: 
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Within the general area of community research, intervention and evaluation 
there is currently great debate about what constitutes knowledge in the field 
and what is evidence, or even whether the notion of evidence is applicable to 
the evaluation of intervention in communities.  In summary, there is non 
consensus on any ‘hierarchy of evidence’ between researchers and 
practitioners in the field” (2001, p. 266). 
Amid this evidence debate (highlighted in Table 1), the major, national resources for evidence-
based programs, such as The Guide to Community Preventive Services and the National Cancer 
Institute’s Research-Tested Intervention Programs (RTIPs), apply and promote more of a 
biomedical or epidemiological approach to determining what constitutes sufficient evidence to 
warrant recommending the widespread adoption and implementation of various public health 
interventions (McQueen, 2001; Task Force, 2007).  Arguably, a broader conceptualization of 
what constitutes sound, valid evidence in public health is necessary to address the gaps that have 
resulted from the field’s longstanding predilection for positivist-driven conceptualizations of 
evidence that rely heavily on results from experimental designs:    
many evidence gaps remain and the gaps are not random.  There are still 
cultural, geographical, economic, and methodological biases in determining 
what is studied and how.  The availability of high-quality evidence often 
seems to favor clinical treatment over prevention, and interventions that 
are…simple over those that are more complex, those with shorter-term 
objectives over those that are longer-term….  Much more work is needed to 
fill these gaps and to shine the light where it is currently dark (Briss, 2005, p. 
829).   
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What counts as evidence in public health is still a contested issue.  Nevertheless, there is 
a general consensus among practitioners that evidence is important in order to:  reduce 
uncertainty in public health decision-making (Raphael, 2000); justify the decisions of public 
health practitioners regarding public health efforts; and to demonstrate the benefits of adopted 
interventions to their organizations, funders, policy-makers, and other stakeholders (McQueen, 
2002; Raphael, 2000).  In addition, it is generally accepted that different evaluation and research 
questions require different methods of inquiry and that it is “irrational to regard any method as 
superior for all purposes” (Kemm, 2006, p. 320).  So, the ongoing evidence debate need not be 
viewed as a hindrance to public health research and program evaluation.  Quite the opposite—as 
in the present case, the principles and concepts such as those listed below that have fueled, and 
grown out of, the evidence debate encourage elevated thinking around the scope, methods, and 
significance of public health research and evaluation: 
• Types of Evidence:  There are several types of evidence that can be drawn upon in 
public health program development and evaluation, including theoretical data, 
feasibility/implementation evidence, contextual information (e.g., constraints, 
history, resources), intended primary outcome evidence, unintended or unanticipated 
outcome results, process results, outcome or clinical data, quality improvement data, 
cost and economic data, qualitative data, local data, internal validity evidence, and 
external validity evidence (Glasgow & Emmons, 2007).   
• Integrating Evidence:  Methods are needed to integrate and synthesize different types 
of evidence (Glasgow & Emmons, 2007).  Evaluators should use a wide range of 
qualitative and quantitative methods to move beyond randomized control trials, which 
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are often not feasible for complex public health programs due to practical and 
resource constraints (Raphael, 2000; Rychetnik, Frommer, Hawe & Shiell, 2002). 
• Best Quality Evidence: The term “best quality” evidence should refer to evaluative 
research that was matched to the stage of development of the intervention; was able to 
detect important intervention effects; provided adequate process measures and 
contextual information, which are required for interpreting the findings; and 
addressed the needs of important stakeholders” (Rychetnik, Frommer, Hawe & Shiell, 
2002, p. 125). 
• Best Available Evidence:  For many public health problems, intervention strategies 
should be recommended based on the best available evidence instead of waiting for 
the best possible evidence (Glasgow & Emmons, 2007). 
This dissertation research will produce process evaluation data, which, as argued above, 
represents a valid contribution to the cancer patient navigation literature that other practitioners 
and researchers can draw upon for public health program development and evaluation.  As 
recommended by Glasgow & Emmons (2007), this evaluation also integrates qualitative and 
quantitative methods to help ensure that the evidence produced regarding the activities and early 
outcomes of the MOPP program is of high quality.  In this dissertation research, the quality of 
evidence is not established by the use of the most scientifically rigorous design, rather by other 
key considerations presented by Rychetnik and colleagues above, including the appropriateness 
of design to program stage and responsiveness to stakeholder needs (2002).  Evaluation findings 
represent a timely contribution to the best available evidence (Glasgow & Emmons, 2007) on 
cancer patient navigation, which will help practitioners—who cannot afford to wait for the best 
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possible evidence base to be developed—make informed decisions about adopting and 
evaluating their navigation interventions. 
1.5.2 Important principles for evaluating community interventions 
Approaching evaluation through the lens of broader conceptualizations of evidence helps 
researchers understand that experimental and quasi-experimental designs, although recognized  
as the most scientifically rigorous designs, are not necessarily the most appropriate or 
informative designs for evaluating complex community health interventions or real-world efforts 
to reduce health disparities (Goodman, 2001; Rust & Cooper, 2007).  Goodman explains that “in 
evaluating single and complex community programs, ‘how’ or ‘why’ an intervention worked (or 
did not work) often is sine qua non, and qualitative case study designs are considered as 
optimum in such evaluations” (2001, p. 300).  Case studies give an in-depth picture of the 
implemented program, its organizational context, and the broader environment by integrating 
qualitative and quantitative information from a variety of sources (Love, 2004).   
 According to Love (2004), case studies are particularly useful for understanding the 
implementation of innovative or demonstration programs.  If “innovative” is defined according 
to its use in Rogers’s Diffusion of Innovation Model (i.e., a practice that is perceived as new by 
an organization), the Minority Outreach Pilot Program is appropriately classified as an 
innovative program and matches well with a case study evaluation design (Oldenburg & Parcel, 
2002).  Case studies are a common and valuable way to pursue qualitative inquiry,  although, it is 
important to note that case study research is not essentially qualitative (Goodman, 2001; Stake, 
2005). In fact, a noted benefit of case studies is their “flexibility and ability to assemble a 
comprehensive array of quantitative and qualitative data to provide in-depth analysis and 
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valuable insight” (Love, 2004, p.82).  Stake (2005) points out that a “case study optimizes 
understanding by pursuing scholarly research questions…[and] gains credibility through 
triangulating the descriptions and interpretations, not just in a single step but continuously 
throughout the period of study” (p. 443)  
Adopting a case study approach to inquiry simply helps to focus the research design.  
Research design is just one component of a sound, comprehensive program evaluation (CDC, 
2005).  The evaluation frameworks discussed in the following section helped to organize the 
overall program evaluation and guide the identification of appropriate data collection and 
analysis methods. 
1.5.3 Guiding evaluation frameworks 
The Centers for Disease Control and Prevention Framework for Program Evaluation in Public 
Health serves as the “basic organizational framework” for the overall program evaluation (CDC, 
1999, p.2).  The MOPP evaluation design also draws on key principles of the RE-AIM 
evaluation framework (i.e., evaluation should focus on issues that are both relevant to 
stakeholders and critical to assessing the public health impact and generalizability of public 
health interventions).  For the purposes of this research, RE-AIM fits nicely within the CDC 
organizational framework.  Specifically, the RE-AIM model was used to help focus the 
evaluation design and methods, which falls under step three of the six-step CDC Framework for 
Program Evaluation in Public Health.      
 The CDC Framework for Program Evaluation in Public Health is based on the premise 
that “good evaluation does not merely gather accurate evidence and draw valid conclusions, but 
produces results that are used to make a difference” (CDC, 2005, p.6).  The CDC Framework 
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defines six steps and four standards for conducting sound evaluations of public health programs.  
The six Framework steps are: 
• Engage stakeholders, those persons involved in or affected by the program and 
primary users of the evaluation. 
• Describe the program based on need, expected effects, activities, resources, stage, 
and context.  Logic models are valuable tools for graphically depicting program 
theory. 
• Focus the evaluation design in terms of purpose, users, uses, questions, methods, and 
feasibility. 
• Gather credible evidence.  Consider indicators and sources of evidence/methods of 
data collection, issues of quality and quantity, and logistics. 
• Justify conclusions according to standards.  Conduct data analysis/synthesis, interpret 
data, and make judgments.  
• Ensure use and share lessons learned.  Provide feedback and draft recommendations.  
Support stakeholder preparation for receiving and utilizing results.  Disseminate 
findings and follow-up with stakeholders (CDC, 1999).   
 During each step of the evaluation process, decisions regarding evaluation activities are 
guided by the four evaluation standards for effective evaluation: 
• Utility:  Serve the information needs of intended users. 
• Feasibility:  Be realistic, prudent, diplomatic, and frugal. 
• Propriety:  Behave legally, ethically, and with regard for the welfare of those 
involved and those affected. 
• Accuracy:  Reveal and convey technically accurate information. 
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The RE-AIM framework “offers a comprehensive approach to considering five 
dimensions important for evaluating the potential public health impact of an intervention”:  
reach, effectiveness, adoption, implementation, and maintenance (Glasgow, Klesges, 
Dzewaltowski, Estabrooks & Vogt, 2006, p.688).  The evaluation model was developed to 
expand assessment of interventions beyond efficacy to multiple criteria that can help better 
identify the translatability and public health impact of health promotion interventions (Glasgow, 
2002; Glasgow, Vogt, & Boles, 1999).  RE-AIM provides a framework for determining if 
programs are worth continued investment and for identifying programs that work in real-world 
environments; it’s a flexible model that can be used to guide and evaluate a wide range of 
interventions, from randomized controlled studies to qualitative research (Glasgow, Vogt, & 
Boles, 1999).  RE-AIM is a particularly useful tool for researchers and practitioners whose goal 
is to translate research into practice (Dzewaltowski, Estabrooks, & Glasgow, 2004; 
Dzewaltowski, Glasgow, Klesges, Estabrooks, & Brock, 2004; Klesges, Estabrooks, 
Dzewaltowski, Bull, & Glasgow, 2005; Sussman, Valente, Rohrbach, Skara, & Pentz, 2006).   
Descriptions for the five dimensions of RE-AIM are listed below; all dimensions are 
considered equally important by framework developers for evaluating the translatability and 
public health impact of interventions (Workgroup to Evaluate and Enhance the Reach and 
Dissemination of Health Promotion Interventions, 2004). 
• Reach:  Reach refers to the absolute number, proportion, and representativeness of 
individuals who participate in a given program.  Representativeness refers to whether 
participants have characteristics that reflect the target population's characteristics.  
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• Efficacy/Effectiveness:  Within the RE-AIM Framework, the efficacy/effectiveness 
dimension refers to the impact an intervention has on important outcomes. These 
impacts include potential negative results, quality of life, and costs. 
• Adoption:  Adoption refers to the absolute number, proportion, and representativeness 
of settings and/or staff who are willing to offer a program. 
• Implementation:  The implementation dimension focuses on how closely staff 
members at the setting level follow the program that the developers provide. 
Implementation measures may also assess consistency of delivery as intended by the 
program, time required for program implementation, and the cost of the program. 
• Maintenance:  Maintenance measures describe the extent to which a program or 
policy becomes part of routine organizational practices and policies. Within the RE-
AIM framework, maintenance also refers to the long-term effects of a program on 
individual level outcomes six or more months after the most recent intervention 
contact (Workgroup to Evaluate and Enhance the Reach and Dissemination of Health 
Promotion Interventions, 2004). 
As it is not necessary to investigate all RE-AIM components in every study (Glasgow, Vogt, & 
Boles, 1999), maintenance was not addressed in the MOPP evaluation because the program is 
newly implemented.  Evaluation questions were developed with attention to reach, effectiveness, 
adoption, and implementation dimensions, and the RE-AIM formula was used to quantify reach 
in the MOPP evaluation.  The RE-AIM framework also includes a formula for calculating 
adoption.  However, this measure was not appropriate for the MOPP program as UPMC 
administration selected the four participating pilot project sites by mandate.   
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2.0  EVALUATION DESIGN AND GENERAL METHODOLOGY 
2.1 MIXED-METHODS CASE STUDY DESIGN 
A case study research design, which included triangulation of data collection and analysis 
methods, was applied in the MOPP evaluation.  The program evaluation utilized a variety of data 
sources (data triangulation), as well as quantitative and qualitative methods (methodological 
triangulation) in an effort to strengthen the study of a single program (Patton, 2002).  The 
purpose of triangulation is to test for consistency in the results yielded by different data sources 
and inquiry approaches (Patton, 2002).  Triangulation allows for a validity cross-check through 
different modes of inquiry (Patton, 2002; Weiss, 1998).  Patton notes that “different types of 
inquiry are sensitive to different real-world nuances”, thus inconsistencies in findings across data 
sources were not interpreted as a weakness in the credibility of study findings (2002, p.556).  
Rather, inconsistencies were noted and examined closely in an effort to understand differences in 
data from divergent sources based on the premise that reasonable explanations for 
inconsistencies in findings can contribute significantly to the overall credibility of evaluation 
findings (Patton, 2002).  Besculides and colleagues provide a useful explanation of the strength 
and value of mixed-methods evaluation research:   
A mixed-methods approach strengthens evaluation research, because no single 
method is without weakness or bias.  Quantitative data, for example, may be 
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objective, but they often lack the depth needed to elucidate how and why a 
program works.  Qualitative data can enhance understanding of program 
implementation and operation, but are considered less objective.  By 
combining the two, research can be both objective and rich (2006, p. 2). 
Table 2 summarizes the various methods that were used to address each evaluation question.  
Details about data collection, analysis and triangulation procedures follow.   
Table 2. Overview of Multiple Methods Used in the MOPP Evaluation 
*RE-AIM reach calculations 
Quantitative Qualitative 
Evaluation Questions Descriptive 
statistical 
analysis 
Observation Patient Interviews
Staff 
Interviews 
Document 
Review 
1. How many participants 
does the program serve, 
and what are the 
characteristics of the 
program participants? 
?  
 
?  
2. What is the program’s 
reach into the target 
population? * 
? ? 
 
?  
3. To what extent is the 
program being 
implemented as planned? 
? ? 
 
? ? 
4. Is the program making 
progress toward the 
achievement of short-term 
outcomes? 
?  ? ? ? 
5. Are there unintended or 
unexpected program 
outcomes? 
 ? 
 
?  
6. What are the costs 
associated with 
implementing the 
program? 
  
 
? ? 
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The evaluation primarily focuses on MOPP implementation, or process, which is 
appropriate for a program that is in its early years of implementation (CDC, 2005).  In relating 
the evaluation questions and focus to the program logic model (Appendix A), data collection 
activities mainly center on program outputs, or the tangible capacities or products produced by 
program activities (CDC, 2005).  As outputs represent a tangible deliverable produced as a result 
of activities, or can be interpreted as “activities redefined in tangible or countable terms”; 
assessing the program’s performance on planned outputs helps to determine whether the program 
is performing as planned (CDC, 2005, p. 22).   
2.2 DATA COLLECTION AND ANALYSIS METHODS 
The evaluation mixed qualitative and quantitative methods, as outlined in Table 2, to collect, 
analyze, and cross-analyze data from the following sources:  the Minority Outreach Pilot 
Program database; internal financial records, logs, and forms; field notes from meeting 
observations; program staff and participant interviews; and public program documents, including 
presentations and promotional material.  Given the multiple evaluation questions, data collection 
methods, and data sources, the following section is organized by data collection procedures in 
order to facilitate a clear and detailed presentation of evaluation methods.  Analysis procedures 
are described for each data collection method.  In addition, the triangulation protocol for the 
evaluation is outlined in this section.     
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2.2.1 Descriptive Statistical Analysis of MOPP Database 
MOPP provided access to a de-identified Excel worksheet file that included demographic, 
diagnosis and referral, treatment, CCT recruitment and participation, barriers to care, and MOPP 
service provision data for all program participants.  A list of the specific database variables 
included in the evaluation’s descriptive statistical analysis is provided in Appendix B.  Data 
collected from the program database covered the period from program implementation (March 
2006) through April 2008, which was the planned end date for evaluation data collection.  Data 
was cleaned, which included a process of working with program staff to accurately code or fill-in 
missing data; recoded as necessary to facilitate analysis; and studied through descriptive 
statistical analyses in SPSS.  As only basic descriptive analyses were performed, recoding 
mainly consisted of transforming text into nominal variables.  For example, the Excel worksheet 
provided by the program listed comorbidities for all patients in one column.  This text data was 
recoded to create a nominal variable (i.e., 0- no, 1-yes) for each comorbidity recorded in the 
database.  This recoding facilitated frequency calculations for each comorbidity, as well as the 
calculation of total number of comorbidities for each patient in the database. 
Data was analyzed as follows to address evaluation questions #1-4: 
? Evaluation Question #1. How many participants does the program serve, and what 
are the characteristics of the program participants?:  The Frequencies procedure was 
used to determine the distribution of the program’s participants by selected 
demographic, cancer diagnosis, and cancer care barriers variables.  Frequencies were 
run for the entire period of March 2006-April 2008 and were also summarized for 
each program year according to program reporting practices (i.e., March 2006-
December 2006;  January 2007-Decemember 2007; and January 2008 to present, 
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which in the case of this evaluation was April 2008).  Findings were organized in this 
manner to facilitate use of evaluation findings by program staff and key stakeholders.      
? Evaluation Question #2. What is the program’s reach into the target population?:  The 
RE-AIM reach calculator was used to quantify dimensions of the program’s reach.  
This online calculator is a simple tool for quickly and easily completing basic 
calculations related to reach.  The calculator prompts researchers and evaluators to 
calculate and present a little more detail than what is typically presented in 
intervention studies (i.e., size of the study sample and the proportion of eligible 
individuals who are willing to participate in the intervention).  Using an estimate of 
the number of individuals in the target population and data on the actual program 
population (i.e., estimated number exposed to recruitment, number who responded to 
recruitment, actual number who are eligible, and actual number who participate) the 
online RE-AIM tool calculates the following measures, which provide useful practice-
focused data for researchers, program managers, and policy makers to consider for 
assessing the appropriateness of various public health interventions for their 
organization and service population: 
- % of target who respond to recruitment= # responded to recruitment ÷ # in 
target population x 100 
- % of eligible who participate= # who participate ÷ # eligible x 100 
- % of reach into the target population = # who participate ÷ # in target 
population x 100 
- % excluded from the study = # ineligible ÷ # responded to recruitment x 
100 
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The number of individuals in the target population, which is limited to newly 
diagnosed African American patients, was estimated by dividing 235 (i.e., number of 
the target population touched by the program, excluding CCT screen only participants 
(see Section 1.3.1), by .85 based on UPMC billing reports and MOPP database entries, 
which indicate that the program consistently touches about 85% of all African 
American patients who are newly diagnosed with cancer and seek treatment at one of 
the four participating program sites.   
All other reach formula components listed above were obtained from the de-identified 
MOPP database file.  “Number who responded to recruitment” was defined as the total 
number of individuals in the program database (n=249).  “Actual number who are 
eligible” (n=235) was calculated by subtracting the 14 individuals contacted for CCT 
screen only (i.e., ineligible for patient navigator services because they did not receive 
care at one of the four participating program sites) from total number of individuals in 
the database (n=249).  “Actual number who participate” was defined as the number of 
individuals in the program database who accepted patient navigator services.      
? Evaluation Question #3. To what extent is the program being implemented as 
planned?:  To help address this evaluation question, frequencies were run to 
summarize priority program outputs, including number and types of services provided 
to program participants.  Specifically, descriptive statistical analysis of the program 
database was conducted to summarize outputs #3, 6, 8, & 10 in the program logic 
model (see Appendix A). 
? Evaluation Question #4.  Is the program making progress toward the achievement of 
short-term outcomes?:  The descriptive statistical analysis of the MOPP database 
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helped to assess the program’s progress on short-term outcomes related to addressing 
barriers to cancer care and increasing CCT participation.  Specifically, MOPP’s effort 
to increase knowledge of CCT opportunities and benefits was quantified based on 
documented outreach for CCT recruitment.  Additionally, progress on the planned 
short-term outcome to increase knowledge of barriers to cancer care and CCT 
participation among participating centers was partially assessed by quantifying the 
numbers and types of barriers to cancer care and CCT participation documented in the 
program database. Lastly the chi-square test procedure was used to quantitatively 
explore association between acceptance of patient navigators and CCT enrollment.  
The desired level of significance was set at p<.05. 
2.2.2   Meeting Observation 
MOPP bi-weekly program staff meetings were observed during the period of January-June 2008, 
and three monthly African American Cancer Care Partnership meetings were attended during the 
evaluation period in the months of March, April and May.  Observation of both staff and 
AACCP meetings helped the evaluator develop a thorough understanding of both how the 
program operates and the context in which it operates.  Additionally observations provided 
valuable qualitative data for addressing evaluation questions #3 and 5.  During meeting 
observations, particular attention was paid to issues related to the program implementation 
experience in an effort to understand whether and how program activities and outputs were being 
delivered as planned (evaluation question #3).  Meeting discussion and oral reports related to 
program outcomes (evaluation question #5) were also studied closely.  Reflective and reflexive 
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field notes were taken during and after meeting observations.  Notes were interpreted through 
careful reading and focused coding of themes. 
2.2.3 Interviews 
The evaluation included interviews with three different groups:  semi-structured interviews of 
program staff and participants, as well as informal interviews with the Program Director.  All 
staff members (1 Director, 1 Social Worker, 1 Cancer Control Specialists, and 2 Navigators) 
were interviewed to help address evaluation questions # 1- 5.  Therefore, interviews covered a 
wide range of topics, including a description of the program and its implementation process from 
each staff person’s perspective.  The interview guide is comprised of six questions, including:  
How would you describe the group of patients you serve through the Minority Outreach Pilot 
Program?, In what ways are program activities being implemented as planned?, and Based on 
your experience, has MOPP had any impact, or have the navigation services led to any outcomes 
that were unplanned?  A complete list of staff interview questions and the evaluation questions 
they were designed to help address is provided in Appendix C.   
Staff interviews took place in a private setting (i.e., conference room or office) at the 
UPMC Cancer Center.  The 30-60 minute interviews were tape recorded and transcribed by the 
evaluator.  Transcripts from the semi-structured staff interviews were analyzed using focused 
coding.  The topics of the interview questions (i.e., participant characteristics, reach, 
implementation achievements, implementation challenges, outcome progress, unintended or 
unexpected outcomes, and costs) were used to organize and provide a first level of coding for the 
texts.  Then, texts were read closely for emergent and prominent themes within these broader 
categories.  Additionally, the texts were studied closely for themes or issues that seemed to be 
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outside or beyond the scope and focus of the topics covered in the interview questions.  These 
“new” themes were coded across interviews to identify the concepts most relevant to them and 
implied relationships between themes.     
Phone interviews were conducted with a small sample of program participants to help 
address evaluation question #4.  Therefore, interview questions focused on the impact the 
program has had on participants and their satisfaction with services received.  The interview 
guide consisted of eight questions, including:  How did you first meet [patient navigator]?, What 
do you like about working with [patient navigator]?, and How would you change what [patient 
navigator] does?  Why?  A complete list of participant interview questions is provided in 
Appendix C.  An open-ended interviewing format was used to capture participants’ thoughts and 
insights in their own words (Patton, 2002); however, interview questions were standardized for 
the following benefits:  1) the exact instrument (interview guide) used in the evaluation can be 
provided for review and use by evaluator stakeholders and parties interested in evaluation 
findings; 2) interviewee time is used efficiently because the interview is highly focused; and 3) 
responses are easy to find and compare, which facilitates analysis (Patton, 2002).  During the 
interviews, patient navigators’ names were used in place of the name of the pilot program to 
avoid confusion that might result from any unfamiliarity with the formal program name.  After 
careful consideration of feasibility and propriety standards (CDC, 2005), phone interviews were 
chosen for this evaluation, rather than face-to-face or mail interviews, to help minimize patient 
burden (i.e., MOPP participants face several barriers to cancer care, including transportation and 
child care issues, and are under the additional emotional and physical strain of  the cancer 
diagnosis and treatment experience).   
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Program participant interviewees were selected through heterogeneity sampling based on 
the following characteristics that are especially relevant to the MOPP mission and services:  type 
of cancer; referral source; acceptance, delayed acceptance or decline of patient navigator 
services; and CCT participation.  Heterogeneity sampling is a non-probability, purposive 
sampling method.  This method samples for diversity in an effort to yield both:  1) high quality, 
detailed description for single patients, which is valuable for documenting the uniqueness of 
patients served by the program, and 2) important shared themes that cut across patients and 
establish their significance from having emerged from a heterogeneous sample (Patton, 2002).  
Based on Patton’s philosophy for qualitative inquiry—there are “no rules for sample size in 
qualitative inquiry”, and the size of the sample depends on the purpose of the inquiry, what will 
be useful and have credibility, and what can be done with available time and resources (Patton, 
2002, p. 244)—eleven interviews were planned.  The actual number of interviews conducted was 
reduced to seven for several reasons, including a decline in the health status of selected 
interviewees, patient refusal, and strict adherence to the planned timeline for data collection 
activities.  However, the seven program participants interviewed satisfied the heterogeneity 
sampling criteria.  Table 3 summarizes participant interviewees by the sampling criteria.   
While the heterogeneity sampling criteria was met, saturation was not reached.  As 
presented in the results section, all interviewees described social support services they received 
through MOPP.  However, information shared during one of the final interviews suggests that it 
may be valuable to further explore patients’ level of understanding about the various services 
MOPP offers. 
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Table 3. Patient Interviewee Characteristics (n=7) 
Characteristic Count 
Age   
20-49 1 
50-64 3 
65-74 3 
total 7 
Gender   
female 6 
male 1 
total 7 
Cancer Diagnosis   
breast 3 
colon 1 
head and neck 1 
lung 1 
multiple myeloma 1 
total 7 
Referral Source  
surgeon 2 
clinical research 
coordinator 
1 
social worker 1 
MOPP case finding 3 
total 7 
Patient Navigator  
accepted 5 
delayed acceptance 1 
decline 1 
total 7 
CCT Participation  
yes 3 
no 4 
total 7 
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Participant interviewees were selected at random from the de-identified database file 
according to the heterogeneous sampling criteria previously described.  Using program-assigned 
patient identification numbers, patient navigators and the MOPP social worker identified the 
patients selected at random by the evaluator and obtained their verbal permission to be contacted 
by a program evaluator interested in conducting a phone interview with them.  Upon patients’ 
approval, the staff screening calls were followed-up by calls from the evaluator during which 
verbal consent for conducting and tape recording was obtained.  Interviewees received $25 Giant 
Eagle supermarket gift cards for their participation.  Interviews were transcribed by the 
evaluator, studied closely, theme coded by interview question topics, then reviewed again to 
identify shared and unique themes.   
Throughout the evaluation, informal interviews and meetings were held with the Program 
Director to gather information about the history and context of the Minority Outreach Pilot 
Program.  These interviews were particularly helpful for addressing evaluation question #7 as 
they provided an opportunity to review internal program reports on spending and to delineate and 
discuss the program’s funding source, in-kind contributions, and start-up and maintenance 
expenses.  Written notes were taken during interviews and meetings with the Program Director, 
which were later summarized and added to the rich qualitative data collected throughout the 
study to help address evaluation questions. 
2.2.4 Document Review 
Document review both directly and indirectly contributed to completion of the evaluation.  
Program marketing material, presentations to stakeholders and UPMC administration, and 
internal meeting notes and informal reports documents were studied closely to obtain useful 
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background and contextual information that facilitated the evaluator’s work with the program 
staff around illustrating the program theory in logic model form.  Documents were reviewed to 
note program data and details that are regularly presented to patients and other stakeholders in an 
effort to identify and develop a solid understanding of program priorities.  Identifying repeated 
themes of focus across program documents facilitated both the development of appropriate 
evaluation questions and the accurate interpretation of evaluation findings.  In a more direct 
sense, review of program records related to use of gap funds and transportation assistance 
provided the actual data on program expenses necessary to calculate the costs associated with 
implementing MOPP (evaluation question #7). 
2.2.5 Triangulation Protocol 
The MOPP evaluation employs both data triangulation (i.e., it uses multiple data sources), and 
methodological triangulation (i.e., a mix of quantitative and qualitative methods) in an effort to 
strengthen the study of a single program (Patton, 2002).  The benefits of triangulation are 
discussed in detail in Section 1.6.1.  As outlined in Table 2, each evaluation question is 
addressed either through more than one mode of inquiry or two or more data sources within the 
same mode of inquiry.   
Evaluation questions #1 and 2 illustrate the evaluator’s method for combining more than 
one mode of inquiry as both statistical analysis of quantitative program data and analysis of 
qualitative data from interviews and meeting observations were conducted to investigate 
participant characteristics and program reach.  Information gathered from interviews and meeting 
observations expanded on, and facilitated accurate interpretation of, quantitative data analysis 
findings.  For example, among the 249 newly diagnosed African American cancer patients 
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touched by the Minority Outreach Pilot Program, 15, or 15.2%, of the 99 men tracked through 
MOPP have a prostate cancer diagnosis.  Cancer facts and national statistics (i.e., African 
American men have higher prostate cancer incidence and mortality rates than men of other racial 
or ethnic groups in the United States (CDC, 2003), and prostate cancer is the most common 
cancer among African American men (ACS, 2007) call the relatively low numbers of  
participants with prostate cancer into question.  However, qualitative data collected through 
meeting observations revealed that a specialty group of physicians from urology treat the 
majority of prostate cancer patients within the UPMC system.  This group was described as 
operating independently, in relation to patient care, from the larger UPMC care centers.  Upon 
reflecting on the quantitative evaluation data on patient characteristics, MOPP Director repeated 
earlier efforts to initiate a partnership with the urology physician group to provide patient 
navigator services to any patients who may need them. 
As an example of using two or more data sources to address an evaluation question, 
MOPP staff and participants served as key data sources for helping to assess whether the 
program was making progress toward the achievement of desired outcomes (evaluation question 
#4).  Findings from staff interviews were compared with findings from participant interviews to 
identify shared perspectives around program benefits, strengths and weaknesses and to note 
where perspectives may differ, which is also valuable information for program improvement.  
It’s worth noting that descriptive statistical analysis was also conducted to help answer 
evaluation #4.  This quantitative analysis included a chi-square test for association between 
patients’ acceptance of a patient navigator and their enrollment in a cancer clinical trial.  Thus, in 
addition to multiple data sources, progress toward the achievement of desired outcomes 
(evaluation question #4) was also addressed through more than one mode of inquiry.   
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In general, triangulation was operationalized in this evaluation as a cross-checking and 
elucidation process.  For each evaluation question, inconsistencies in findings and differing 
perspectives, both within and between data collection methods, were noted, and all evaluation 
data was studied closely to identify possible explanations for inconsistencies.  Additionally, 
qualitative data from interviews and meeting observations added context or depth to results from 
the statistical analysis of quantitative data from the program database.  These triangulation 
procedures are reflected in the reporting of evaluation findings.        
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3.0  EVALUATION FINDINGS 
3.1 OVERVIEW 
This section presents key findings from the MOPP evaluation.  Findings are organized by the 
focus of each of the six evaluation questions.  Additionally, the summary of findings under each 
evaluation question topic reflects key insights obtained through the various methods of inquiry or 
data sources used (See Table 2).  This chapter of detailed evaluation findings is followed by 
three manuscript drafts (Chapter 4.0, 5.0, 6.0) that include selected evaluation findings from this 
chapter.   
The content of each of the following manuscript chapters is aligned with the focus of 
targeted journals.  Specifically, the first article will be submitted to the Centers for Disease 
Control and Prevention’s Preventing Chronic Disease journal and includes evaluation 
descriptions and findings believed to be most relevant to public health practitioners.  The second 
article focuses on the potential for cancer patient navigator programs to help address racial 
disparities in cancer clinical trial participation.  Thus, it includes key evaluation findings related 
to cancer clinical trials.  The second article will be submitted to the Journal of Urban Health as 
racial/ethnic health disparities are one of the major urban health issues the journal focuses on.  It 
is worth noting that Dr. Freeman (2006) recently published an article about cancer patient 
navigation in the Journal of Urban Health—the planned manuscript could expand nicely on 
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Freeman’s article by exploring CCT education and recruitment efforts within navigator 
programs.  The last article, a critical analysis piece, provides an in-depth study of the translation 
and evidence arguments that helped to inform the development of this research.  It will be 
submitted to The Milbank Quarterly, which is devoted to scholarly analysis of significant issues 
in health and health care policy.  Rather than focusing on specific evaluation findings, the third 
article applies what was learned about the patient navigation movement throughout this research 
to higher-level, conceptual thinking about improving public health research translation and, in 
turn, the public’s health.  
3.2 CHARACTERISTICS OF PROGRAM PARTICIPANTS 
The first evaluation question focuses on describing the characteristic of MOPP program 
participants.  Proper interpretation of descriptive statistical analysis of participant characteristics 
requires an understanding of the different ways in which MOPP connects and serves African 
Americans who are newly diagnosed with cancer and receiving care in the UPMC system.  Thus, 
qualitative data collection from both formal and informal interviews with program staff was 
critical for the effective study of the first evaluation question.  The quantitative and qualitative 
descriptions of program participants presented in this section cover patients referred to, tracked 
and serviced by MOPP since its implementation in March 2006 through the end date for 
evaluation data collection, April 2008.  
MOPP touches the target population through referrals and case findings.  Referrals come 
from several sources, including: 
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? UPMC Cancer Centers Cancer Information and Referral Service (CIRS), which is a 
free cancer information service for the public, staffed by UPMC oncology nurses and 
social workers.  Through CIRS, the general public can obtain information about 
cancer and cancer-related topics, including general disease sites, prevention, early 
detection, clinical trials, symptom management, support services, community 
resources and educational programs (UPMC Cancer Centers, n.d.).  
? Clinical research coordinators 
? Collaborative practice nurses 
? Community agencies 
? Self referrals from patients, and referrals from family and friends of the patient 
? Oncologists, primary care physicians, surgeons, and other doctors 
? UPMC sites  (outside of the four MOPP participating sites) 
? UPMC Prevention and Early Detection Center (PEDC) 
? Social workers within the UPMC system 
Case finding is conducted by the MOPP social worker and involves reviewing tailored weekly 
internal reports on new cancer patients. 
 All patients from the target population who are identified through referrals and case 
findings are entered in the MOPP database (n=249).  Basic demographic and health care status 
(e.g., cancer diagnosis, stage, and comorbidities), is recorded in the database using information 
from patient intake and barrier assessment and from the larger UPMC medical record database. 
All patients the program connects with, regardless of their UPMC cancer care site, are screened 
for cancer clinical trial eligibility and, as applicable, are provided information about CCT 
participation. Beginning in 2008, extended CCT recruitment efforts were documented in the 
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MOPP database, and so the total program population includes individuals who were targeted for 
cancer clinical trial screening (n=14) although they were not receiving care at one of the four 
MOPP participating sites.  Many patients identified barriers, even some who decline patient 
navigator services.  So, there are also cases in which patients officially decline the offer to be 
assigned a patient navigator, but request and receive some kind of service from the program, 
such as assistance from the social worker in successfully applying for health care insurance.  
Lastly there are some patients in the MOPP database who were self-referred or referred through 
the Prevention and Early Detection Program for assistance, usually related to insurance coverage, 
with follow-up on suspicious cancer screening findings.  This follow-up diagnostic care 
frequently determines that the patients do not have cancer.  Of these 14 non-cancer patients, one 
utilized patient navigator services.     
 For the purposes of this evaluation, the term program participants refers to all 249 
patients that are tracked in the MOPP database as they are each contacted by the program with 
information about program services, patient navigator services and/or cancer clinical trial 
participation—any analysis on subsets of the program participants (e.g., CCT screen only 
patients, non-cancer patients, or navigated patients) are clearly noted throughout the text.  
Selected participant characteristics are highlighted in Table 4 (see Appendix D for a presentation 
of Table 4 by program year).  About 30% of the 249 program participants are between 20 and 49 
years of age, while the majority of program participants fall within the 50-64 age group.  Almost 
60% of participants are female.  Most (26.1%) of the program participants were identified 
through MOPP case finding.  However, a fairly large number of referrals are received from 
UPMC social workers (18.5%) and through CIRS (15.3%).  Seventy-five patients are working 
with patient navigators.  Most patients (37.3%) entered the program with a stage IV cancer 
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diagnosis.  Among program participants, the four most common cancer diagnoses are breast 
(17.7%); lung, non-small cell (15.3%); colon (7.2%); and head and neck (6.4%).  The majority of 
program participants (73.5%) receive care at the Hillman Cancer Center site.  Forty-one (16.5) 
patients entered the program with a self-pay or uninsured status, while 27.3% were insured 
through Medicare Managed Care and 22.1% were insured through Medicaid Managed Care. 
Table 4. Program Participant Characteristics (n=249) 
Characteristic Count Percent 
Age Group 
<20 
20-49 
50-64 
65-74 
75+ 
Unknown 
Total 
 
1 
74 
104 
43 
24 
3 
249 
.4
29.7
41.8
17.3
9.6
1.2
100
Gender 
Female 
Male 
Missing 
Total 
 
148 
99 
2 
249 
59.4
39.8
.8
100
Referral Source 
Case Finding (MOPP Social Worker) 
CIRS 
Clinical Research Coordinator 
Collaborative Practice Nurse 
Community Agency 
Oncologist 
Other 
Other Medical Doctor 
Other UPMC Site 
Primary Care Physician 
PEDC 
Self/Family/Friend 
Social Worker 
Surgeon 
Missing 
Total 
 
 
65 
38 
20 
12 
8 
7 
1 
1 
4 
3 
11 
6 
46 
14 
13 
249 
26.1
15.3
8.0
4.8
3.2
2.8
.4
.4
1.6
1.2
4.4
2.4
18.5
5.6
5.2
100
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Characteristic Count Percent 
Patient Navigator 
Yes 
No 
Total 
 
75 
174 
249 
30.1
69.9
100
Cancer Stage 
I 
II 
III 
IV 
Screening 
Unable to Stage 
Missing 
Total 
 
15 
24 
52 
93 
20 
42 
3 
249 
6.0
9.6
20.9
37.3
8.0
16.9
1.2
100
Cancer Diagnosis 
no cancer diagnosis 
not yet diagnosed 
Acute Lymphoblastic Leukemia, Adult 
Acute Myeloid Leukemia, Adult 
Bile Duct Cancer, Extrahepatic 
Bladder Cancer 
Brain Tumor, Adult 
Brain Tumor, Cerebral Astrocytoma/Malignant Glioma 
Brain Tumor, Childhood (Other) 
Breast Cancer 
Cervical Cancer 
Chronic Myelogenous Leukemia 
Colon Cancer 
Esophageal Cancer 
Head and Neck Cancer 
Hodgkin's Lymphoma, Adult 
Kaposi's Sarcoma 
Laryngeal Cancer 
Lung Cancer, Non-Small Cell 
Lung Cancer, Small Cell 
Lymphoma, Non-Hodgkin’s Adult 
Melanoma 
Mesothelioma, Adult 
Multiple Myeloma/Plasma Cell Neoplasm 
Myelodysplastic Syndromes 
Non-malignant Hematologic Disorder 
Osteosarcoma/Malignant Fibrous Histiocytoma 
Ovarian Epithelial Cancer 
Pancreatic Cancer 
Prostate Cancer 
 
14 
13 
1 
3 
1 
1 
5 
3 
1 
44 
1 
3 
18 
3 
16 
4 
1 
2 
38 
4 
6 
3 
1 
6 
2 
4 
1 
1 
11 
15 
5.6
5.2
.4
1.2
.4
.4
2.0
1.2
.4
17.7
.4
1.2
7.2
1.2
6.4
1.6
.4
.8
15.3
1.6
2.4
1.2
.4
2.4
.8
1.6
.4
.4
4.4
6.0
Table 4 Continued
 66 
Characteristic Count Percent 
Rectal Cancer 
Renal Cell (Kidney) 
Renal Pelvis and Ureter, Transitional Cell Cancer 
Sarcoma, Soft Tissue 
Stomach (Gastric) Cancer 
Thymoma and Thymic Carcinoma 
Unknown Primary Site 
Missing 
Total 
5 
4 
1 
3 
2 
1 
2 
5 
249 
2.0
1.6
.4
1.2
.8
.4
.8
2.0
100
Cancer Care Site 
Beaver Med Oncology 
Hillman 
Jefferson Med Oncology 
Magee 
McKeesport 
Mercy 
Moon Med Oncology 
Murtha Radiology Oncology 
Natrona Med Oncology 
New Castle 
Passavant 
Shadyside Hospital or Radiology Oncology 
St. Margaret Med Oncology 
Missing 
Total 
 
5 
183 
3 
7 
8 
1 
1 
1 
2 
1 
1 
5 
4 
27 
249 
2.0
73.5
1.2
2.8
3.2
0.4
0.4
0.4
0.8
0.4
0.4
2.0
1.6
10.8
100
Insurance 
Commercial Indemnity Insurance 
Commercial Managed Care (HMO/PPO/POS) 
Medicaid Managed Care (HMO/PPO/POS) 
Medicaid/Public Assistance 
Medicare 
Medicare Managed Care (HMO/PPO/POS) 
Military (DOD,CHAMPUS,VA) 
Other Public Coverage 
Self Pay or No Insurance 
Missing 
Total 
 
1 
48 
55 
6 
7 
68 
1 
3 
41 
19 
249 
0.4
19.3
22.1
2.4
2.8
27.3
0.4
1.2
16.5
7.6
100
 
While descriptions of program participants collected in staff interviews included a 
summary of MOPP’s target population (i.e., African American patients newly diagnosed with 
cancer), diversity was a shared and notable theme.  As illustrated by the selected quotes from two 
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staff members that follow, program staff recognize that, although they serve a group of patients 
who share a racial classification and disease diagnosis, the program population markedly diverse. 
“Other than being African American, …I think there’s a lot of variation…it’s 
a heterogeneous group.” 
“…all their needs are different.  They come from all walks of life….there’s no 
set mold that our patients are coming from.” 
In addition to acknowledging differences among the patient population, staff recognizes 
differences in individual patients; that is their needs may change over time, often due to changes 
in employment status and consequential changes in insurance coverage:   
“I see different patterns of people:  at the beginning not needing anything, 
then needing something later; or patients needing a lot at the beginning and 
you get it all squared away for them, and they’re like, ‘I’m fine.’ …. Some of 
our patients have insurance in the beginning because they were working, and 
then, getting really sick, they haven’t been able to work….A lot of these 
people don’t have jobs where they have a lot of money—it’s expensive to pick 
up your insurance. It’s expensive even to pay for just your contributions to 
your insurance even if your company continues to cover you, but you’re on 
their disability and you’re now down to 60% of your salary.  So, some people 
just let it go.  So, you know, there’s a lot of issues that come up after they’ve 
been in treatment for a little while and realize they can’t go to work.”     
Other key themes related to participants characteristics that emerged across staff 
interviews and meeting observations include: a desire to reach participants at earlier diagnosis 
stages, and the relationship between the UPMC organizational and operating structure and  
 68 
MOPP recruitment & reach.  MOPP staff believes that the low numbers of participants with 
prostate cancer is largely explained by the organizational and operating structure of UPMC in 
that the vast majority of prostate cancers are seen through a group of urologist specialists and, 
therefore, are not readily accessible for MOPP recruitment.  Additionally, Magee, one of the four 
participating sites, was described as conducting a great deal of research, which, due to policies to 
protect patients from heavy recruitment to various studies and pilot projects, limits the 
availability of Magee patients available for participation in MOPP.  Program staff also explained 
that McKeesport, another MOPP site, has a patient navigator program through an NCI radiation 
oncology grant.  Although the McKeesport navigator program functions very differently than 
MOPP—“the patient navigators there are actually like registrars”—that resource at McKeesport 
may affect their number of referrals to MOPP.  However, staff do report a good communication 
connection and “network” with the McKeesport site.   
These findings can facilitate program planning and comparison within the patient 
navigation movement.  Specifically, it encourages program planners to be alert to the diversity of 
seemingly homogeneous groups, and the detailed quantitative description of the patient 
population may help other organizations considering patient navigation models determine 
whether the MOPP approach is a good fit.  Additionally, findings suggests that patient navigation 
programs implemented within large health care systems will need to identify and develop plans 
for addressing the limitations that varied organizational and operating structures and policies 
within the larger system may place on participant recruitment and the related issue of program 
reach, which is discussed in detail in the following section. 
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3.3 PROGRAM REACH 
Reach refers to the absolute number, proportion, and representativeness (i.e., whether 
participants have characteristics that reflect those of the program’s target population) of 
individuals who participate in a program (Workgroup to Evaluate and Enhance the Reach and 
Dissemination of Health Promotion Interventions, 2004).  Reach is one of five dimensions in the 
RE-AIM framework, which was developed by Glasgow and colleagues to help better identify the 
translatability and public health impact of health promotion interventions (Glasgow, 2002).   
Using the online RE-AIM reach calculator, which is available for public use at www.re-
aim.org, the following reach measures were obtained: 
? % of target who respond to recruitment:  90.2 
? % of eligible who participate:  31.9 
? % of reach into target population 27.2 
? % excluded from the intervention:  5.6 
? % participation among eligible:  31.9 
As outlined in the methodology section, these reach-related measures are calculated based on the 
number of program participants who accepted a patient navigator.  Also, as indicated in 
quantitative data analysis summaries related to program services presented in the sections that 
follow, there are some program participants who declined the opportunity to be assigned a 
patient navigator, but received some form of assistance from the program.  It is worth noting that 
CCT eligibility and barriers assessments are conducted for all program participants (n=249).  
However, patients who accepted navigator services received ongoing support, individualized 
support, and follow-up by one of the program’s two patient navigators throughout their course of 
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cancer care.  Therefore, the “intervention” is defined as patient navigator acceptance in the reach 
assessment.   
Table 5 describes the characteristics of patients who accepted patient navigators (n=75) 
and in doing so provides important output data (see output #3 of the logic model in Appendix A) 
for program description, monitoring, and improvement planning.  Almost half of the patients 
who accept navigators are between 50-64 years of age.  Close to 80% of the program participants 
who accept navigators are female.  Among those who accept navigators, most entered MOPP 
upon case finding by the program social worker (28.0%) and referrals from UPMC social 
workers (21.3%).  Most patients with navigators (42.7%) entered the program with a stage IV 
cancer diagnosis.  Among program participants who accepted navigators, the two most common 
cancer diagnoses are breast (24.0%) and lung, non-small cell (21.3%).  The majority (89.3%) of 
navigated program participants receive care at the Hillman Cancer Center site.  Patients who 
accept navigators are mostly insured through Medicare Managed Care (33.3%) and Medicaid 
Managed Care (28.0%). 
Table 5. Characteristics for Program Participants Who Accepted Patient Navigators (n=75) 
Characteristic Count Percent 
Age Group 
<20 
20-49 
50-64 
65-74 
75+ 
Total 
 
1 
14 
36 
18 
6 
75 
1.3
18.7
48.0
24.0
8.0
100
Gender 
Female 
Male 
Total 
 
58 
17 
75 
77.3
22.7
100
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Characteristic Count Percent 
Referral Source 
Case Finding (MOPP Social Worker) 
CIRS 
Clinical Research Coordinator 
Collaborative Practice Nurse 
Community Agency 
Oncologist 
Other 
Other UPMC Site 
PEDC 
Self/Family/Friend 
Social Worker 
Surgeon 
Total 
 
21 
10 
9 
3 
2 
5 
1 
1 
1 
1 
16 
5 
75 
28.0
13.3
12.0
4.0
2.7
6.7
1.3
1.3
1.3
1.3
21.3
6.7
100
Cancer Stage 
I 
II 
III 
IV 
Screening 
Unable to Stage 
Total 
 
4 
11 
26 
32 
1 
1 
75 
5.3
14.7
34.7
42.7
1.3
1.3
100
Cancer Diagnosis 
no cancer diagnosis 
Acute Myeloid Leukemia, Adult 
Brain Tumor, Adult 
Breast Cancer 
Chronic Myelogenous Leukemia 
Colon Cancer 
Esophageal Cancer 
Head and Neck Cancer 
Hodgkin's Lymphoma, Adult 
Lung Cancer, Non-Small Cell 
Lung Cancer, Small Cell 
Lymphoma, Non-Hodgkin’s Adult 
Melanoma 
Multiple Myeloma/Plasma Cell Neoplasm 
Ovarian Epithelial Cancer 
Pancreatic Cancer 
Prostate Cancer 
Rectal Cancer 
Renal Cell (Kidney) 
Renal Pelvis and Ureter, Transitional Cell Cancer 
Sarcoma, Soft Tissue 
 
1 
1 
1 
18 
1 
7 
2 
6 
1 
16 
3 
1 
1 
2 
1 
5 
2 
3 
1 
1 
1 
1.3
1.3
1.3
24.0
1.3
9.3
2.7
8.0
1.3
21.3
4.0
1.3
1.3
2.7
1.3
6.7
2.7
4.0
1.3
1.3
1.3
Table 5 Continued 
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Characteristic Count Percent 
Total 75 100
Cancer Care Site 
Hillman 
Magee 
McKeesport 
Shadyside Hospital or Radiology Oncology 
Missing 
Total 
 
67 
1 
3 
1 
3 
75 
89.3
1.3
4.0
1.3
4.0
100
Insurance 
Commercial Indemnity Insurance 
Commercial Managed Care (HMO/PPO/POS) 
Medicaid Managed Care (HMO/PPO/POS) 
Medicaid/Public Assistance 
Medicare 
Medicare Managed Care (HMO/PPO/POS) 
Self Pay or No Insurance 
Missing 
Total 
 
1 
14 
21 
3 
2 
25 
8 
1 
75 
1.3
18.7
28.0
4.0
2.7
33.3
10.7
1.3
100
 
3.4 PROGRAM DELIVERY 
The third evaluation question examined the extent to which the MOPP program is being 
implemented as planned.  Document review, which included presentation slides, promotion 
cards, intake forms, provided valuable background related to program priorities and planned 
activities and outcomes.  Descriptive statistical analysis quantified the program’s progress to date 
on priority outputs.  Output data is particularly useful for assessing program implementation 
because they represent the tangible products of program activities (CDC, 2005).  Qualitative data 
collection (i.e., interviews with staff members and participants and meeting observation) and 
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analysis provided rich data on implementation achievements, elucidating implementations 
challenges, and identified key considerations for program improvement.   
Assessing patients’ barriers to cancer care and providing individualized solutions 
planning and assistance services, which in the case of some patients includes assigning a 
navigator, is the program’s foremost activity.  In working with program staff members to 
describe the program through logic modeling, staff insisted on graphically highlighting this 
activity to illustrate its significance (see Appendix A).  Similarly,  cancer clinical trial education 
and recruitment is a priority program activity as it is one of the main reasons UPMC and UPMC 
Cancer Centers’ invested in the pilot program—an investment that included significant gap funds 
intended to cover potential medical expenses for members of the target population receiving 
cancer care on a clinical trial.  The evaluation focused on measuring progress on outputs related 
to these two priority program activities (i.e., outputs #5-12).  The following tables and 
quantitative descriptions fill in output numbers. Whereas the qualitative data found at the end of 
this section provides valuable contextual information for the proper interpretation and informed 
utilization of quantitative data on program outputs. 
Outputs #5-7 focus on barriers assessment, identification, and the provision of 
individualized services to address barriers to care.  Program participants, excluding those 
designated CCT screen only, receive barrier assessments (n=235).  Although, data from 
interviews explains that assessments may be subjectively modified to minimize participant 
burden.  A total of 146 program participants identified at least one barrier to cancer care.  Table 6 
and Figure 1 present the numbers and types of barriers patients identified for themselves.  
Comorbidities were documented for 204 of the 235 program participants (excludes CCT screen 
only).  Table 7 and Figure 2 describe the burden of comorbidities among program participants.  
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Comorbidity data is based on medical record review and is collected by the program because it is 
a widely recognized barrier for participation in cancer clinical trials (EDICT, n.d.) and because it 
provides important context related to the other issues participants face in addition to their cancer 
care.  
Table 6. Participant-Identified Barriers to Care (n=235) 
Barrier* Count Percent 
Child Care 
Co-morbid Chronic Illness 
Elder Care 
Financial Problems 
Health Beliefs 
Housing 
Insurance 
Job Responsibilities 
Other 
Poor Support System 
Spiritual/Religious Beliefs 
Transportation 
None Identified 
6
33
5
38
4
7
57
5
19
5
1
51
89
2.6 
14.0 
2.1 
16.2 
1.7 
3.0 
24.3 
2.1 
8.1 
2.1 
.4 
21.7 
37.9 
* Patients may have identified more than one barrier 
 
 
 
 
 
 
 
 
 
Figure 1.  Total Number of Barriers Identified by Program Participants (n=235) 
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Figure 2.  Total Number of Comorbidities Among Program Participants (n=235) 
Table 7. Program Participant Comorbidites (n=235) 
Comorbidity* Count Percent 
Addiction 
Arthritis 
Asthma 
Coronary Artery Disease 
Other Cancer 
Chronic Obstructive Pulmonary Disease 
Dementia 
Diabetes 
Gastroesophageal Reflux Disease 
Gastrointestinal Condition 
Gout 
Hearing  
Hypercholeserolemia 
Hyperlipidemia 
Hypertension 
Kidney Disease 
Liver Disease 
Other 
Psychiatric 
Pulmonary 
Stroke 
Thyroid Disease 
Vision 
21
26
15
25
13
19
6
37
27
6
5
1
24
15
99
12
10
62
30
1
7
9
4
8.9
11.1
6.4
10.6
5.5
8.1
2.6
15.7
11.5
2.6
2.1
.4
10.2
6.4
42.1
5.1
4.3
26.4
12.8
.4
3.0
3.8
1.7
69
37
32
37 35
11 12
1 1
0
10
20
30
40
50
60
70
80
None One Two Three Four Five Six Seven Nine
Total Number of Comorbidities
Nu
m
be
r 
of
 P
ar
tic
ip
an
ts
 76 
Comorbidity* Count Percent 
None Identified  
Unknown 
31
38
13.2
16.2
* Patients may have more than one comorbidity 
As presented in the Introduction Section, 75 program participants accepted patient 
navigators.  However, at times, per the request of patients or the program social worker, 
navigators provided services for patients who declined the opportunity to work with a navigator.  
Since the program’s implementation, patient navigators have documented the provision of 
services for 78 patients, most of whom accepted navigators.  Patient navigators use the following 
codes to classify and record the services they provide:   
? Emotional support- providing an outlet for patients to share emotional responses and 
challenges related to their cancer diagnosis and care; providing encouragement 
throughout the care process. 
? Transportation- obtaining and delivering vouchers for transportation to and from 
cancer care appointments. 
? Check-in- contacting patients via phone or in person to assess satisfaction with, and 
progression through, cancer care treatment and to determine if patients have any new 
service needs.  
? Appointment reminder. 
? Informational or educational call or visit- providing patients with relevant information 
and literature from the Hillman library, or information about support groups and other 
services that are available through UPMC sites and community partners.  
? Other- may include introductory and follow-up calls to inform patients of MOPP 
program services.   
Table 7 Continued
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The number of patients receiving each service is presented in Table 8.  It’s important to 
note that one patient may both receive more than one service and receive a particular service on 
more than one occasion.  Additionally, the patient navigator services described in Table 8 do not 
include services provided by the program social worker; who provides barrier assessments for 
participants; works with the Cancer Control Specialist to inform participants about, and recruit 
them for, CCTs; assists patients in obtaining new or additional insurance coverage; and disperses 
cab vouchers to ensure that patients have transportation to their cancer care site.    
It is also important to clarify that the program maintains additional program logs and 
receipt records to ensure that transportation assistance provided by staff other than the navigators 
is accurately tracked.  Based on this additional transportation data, a total of 23 patients received 
cab vouchers through the program, and a total of 32 people received assistance accessing various 
transportation resources, including Older Persons Transportation (OPT), a shared-ride service 
sponsored by the Allegheny County Area Agency on Aging (ACAAA), and the Medical 
Assistance Transportation Program (MATP), which is  offered by the Allegheny County 
Department of Human Services.  In some cases, patients were eligible for transportation services 
like MATP, but were too ill at times to use those services.   
Table 8. Patient Navigator-Provided Services for Program Participants (n=78) 
Service* # of Participants Receiving Service Percent 
Emotional Support 
Transportation 
Check-in  
Appointment Reminder 
Info or Ed Call or Visit 
Other 
36
4
58
3
38
16
46.2 
5.1 
74.4 
3.8 
48.7 
20.5 
* Patients may receive more than one service and most receive a service more than one time. 
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Outputs #8 & 9 focus on participant insurance status and services.  Type of insurance 
coverage is identified for all program participants, except those who are CCT screen only.  One 
of the social worker’s responsibilities is to assist all patients with no or inadequate insurance in 
obtaining coverage either through medical assistance or UPMC financial assistance.  Because 
this insurance service is standard practice, as indicated by staff’s description of the intake 
process and program intake forms, the provision of the service is not routinely recorded.  The 
program database documents that at least 10 patients entered the program with a self pay or no 
insurance status and received assistance from the program to successfully enroll in Medicaid 
Managed Care or Medicaid/Public Assistance plans.  However, given the standard program 
practice of assisting all uninsured or underinsured patients with obtaining adequate health care 
coverage, and the fact that 41 patients of the 235 participants (excluding CCT screen only) are 
identified as falling into this category, the number of participants receiving insurance services 
through MOPP is likely much higher.  Based on staff interviews and meeting observations, it is 
clear that staff realize the need to tighten participant records and strengthen the program database 
to better capture key program data, such as number of patients insured or receiving expanded 
coverage as a result of assistance provided through the MOPP program.  This data is particularly 
useful for estimating some aspects of the program’s cost benefits, which is often a major factor 
in an organization’s decision to maintain and expand initiatives. 
Outputs #10-12 focus on CCT education and recruitment.  As with insurance assistance, 
it is standard program practice to inform all program participants about cancer clinical trials.  
However, data related to CCT is more easily and routinely recorded and tracked via fields in the 
MOPP database.  Tables 9 and 10 (see page 116) outline the proportion of total program 
 79 
participants (n=249, includes CCT screen only) who are enrolled in CCTs and reasons for non-
enrollment among participants.   
Cancer clinical trial participation rates are one of the program highlights shared at the 
African American Cancer Care Partnership meetings, as well as through presentations to UPMC 
Cancer Centers’ administration.  It was noted through staff and AACCP meeting observation that 
discussion of the near 11% CCT enrollment rate virtually always included acknowledgement that 
many patients were ineligible for CCT for medical reasons, including comorbidities and late 
stage cancer diagnosis.  During evaluation planning and implementation, the value of refining 
the denominator to get a more accurate CCT enrollment rate was discussed with staff.  In 
identifying the number of participants who are actually eligible for CCTs, the program would be 
able to provide more detailed and informative CCT participation descriptions to community 
partners, administration and policy makers, and national agencies and organizations that are 
interested in learning more about MOPP.   
The number of participants eligible for CCTs (n=167) was defined as those patients who 
were not documented as medically ineligible (n=52) or non-cancer (n=30).  In calculating the 
CCTT participation rate as the proportion of program participants enrolled in cancer clinical 
trials among those who are eligible, MOPP has a 16.2% CCT enrollment rate.  Shortly after 
reviewing the evaluation findings presented in this dissertation from the descriptive statistical 
analysis of CCT data, program staff worked to further investigate the issue of CCT eligibility 
among their participants.  Based on eligibility criteria for current UPMC trials, staff reviewed 
program and medical record records to determine whether each patient in the database (n=250 at 
the time of this additional assessment) was eligible to participate in a CCT.  Sixty (24%) of the 
250 MOPP participants met eligibility criteria for available trials.  Among the 60 participants 
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who were eligible, 31 were enrolled in a trial.  The program’s additional assessment of CCT 
eligibility indicates that, when excluding ineligible patients, there is a 51.6% CCT participation 
rate among MOPP participants.  The second article in this dissertation provides additional 
descriptive statistics on CCT enrollment within MOPP and reviews challenges related to 
increasing CCT participation in MOPP and nationally.  
As expected and described in the descriptive statistical summaries on program outputs 
presented throughout this section, qualitative data provided valuable information on the context 
within which program activities are being carried out.  This context aided in the proper 
interpretation of quantitative analysis.  In addition, qualitative data helped to identify 
implementation achievements and concerns beyond what was possible through descriptive 
statistical analysis of the program database.  Specifically, three broad themes dominated 
discussion of program implementation (the focus of evaluation question #3) in both staff 
interviews and meeting observations: time, money, and momentum.  These themes are described 
in more detail below. 
Time, more specifically the realization that initiating and successfully conducting many 
of the program activities would require more time than initially anticipated, was a prominent 
theme in discussions of program implementation progress.  For example, time was presented as a 
major factor leading to patients’ acceptance of patient navigators and other MOPP services: 
“…we can’t just jump in there and expect people to welcome us.  We have to 
get to know them, we have to let them know that they can trust us…you tread 
along in a very careful and cautious way.” 
Similarly, time, specifically maintaining MOPP promotion and outreach efforts and 
developing a solid program reputation over time, is identified as a key factor for building a 
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strong referral base among physicians and clinics within the UPMC system and surrounding 
service communities: 
“I think they’d hoped to get more referrals from like primary care doctors, and 
we…really haven’t had that….  I would say the process by which we get 
referrals has been a little bit rocky, and I think we’re still working on that, and 
I think that we, over time, have made it smoother just by [having] us more 
integrated into all the services that are already at the Hillman—just have 
[to]continue to have people know who we are and what we do.” 
“…I think it’s [MOPP] impacted a number of different physicians or clinics—
I think it could do more.  In my opinion, I think it’s because it just takes time.  
We routinely go and visit different PCPs or clinics, etc., and unless, I think, 
they have a bite initially—like there’s really a patient there within the next 
week or so, they probably forget about it.  But once they use it, then it’s on 
their minds.”  
Lastly, staff generally acknowledged that more time than originally anticipated was 
required for two major program components:  1) completion of participant barriers and needs 
assessments, 2) tracking participants and facilitating program monitoring, reporting and 
improvement through the use of a database.  With one respect to time, barriers and needs 
assessments, which are conducted at intake, were sometimes modified and shortened to minimize 
patient burden: 
[The program] had planned to do like a longer assessment on each patient, but 
I think that some times that works out, and sometimes it’s really too 
intrusive.” 
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While a converse issue of time was the significant amount of time it sometimes took to gather 
the information (e.g., insurance coverage details) necessary to address patients’ individual needs 
and to help patients who had a complex set of needs.   
The amount of time required to build a useful and effective program database has far 
exceeded program projections and has presented challenges for efficient program monitoring and 
program reporting: 
“…when you try to build a database…it becomes very cumbersome.  It seems 
like you never get to where you want to be until you’re almost finished with 
the project….  I think in the end we will probable have a good database, but it 
has been so cumbersome….” 
It is standard practice to build a database for projects within the UPMC system, partly to ensure 
compliance with HIPAA requirements related to the protection of patients’ health information.  
Based on information shared during observed meetings between program staff and the database 
administrator, the database accessed and used by program staff is primarily a Microsoft Access 
interface, and so staff have no access to the raw program data.  Additionally, the interface lacks 
some features (e.g., error checks for date fields and links between administrator-assigned patient 
identification numbers and database-assigned identification numbers) that would facilitate 
accurate data entry and efficient progress reporting.  Simple program reports (i.e., frequency 
reports on various database fields) are generated by the program administrator and provided at 
the program’s request.  However, this limits the program’s ability to monitor the quality and 
accuracy of data collection.  These challenges and resulting data limitations are reflected 
throughout the summaries of descriptive statistical analyses of program data provided in this 
dissertation.  Program staff note improvements in the database, but also maintain that a great deal 
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more work needs to be done to create a database that effectively supports program practice, 
evaluation and reporting.   
Money was another major implementation-related theme identified through interviews 
and meeting observation.  Specifically, that “it was anticipated that the money [$750,000 set 
aside to cover gaps in coverage for patients receiving cancer care on a clinical trial] would be 
used overnight”, when in fact only about $600 in gap funds have been used since program 
implementation.  More money, about $7,000 worth of cab vouchers, has been spent meeting 
participants’ transportation needs.   
Finally, momentum was a major theme that came out at program meetings and staff 
interviews, in the sense that referrals from outside of the UPMC system and participation from 
patients at sites other than Hillman have been lower than anticipated.  These lower rates of 
referrals and site participation are reflected in the previously reported descriptive statistical 
summaries of program data.  Certainly, this issue of momentum is related to program staff’s 
notion that it takes time to build effective referral relationships for the program.    
3.5 PROGRESS TOWARD SHORT-TERM OUTCOMES 
In general, program staff believes the program is making progress toward short-term 
outcomes, and, in so far as accomplishment of activities are expected to lead to the desired 
outcomes, quantitative data analysis supports this claim.  Short-term outcomes for  participants 
include increased knowledge and resources for overcoming barriers to cancer care; increased 
knowledge of CCT opportunities and benefits; increased social support; and improved financial 
means for health care.  While there are no standard measures (e.g., social support scale) used to 
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measure these increases in patients’ knowledge or social support status prior to and post MOPP 
intervention, several data points recorded in the program database serve as reasonable proxy 
measures for these short-term outcomes.  For example, program records show that all 
participants are contacted by the program and informed of available MOPP services, which 
include patient navigators. In this sense, MOPP is contributing to patients’ knowledge about 
available resources for overcoming barriers to cancer care.  Additionally, the program database 
tracks the social support services patient navigators provide to their assigned patients, and the 
social worker works to assist all uninsured or underinsured program participants obtain adequate 
insurance coverage.  Documentation of these services, which was presented in previous sections, 
arguably reflect progress on short-term outcomes to increase patients’ social support and to 
improve patients’ financial means for health care.  
Moreover, findings from participant interviews also suggest that the program is making 
progress on its short-term outcomes for participants.  As outlined in Table 3, interviewees 
represent a heterogeneous sample of program participants (i.e., age, gender, cancer diagnosis and 
stage, acceptance of navigator services).  Even with this diversity, there was a great deal of 
similarity in interview responses.  Each interviewee readily identified ways in which they 
benefited from working with a patient navigator and/or participation in MOPP, which included 
receipt of transportation assistance, social support, and financial assistance to cover care and 
prescriptions: 
“She helped me, you know, with the vouchers to get back and forth, when I 
needed them, when I had…transportation problems….she helped me get 
this…patient aid thing where I was getting a gift card every month, and I 
appreciated that.” 
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“She sits down, and she talks with me, and that helps a lot.” 
“…getting the prescription, …getting in touch with the people in the study 
program [CCT], you know she helped me with getting into that.” 
Short-term outcomes for MOPP participating centers include:  increased knowledge of 
barriers to cancer care and CCT participation and increased awareness of effective strategies for 
addressing barriers.  Quantitative data analysis (see Table 10 on page 116) indicates that the 
program is achieving these short-term outcomes.  A program staff member explains the 
significance of success on these outcomes: 
“…what it [MOPP] is doing for the first time is clearly demonstrating what 
are the barriers as to why they don’t enter trials, which is totally different than 
what people were sort of guessing because everyone, at least here, was saying 
it was money, or it’s Tuskegee.  That’s not what we’re finding, we’re finding 
the number of comorbidities, the number of other chronic diseases, the late 
stage diagnoses is what is inhibiting them [large proportion of newly 
diagnosed African American patients receiving cancer care at participating 
UPMC sites] from entry on the trial, which allows us to make some decisions 
internally:  Do we write trials that can address patients that have comorbidities 
of three or better?  Do we, you know, really maybe do some further research 
into does it really make a difference if you have certain comorbidities in 
regards to trials already here?  …it really gives us a clear picture of what the 
issues are.” 
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3.6 UNINTENDED OR UNEXPECTED OUTCOMES 
For the purposes of this evaluation, unintended or unexpected outcomes were defined as those 
that were not initially planned for or anticipated, as documented in program documents and the 
logic model; or those outcomes the program staff expresses being insufficiently prepared for, or 
surprised by.  Unintended or unexpected outcomes can include positive and negative 
consequences.  Three significant unintended or unexpected outcomes emerged from the 
qualitative data from staff interviews and meeting observations.  Interestingly, staff identified 
unintended or unexpected outcomes at various intervention impact, or ecological levels:  patient 
(i.e., individual), patient-navigator relationship (i.e., interpersonal), and the program (i.e., 
institutional/organizational). 
Related to the patients, staff reported seeing more addiction or substance abuse problems 
than expected, and noting the absence of a drug counselor on staff at Hillman, which is the 
cancer care site for the majority of the program participants, staff report that it has been 
challenging, and requires significant time and staff resources, to assist patients with substance 
abuse problems with their cancer care: 
“There are a little more drug problems than—I mean don’t get me wrong, 
there’s not a ton of them, but there is a significant little subset, I think….  So, 
I was a little bit surprised by that…..we have patients that come from those 
…backgrounds—if you want to treat them, we do need a lot more intensive 
contact, or they’re just going to get lost.”   
“One thing I’ve found, which I was enlightened, but I thought that if 
somebody was diagnosed with cancer, behaviors changed—like if you smoke, 
if you drank, all that would change.  What I found out was that doesn’t 
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happen.  So, those are other things that people content with because those 
types of appetites, they take a greater role when you come in here taking 
treatment….  So, I was just really surprised about that.” 
Descriptive statistical analysis of program data identified the percentage of medically 
documented addiction and substance abuse problems among MOPP program participants.  The 
“little subset” described above amounts to 21 patients, or 8.9% of program participants (n=235, 
excludes CCT screen only patients).  However, these numbers may underrepresent the issue 
because they may not capture non-illicit drug addictions, such as alcohol or nicotine additions, as 
the substance abuse literature notes inadequate diagnosis and treatment of these conditions by 
physicians (Klamer & Miller, 1997).    
Another unintended or unexpected outcome identified by staff was the impact, both 
positive and burdensome, that the patient navigator-patient relationship has had on navigators.  
Staff recognize the potential closeness of navigator-patient relationships:  “I’ve seen some 
patients get really attached [to the navigators].”  However, the closeness of the navigator-patient 
relationship was also described as the source of some emotional burden as many patients are 
very sick and may die from cancer while under their navigators’ care: 
“You meet the patient, you get to know the patient…okay, so all of that is an 
emotional impact on the individual.  You know, so everybody’s different, just 
they have to be, and I don’t know how they can be,  prepared for the 
emotional impact that you might encounter.  Patients die…sadly…you may 
follow somebody a year, or you may follow somebody for six months, or if 
you meet somebody today—‘well, the doctor gave me six months to live’—
and in seven or eight months, they’re gone.” 
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“You see these people, and you know they are sick.  And, unfortunately, a lot 
of the patients we get are already stage III or stage IV…when we’re 
introduced to them, we know that there’s a good chance they’re going to die.  
That’s a definite downside because you get attached to them…and then you 
start seeing that rapid decline in their health—that’s very disturbing, but that’s 
the nature of the beast.” 
Indeed, the majority of patients navigated (77%), and, for that matter, the majority of 
MOPP program participants (58%) have a stage III or IV cancer diagnosis, which, given the fact 
that treatment is often more effective when cancer is detected early (DHHS, Office of Minority 
Health, 2005), suggests that many of these patients face bleak prognoses, depending, of course, 
on other relevant factors like cancer type and location.  Navigators without a medical 
background or with limited experience with terminal chronic disease may be particularly affected 
by the sickness and death they must confront in their work.   
Finally, at the program level, the growth of the program, and consequently the expansion 
of program focus and activities, is generally considered an unexpected outcome among program 
staff:   
“It’s grown into more than what I thought.  I really, I didn’t anticipate that 
we’d have this many participants….  Lots of things are happening because 
we’re becoming known because of the program [MOPP], so we’re being 
asked to do this, do we do that, would we help with this.” 
“We’ve had every diagnosis come.” 
“There are some referrals…from the Prevention and Early Detection Clinic 
and from some of the outside health clinics, and they’re not cancer patients 
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but they’re patients that need a work-up.  So they’re getting referred in to [the 
program, and we’re] getting them in for screening, helping them with their 
insurance.  So I think that what we need to look at is the other piece of what’s 
happening to them.” 
These descriptions of program growth and expansion (e.g., providing services for patients with 
all cancers, and even those who are in the process of receiving diagnostic work-ups) are 
consistent with the descriptive statistical analysis of program participants presented in Table 4.  
However, the qualitative data provides valuable information regarding the ways in which shifts 
in program numbers have affected program practices and delivery and monitoring needs.  
3.7 PROGRAM COSTS 
Cost categories for the Minority Outreach Pilot Program were developed based on the patient 
navigation literature and MOPP’s unique set of program activities, as described in the program 
logic model.  Informal meetings were held with the Program Director to review internal expense 
logs (e.g., gap funds and cab voucher logs) and to identify program expenses related to the 
following major budget categories: 
? One-time or up-front costs:  Includes expenses related to research and program 
development, and the costs for the development of the program database.  
? Recurring Costs:  Which include personnel salary, staff training, program marketing 
and outreach, information technology support, and the provision of program services 
(i.e., primarily transportation costs for MOPP). 
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It is important to note that many common expenses related to program operation, such as office 
space and utilities, office supplies, landline and mobile telephones, are not directly absorbed by 
the program—they are covered by virtue of the pilot program’s placement within the larger 
UPMC Cancer Center’s system.  In this sense, they can be considered in-kind contributions to 
the pilot program from the Center.  Additionally, use of gap funds, which are designated to 
address gaps in coverage for cancer care on a clinical trial, are monitored as a separate 
component of the program budget.  Almost $600 of gap funds have been used by the program 
since its initiation.   
Start-up costs for the Minority Outreach Pilot Program amounted to $13,500.  This one-
time expense consisted of $7,500 for research, program development and initial program 
promotion material and events and $6,000 for the development of the MOPP database.  Due to 
the sensitive and confidential nature of personnel salaries, recurring costs must be presented as 
the total cost per year for all of the items that fall under this category as listed above.  Recurring 
costs total approximately $95,000 per year.  This is a relatively reasonable cost considering the 
program serves roughly 100 new patients a year and has reached a program population of 249 (as 
of April 2008).   
MOPP’s annual program budget can be viewed as fairly low considering the grant funds 
(a total of $19.5 million over 5 years) NCI recently awarded to 8 research institutions under the 
Patient Navigation Research Program (PNRP); the American Cancer Society provided additional 
dollars to fund a ninth site (NCI, 2005).  An exact amount of the individual site awards could not 
be found. But, assuming equitable distribution for the sake of comparison, a single program 
could be funded at $487,500 a year—this estimate is consistent with the .8 million per year 
ceiling for applicants listed in the Patient Navigation Research Program RFA (NCI, 2004).  As of 
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June 30, 2007, 806 patients across the PNRP nine sites representing four cancers (breast, 
cervical, colorectal, and prostate) have received navigators and another 429 received program 
services that did not include a navigator (Greene et al., 2007).   If the PNRP were operational 
within one year after the program start date (anticipated as 7/2005 in the RFA) as outlined in the 
funding announcement, these numbers represent about a year’s worth of program data.  Again, 
assigning an equal distribution of patients for the purposes of comparison, an NCI PNRP site 
could potentially be spending up to $487, 500 a year to serve about 137 patients.  Although a 
PNRP site’s annual budget undoubtedly includes costs related to conducting rigorous research 
and evaluation of the intervention.    
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4.1 ABSTRACT 
Introduction:  An evaluation was conducted to systematically collect, analyze, and share 
information about the context, activities, and early impacts of the University of Pittsburgh 
Medical Center Cancer Centers’ patient navigation initiative, the Minority Outreach Pilot 
Program (MOPP).   
Methods:  The Centers for Disease Control and Prevention Framework for Program Evaluation 
and the RE-AIM framework informed and guided evaluation activities.  The evaluation 
employed a case study design that mixed qualitative (e.g., program document review and 
interviews) and quantitative (e.g., descriptive statistical analysis of program database) methods.     
Results:  From program launch in March 2006 to the end-date for evaluation data collection 
activities (April 2008), MOPP served a total of 249 patients, among whom 146 experienced at 
least one barrier to cancer care.  Common patient-identified barriers included:  no or limited 
insurance, transportation, and co-morbid chronic illness.  During this same period, a total of 75 
patients worked with navigators and received services from them, including emotional support 
(e.g., accompanying patients to treatment appointments) and transportation assistance.  
Ultimately, 31 program participants enrolled in cancer clinical trials, and reasons for non 
enrollment were documented for all others.  Common reasons for non-enrollment included 
medical ineligibility and choice of other treatment by medical doctor.  A key program 
implementation challenge identified in the evaluation was the significant amount of time 
required to develop the program database.  Additional issues emerged in the evaluation that have 
not been found in the literature, such as the difficulty of serving patients with a complex, 
interrelated set of cancer care barriers and substance abuse problems.   
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Conclusions:  Evaluation findings indicate that MOPP is largely being implemented and is 
providing services as planned, except for the minimal expenditure of cancer care funds.  
Evaluation activities and findings facilitated program improvement, including database 
refinement. 
4.2 INTRODUCTION 
A mixed-methods evaluation was conducted to systematically collect, analyze, interpret and 
share information about the context, activities, and early impacts of the University of Pittsburgh 
Medical Center (UPMC) Cancer Centers’ Minority Outreach Pilot Program (MOPP).  MOPP is a 
patient navigator program that works to ensure access to the latest innovations in cancer 
treatment, regardless of financial means, for newly diagnosed African American cancer patients 
seeking care at one of four UPMC medical centers.  UPMC and UPMC Cancer Centers 
implemented the Minority Outreach Pilot Program in March 2006 with input from the African 
American Cancer Care Partnership (AACCP)—a task force of representatives from the 
Pittsburgh community, local health care centers, academic institutions, and community 
organizations working to facilitate collaboration among, and guide and coordinate the efforts of, 
various groups whose goals are to improve the health of African Americans.  The navigator 
program represents one of UPMC Cancer Centers’ efforts to address racial and ethnic disparities 
in cancer care. 
C-Change, a national organization comprised of the nation’s key cancer leaders from 
government, business, and non-profit sectors, defines cancer patient navigation as follows: 
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Patient navigation in cancer care refers to individualized assistance offered to 
patients, families, and caregivers to help overcome health care system barriers 
and facilitate timely access to quality medical and psychosocial care from pre-
diagnosis through all phases of the cancer experience. Navigation services and 
programs should be provided by culturally competent professional or non-
professional persons in a variety of medical, organizational, advocacy, or 
community settings. The type of navigation services will depend upon the 
particular type, severity, and/or complexity of the identified barriers (C-
Change, 2005).  
 Strategies for addressing inequalities in cancer care, such as patient navigation, are greatly 
needed as critical racial/ethnic and socioeconomic cancer burden disparities persist in the United 
States (Dohan & Schrag, 2005).  For all cancer sites combined, African Americans are more 
likely to develop and die from cancer than persons of any other racial or ethnic group, and they 
are also at greater risk of dying of the four most common types of cancer (lung, breast, colon, 
and prostate cancer) than any other minority group (American Cancer Society [ACS], 2005).   
Underserved populations face a number of barriers that impede timely quality cancer care 
beyond  being uninsured or underinsured, including:  cultural orientations and differences that 
may contribute to lack of trust in medical systems or difficulties in negotiating relationships with 
health care providers and organizations; and logistical barriers, such as lack of transportation or 
child care, inconvenient clinic schedules, rural residence and distance from health care centers 
(Dohan & Schrag, 2005; Fowler, Steakley, Garcia, Kwok. & Bennet, 2006).  Such barriers can 
be placed within a larger context of the “complex and overlapping interplay of poverty, culture, 
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and social injustice” in the United States, which Freemen posits “underscore the challenge of 
reducing cancer disparities (2004, p. 44) 
In addition to cancer burden disparities, significant disparities exist in cancer clinical trial 
participation.  Participation in cancer clinical trials (CCT) helps researchers make significant 
advances in the fight against cancer and provides patients with access to state-of-the-art 
treatments (C-Change, n.d.).  An estimated 1.2 million Americans will receive a diagnosis of 
cancer this year, but only 3-5% of these new cancer patients will participate in a cancer clinical 
trial (C-Change), and this participation rate is even lower among minority groups and women 
(Baquet, Commiskey, Daniel Mullins, & Mishra, 2006; Bolen et al., 2006; Ford et al., 2005; 
Sheppard et al., 2005).   
The literature identifies several barriers and facilitators of participation in cancer clinical 
trials, including patient and provider knowledge, attitudes and beliefs; access; religious and 
cultural beliefs; and strict inclusion and exclusion eligibility criteria for trials (Bruner, Jones, 
Buchanan, & Russo, 2006; Christian & Trimble, 2003; Comis, Miller, Aldige, Krebs, & Stoval, 
2003; Ford et al., 2005).  It is widely assumed that racial and ethnic disparities in cancer clinical 
trial participation are the result of unwillingness on the part of minorities to participate in health 
research; however, there is little evidence to support this claim (Wendler et al., 2006; Trauth et 
al., 2005).  In fact, some studies suggest that the primary challenge with CCT recruitment and 
accrual is not the attitudes of patients or their unwillingness to participate, but rather the limited 
availability of appropriate trials and the disqualification of large numbers of patients due to 
comorbidities, insurance coverage issues, or even transportation barriers (Comis et al., 2003).   
In an effort to help patients overcome myriad cancer care barriers, the nation’s first 
patient navigator program was implemented in 1990 by Freeman and colleagues at Harlem 
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Hospital in New York City (Fowler et al., 2006; Freeman 2006).  The initial positive findings 
from the early navigator model, along with the significant need for interventions that are 
effective in reducing cancer care disparities, have led to widespread implementation of cancer 
patient navigation across the country (Vargas et. al, 2008).  Despite its popularity and 
widespread use, there is limited study of patient navigation in the peer-reviewed literature 
(Vargas et al, 2008).  However, patient navigation is receiving a great deal of attention at the 
federal government level, and efforts, such as the National Cancer Institutes’ Patient Navigation 
Research Program (NCI, 2005), are underway to address the lack of sufficiently rigorous 
research on the true effects of patient navigator programs.  Of course, hundreds of patient 
navigator programs have already been established in the world of public health practice (Dohan 
& Schrag, 2005; Hede, 2006).  Hence, timely and practical program evaluation is needed to help 
guide and support practitioners’ efforts to address cancer care needs and disparities in their 
communities through navigator programs. 
The mixed methods evaluation of the UPMC Cancer Centers’ Minority Outreach Pilot 
Program was designed to accomplish two broad goals:  1) to facilitate enhancements in MOPP 
implementation, expansion, and ongoing monitoring and evaluation; and 2) to contribute to the 
growing national evidence base for cancer navigation by illuminating navigator programs’ real-
world contexts and experiences.  The Centers for Disease Control and Prevention Framework for 
Program Evaluation in Public Health and the RE-AIM framework were integrated and applied to 
help achieve these evaluation goals. 
Cancer patient navigator programs are complex and comprehensive by the nature of both 
the problems they seek to address and the fragmented system they operate within; thus, 
evaluations of these interventions, particularly within the context of limited resources can be 
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challenging.  The CDC framework created a process (Engage Stakeholder, Describe the 
Program, Focus the Evaluation Design, Gather Credible Evidence, Justify Conclusions, and 
Ensure Use and Share Lessons Learned) and established standards (Utility, Feasibility, Propriety, 
and Accuracy)  that organized the evaluation of a multifaceted, broad intervention; thereby, 
helping to ensure that a sound, thorough evaluation was conducted (CDC 2005, 1999).  Where 
CDC provided a valuable organizational framework for the complex evaluation task at hand, 
dimensions of the RE-AIM framework (Reach, Effectiveness, Adoption, Implementation, and 
Maintenance) helped to achieve the second evaluation goal by calling the evaluator’s attention to 
issues that are relevant for public health practice and translation (Glasgow, Klesges, 
Dzewaltowski, Estabrooks & Vogt, 2006, p.688).     
4.3 METHODS 
The following section describes both the evaluation process and methods, in an effort to share an 
approach that was found to be particularly useful and effective for evaluating a complex cancer 
patient navigator program within the context of real-world program practice and constraints. 
Step 1:  Engage Stakeholders 
Several steps were taken to ensure that key stakeholders were actively engaged 
throughout the evaluation process.  The MOPP evaluation was a dissertation project, so the 
MOPP Program Director was included on the dissertation committee, which informs and 
approves all dissertation activities.  Additionally, prior to initiating the evaluation, planning 
meetings were held with program staff to learn about evaluation needs and priorities.  Weekly 
program staff and three monthly AACCP meetings were attended throughout the evaluation 
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period (January-May 2008) to develop a better understanding of program context and operations, 
share and receive feedback on evaluation progress reports, and to facilitate utilization of 
evaluation findings.   
Step 2:  Describe the Program 
A draft description of the program theory, which was depicted graphically in a logic 
model, was developed based on a review of program documents.  Then, working meetings were 
held with staff to review and revise the model.  Any suggested modifications were discussed and 
refined through group consensus.  The MOPP logic model (Appendix A) was a useful and 
immediate product of the program evaluation—the Program Director expressed plans for using 
the model in presentations for administrators and other cancer care partners and stakeholders.   
Step 3:  Focus the Design 
A case study design was chosen for the MOPP evaluation.  Evaluation design, as well as 
evaluation questions, were determined based on a number of factors, including:  the complexity 
of the intervention (Goodman, 2001), the early stage of the program, stakeholder evaluation 
needs, and CDC Framework standards.  Case studies give an in-depth picture of the implemented 
program, its organizational context, and the broader environment by integrating qualitative and 
quantitative information from a variety of sources (Love, 2004).  Table 2 provides an overview 
of the evaluation design.   
Step 4:  Gather Credible Evidence  
The following methods and data sources were used to address the evaluation questions:  
descriptive statistical analysis of de-identified, raw data from the MOPP database, which 
included demographic, diagnostic and service variables; review of program documents, including 
outreach material and presentations; and qualitative analysis (i.e., close reading, focused-coding, 
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and theme identification) of transcripts from semi-structured staff and patient interviews and 
field notes from meeting observations.  The data from the program database that was analyzed 
for this evaluation covered the period from program initiation (March 2006) to April 2008, 
which was the end date for evaluation data collection. 
All five program staff members (1 Director, 1 Social Worker, 1 Cancer Control 
Specialists, and 2 Navigators) were interviewed to help address evaluation questions #1-5.  In 
addition, phone interviews were conducted with a small sample of program participants to help 
address evaluation question #4.  Participant interviews focused on the impact that the program 
has had on patients and their satisfaction with services received.  Staff and patient interview 
questions are listed in Appendix C.  Seven program participant interviewees were selected 
through heterogeneity sampling based on the following characteristics that are especially 
relevant to the MOPP mission and services:  type of cancer; referral source; acceptance, delayed 
acceptance, or decline of patient navigator services; and CCT participation.  Heterogeneity 
sampling was used to yield both:  1) high quality, detailed description for single patients, which 
is valuable for documenting the uniqueness of patients served by the program, and 2) important 
shared themes that cut across patients and establish their significance from having emerged from 
a heterogeneous sample (Patton, 2002).  Program participants received gift card incentives for 
their participation.  The evaluation research was approved by the University of Pittsburgh 
Institutional Review Board. 
 
 
 101 
4.4 RESULTS 
Step 5:  Justify Conclusions 
The MOPP evaluation provided a wealth of data. The following summary of findings 
focuses on those issues the authors believed to be most relevant to practitioners interested in 
navigator program development or improvement, as well as key issues that emerged from the 
data that have not previously been reported in the patient navigation literature.     
Participant Characteristics 
   A total of 249 patients participated in the MOPP program.  About 30% of MOPP’s 249 
program participants are between 20 and 49 years of age, while the majority of program 
participants fall within the 50-64 age group.  Almost 60% of participants are female.  Most 
(26.1%) of the program participants were identified through case finding, which involves the 
MOPP social worker regularly reviewing tailored system billing reports to identify patients who 
fall within the program target population.  However, a fairly large number of referrals are 
received from UPMC social workers (18.5%).  Seventy-five patients are working with patient 
navigators.  Most patients (37.3%) entered the program with a stage IV cancer diagnosis.  
Among program participants, the four most common cancer diagnoses are breast (17.7%); lung, 
non-small cell (15.3%); colon (7.2%); and head and neck (6.4%).  The majority of program 
participants (73.5%) receive care at the Hillman Cancer Center site.  Forty-one (16.5%) patients 
entered the program with a self-pay or uninsured status, while 27.3% were insured through 
Medicare Managed Care and 22.1% were insured through Medicaid Managed Care. 
Descriptions of program participants obtained from staff interviews were aligned with the 
descriptive statistical data presented above, but also emphasized program participants’ diversity:   
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“…all their needs are different.  They come from all walks of life….there’s no set mold that our 
patients are coming from.” 
Program Reach 
The REACH calculator, which is available on the RE-AIM website (www.re-aim.org) 
was used to calculate the following measures:  percent of target population who responded to 
recruitment (90.2); percent of eligible who participate (31.9); percent of reach into target 
population (27.2); and percent excluded from the intervention (5.6).  While these reach-related 
measures are calculated based on the number of program participants who accepted patient 
navigators (75), it is important to note that patients do not have to accept a navigator to receive 
assistance from the MOPP program.  The total number of MOPP participants (249) includes the 
75 patients who accepted navigators and 174 who did not.   
Implementation Progress  
Assessing patients’ barriers to cancer care and providing them with individualized 
solutions and services to help reduce or eliminate those barriers is MOPP’s chief program 
activity.  Virtually all participants, excluding a small number (n=14) who receive care at non-
participating MOPP sites and are designated as “CCT screen only”, receive barrier assessments.  
A total of 146 program participants identified at least one barrier to cancer care.  Barriers most 
commonly identified by patients included:  no or limited insurance (24.3%), transportation 
(21.7%), financial problems (16.2%), and co-morbid chronic illness (14.0%).  Program records 
indicated that patient navigators provided services to 78 participants, including a few patients 
who declined the opportunity to work with a navigator, but requested and received some 
assistance from navigators at some point during their care.  Patient navigator services included 
the provision of emotional support (e.g., accompanying patients to treatment appointment), 
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transportation assistance, and appointment reminders.  In addition to the patient navigator 
services provided, the program social worker assists all program participants who are classified 
as self pay or uninsured with obtaining adequate insurance coverage.  The social worker also 
provides transportation assistance to program participants (n=32), and other related social 
services.   
Cancer clinical trial education and recruitment is also a major program activity.  During 
the period covered by this evaluation (March 2006-April 2008), twenty-seven program 
participants enrolled in cancer clinical trials, and reasons for non enrollment were identified and 
documented for all program participants who were not enrolled in trials (n=222).  Top reasons 
for non-enrollment included:  medical ineligibility (23.4%) and choice of other treatment by 
medical doctor (23.9%).  Excluding non-cancer and medically ineligible patients, MOPP has a 
16.2% CCT participation rate, which is a significant achievement considering the 3-5% national 
rate for CCT participation among new cancer patients (C-Change, n.d.).  Only 2.7% of program 
participant actually refused to participate in a trial.  It is worth noting that, shortly after reviewing 
these evaluation findings, program staff worked to further investigate the issue of CCT eligibility 
among their participants.  Based on eligibility criteria for current UPMC trials, staff reviewed 
program and medical record records to determine whether each patient in the database (n=250 at 
the time of this additional assessment) was eligible to participate in a CCT.  Among the 60 
MOPP participants who met eligibility criteria for available trials, 31 were enrolled in a trial.  
The program’s additional assessment of CCT eligibility indicates that, when excluding ineligible 
patients, there is a 51.6% CCT participation rate among MOPP participants! 
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Costs 
It is important to note that many expenses commonly related to program operation, such 
as office space and utilities, are not directly absorbed by the program as they are covered by 
virtue of the pilot program’s placement within the larger UPMC Cancer Center’s system.  In this 
sense, they may be considered as in-kind contributions to the program from the Center.  
Additionally, use of $750,000 in gap funds, which are provided by UPMC to address gaps in 
coverage for cancer care on a clinical trial, are monitored separately from the program budget.  
Only about $600 in gap funds have been used by the program since its initiation.   
Start-up costs for the Minority Outreach Pilot Program amounted to $13,500.  This one-
time expense included $7,500 for research, program development and initial program promotion 
material and events costs, as well as $6,000 for the development of the MOPP database.  Due to 
the sensitive and confidential nature of personnel salaries, recurring costs (i.e., personnel salary, 
staff training, program marketing and outreach, information technology support, and the 
provision of program services) are presented in total.  These expenses total approximately 
$95,000 per year. 
Noteworthy Themes 
Several themes emerged from the qualitative evaluation data that are relevant to navigator 
program planning and worthy of additional investigation.  Time was a dominant theme in the 
qualitative evaluation data.  Staff generally acknowledged that more time than originally 
anticipated was required for two major program components:  1) completion of participant 
barriers and needs assessments, and 2) developing a useful and effective program database. 
Another key issue that emerged during the evaluation was the difficulty of serving 
patients with a complex set of interrelated cancer care barriers and substance abuse problems.  
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Related to the patients, concerns about substance abuse were widely expressed.  Staff reported 
seeing more addiction or substance abuse problems than expected.  Noting the absence of a drug 
counselor on staff at the site, where most participants receive care; staff report that serving 
patients with substance abuse issues has required significant time and staff resources:    
“There are a little more drug problems than —I mean don’t get me wrong, 
there’s not a ton of them, but there is a significant little subset, I think….  So, 
I was a little bit surprised by that…..we have patients that come from 
those…backgrounds—if you want to treat them, we do need a lot more 
intensive contact, or they’re just going to get lost.”   
The descriptive statistical analysis of program data identified the percentage of MOPP 
participants with documented addiction and substance abuse problems.  The “little subset” 
mentioned above is actually 21 patients, or 8.9% of program participants (n=235, excluding CCT 
screen only patients).   
Also worth noting from evaluation findings is the concern for the emotional burden 
patient navigators may experience due to their exposure to patient morbidity and death: 
“You meet the patient, you get to know the patient…okay, so all of that is an 
emotional impact on the individual.  You know, so everybody’s different, just 
they have to be, and I don’t know how they can be, prepared for the emotional 
impact that you might encounter.  Patients die…sadly…you may follow 
somebody a year, or you may follow somebody for six months, or if you meet 
somebody today—‘well, the doctor gave me six months to live’—and in seven 
or eight months, they’re gone.” 
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Perhaps this emotional burden is particularly an issue for lay patient navigators who do not have 
a clinical background or extensive clinical experience that might better prepare and equip them 
to deal with the illness and death they witness. 
4.5 DISCUSSION 
Step 6:  Ensure Use and Share Lessons Learned 
The MOPP evaluation provided valuable qualitative and quantitative data related to 
program implementation achievements and challenges.  Moreover, the evaluation produced 
useful products (e.g., logic model and data reporting templates) and sparked immediate small-
scale enhancements (e.g., database modifications).  The evaluation also called attention to key 
issues that should be monitored closely within the MOPP program, and, perhaps, within the 
larger public health movement.   These key concerns include effectively navigating patients with 
substance abuse and minimizing the emotional burden work has on patient navigators.   
There were several limitations to this study.  While the evaluation collected rich data 
from staff and participant interviews, the absence of input from other stakeholders (e.g., referring 
physicians and representatives of UPMC administration) is a study limitation.  However, 
evaluation findings will be shared with stakeholders and it is recommended that, as program 
resources allow, additional stakeholders be involved in future evaluations.  Additionally, 
quantitative data analysis in the evaluation is limited to descriptive statistical analysis, which 
produces useful information, but cannot provide causal information related to the impact of 
program activities.  More advanced statistical analysis would have required additional data 
cleaning and collection—likely an extensive medical record review, which could have enhanced 
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the evaluation by assessing the relationship between program services provided and objective 
measures of treatment compliance or completion.  Although, this would have required a great 
deal of time and staff resources that were not available for this evaluation, as well as additional 
precautions for human subjects and health care information protection.   
Fleisher rightly insists that “as the practice of patient navigation expands, there is a great 
deal to be learned about the process, political climate, and day-to-day challenges in planning and 
implementing a navigation program” (2008, p.2).  Ultimately, the MOPP evaluation may prove 
valuable as a model for conducting program evaluation for cancer patient navigation that 
enhances local program practice; respects real-world time, funding, and ethical constraints; and 
systematically collects and disseminates valuable information on program context, 
implementation, and early outcomes.    
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5.1 ABSTRACT 
Participation in cancer clinical trials (CCT) helps researchers make significant advances in the 
fight against cancer and provides patients with access to state-of-the-art treatments.  An 
estimated 1.2 million Americans will receive a diagnosis of cancer this year, but only 3-5% of 
these new cancer patients will participate in a cancer clinical trial, and this participation rate is 
even lower among minority groups and women.  Cancer patient navigation is one potential 
strategy for improving cancer clinical trial participation among minority and underserved 
populations.  An evaluation was conducted to systematically collect, analyze, and share 
information about the context, activities, and early impacts of the University of Pittsburgh 
Medical Center Cancer Centers’ patient navigation initiative, the Minority Outreach Pilot 
Program (MOPP).  This article reports detailed evaluation findings related to MOPP’s CCT 
education and recruitment activities in an effort to help address the need to develop and expand 
the cancer patient navigation literature.  Additionally, it is expected that the presentation of 
MOPP’s process for integrating CCT screening and recruitment into their patient navigator 
program services, which has achieved a 51.6% CCT participation rate among eligible program 
participants will serve as a national model for other health care centers and organizations that 
seek to address disparities in CCT participation.  Lastly, findings related to reasons for non-
enrollment and their relationship to the calculation of CCT participation rates can help influence 
CCT criteria and policies at both the local level within the UPMC system and, potentially, 
national level efforts to study and address CCT disparities.   
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5.2 INTRODUCTION 
A mixed-methods evaluation was conducted to systematically collect, analyze, interpret and 
share information about the context, activities, and early impacts of the University of Pittsburgh 
Medical Center (UPMC) Cancer Centers’ Minority Outreach Pilot Program (MOPP).  MOPP is a 
patient navigator program that works to ensure access to the latest innovations in cancer 
treatment, regardless of financial means, for newly diagnosed African American cancer patients 
seeking care at one of four UPMC medical centers.  Informing program participants about cancer 
clinical trials and recruiting them for trial participation is a key program activity.  This article 
shares important evaluation findings related to the achievements and challenges the program has 
experienced around CCT recruitment efforts.  Quantitative (e.g., descriptive statistical analysis of 
the MOPP database) and qualitative (e.g., observation of staff and partnership meetings) methods 
were used to evaluate MOPP’s success with identifying barriers to CCT participation among 
program participants and CCT recruitment.   
5.3 BACKGROUND 
5.3.1 Cancer clinical trial disparities 
Participation in cancer clinical trials (CCT) helps researchers make significant advances in the 
fight against cancer and provides patients with access to state-of-the-art treatments (C-Change, 
n.d.).  An estimated 1.2 million Americans will receive a diagnosis of cancer this year, but only 
3-5% of these new cancer patients will participate in a cancer clinical trial (C-Change), and this 
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participation rate is even lower among minority groups and women (Baquet, Commiskey, Daniel 
Mullins, & Mishra, 2006; Bolen et al., 2006; Ford et al., 2005; Sheppard et al., 2005).     
Brawley (2004) asserts that racial/ethnic disparities in cancer clinical trial participation is 
also an issue of social justice.  Clinical trials provide opportunities for patients to receive state-
of-the-art treatments.  Among all cancer patients in the United States, those of higher 
socioeconomic status have led the increases in CCT accrual over the past several years and, thus, 
are major beneficiaries of clinical trial participation (Sateren et al., 2002).  In addition, 
examination of the 20% increase in CCT admission to National Cancer Institute trials since the 
mid-1990s shows that the number of Asian, African American, Hispanic and Native American 
patients entering trials has remained relatively stable while the enrollment of whites has 
increased (Christian & Trimble, 2003). 
The literature identifies several barriers to and facilitators of participation in cancer 
clinical trials, including patient and provider knowledge, attitudes and beliefs; access; religious 
and cultural beliefs; and strict inclusion and exclusion eligibility criteria for trials (Bruner, Jones, 
Buchanan, & Russo, 2006; Christian & Trimble, 2003; Comis, Miller, Aldige, Krebs, & Stoval, 
2003; Ford et al., 2005).  It is widely assumed that racial and ethnic disparities in cancer clinical 
trial participation are the result of unwillingness on the part of minorities to participate in health 
research; however, there is little evidence to support this claim (Wendler et al., 2006; Trauth et 
al., 2005).  In fact, some studies suggest that the primary challenge with CCT recruitment and 
accrual is not the attitudes of patients or their unwillingness to participate, but rather the limited 
availability of appropriate trials and the disqualification of large numbers of patients due to 
comorbidities, insurance coverage issues, or even transportation barriers (Comis, Miller, Aldige, 
Krebs, & Stoval, 2003).  The use of patient navigators is considered a promising strategy for 
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helping to address the myriad barriers to CCT participation minority and underserved 
populations face (Fowler et al, 2006).   
5.3.2 Patient navigation and cancer clinical trials 
The National Cancer Institute explains that patient navigation for cancer care “refers to 
support and guidance offered to persons with abnormal findings in accessing the cancer care 
system and overcoming barriers to quality, standard care.  Navigation spans the period from 
abnormal finding from cancer detection procedure through necessary cancer diagnostic tests to 
completion of cancer treatment” (United States Department of Health and Human Services, 
National Institutes of Health, National Cancer Institute [NCI], 2004, p. 2).  Patient navigation is a 
context-driven intervention as the services navigators provide are specific to the needs of their 
patients and the barriers they identify.  Consequently, navigator programs throughout the nation 
vary widely in the strategies they adopt and apply in order to reduce or eliminate cancer care 
barriers, but often include: 
• Providing emotional support to cancer patients, as well as information on what to 
expect during their cancer care;  
• Helping patients understand their diagnoses; 
• Coordinating appointments with providers to ensure that patients with suspicious 
findings receive timely diagnosis and treatment; 
• Helping to arrange transportation and/or child/elder care for visits to cancer 
treatments; 
• Helping to arrange language translation or interpretation services; 
• Helping patients and their families access support systems; and 
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• Facilitating access to available financial support and assisting with related paperwork. 
(Dohan & Schrag, 2005; NCI, 2006).   
Navigator program activities may also include community outreach and screening 
services, efforts to improve access to cancer clinical trials, and partnership building with local 
organizations and groups to link patients to cancer support groups or needed social services 
(NCI, n.d.). 
Freeman (2006) explains that patient navigators are charged with identifying, 
anticipating, and helping to alleviate barriers to cancer care that patients encounter.  Thus, they 
should be sensitive, compassionate, and culturally attuned to the patients and community being 
served; knowledgeable about the healthcare system and environment; and connected with critical 
decision makers within the healthcare system, particularly with financial decision makers 
(Freeman, 2004, 2007).  Considering their roles and corresponding essential qualities, patient 
navigators are uniquely positioned to promote access to cancer clinical trials (Fowler et al., 
2006).   
5.4 UPMC CANCER CENTERS’ MINORITY OUTREACH PILOT PROGRAM 
5.4.1 Program description 
UPMC and UPMC Cancer Centers implemented the Minority Outreach Pilot Program in March 
2006 with input from the African American Cancer Care Partnership (AACCP)—a task force of 
representatives from the Pittsburgh community, local health care centers, academic institutions, 
and community organizations working to facilitate collaboration among, and guide the efforts of, 
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various groups whose goals are to improve the health of African Americans.  The navigator 
program represents one of UPMC Cancer Centers’ efforts to address racial and ethnic disparities 
in cancer care. 
According to MOPP’s program theory, the intervention is based on certain assumptions 
that are consistent with the Freeman patient navigation model.  Specifically, patient navigation 
operates as a process by which navigators provide social support to remove the barriers to care 
that patients experience.  This social support includes emotional support—such as expressions of 
empathy and caring; instrumental support—tangible aid and service; and informational 
support—such as providing educational information, advice and suggestions that patients can use 
to address problems (Heaney & Israel, 2002).  The patient navigation process also includes the 
documentation of barriers, and the feeding back of barrier information to health care system 
management to support system level change.  The program also operates under the assumption 
that navigators need to be sensitive, compassionate, and culturally attuned to the patients and 
community being served; knowledgeable about the health care system & environment; and 
connected with critical decision makers within the health care system. 
The program’s resources (including community partnerships, program staff and funding) 
support the delivery of navigation services, which include barrier assessments, financial 
counseling and assistance, and cancer clinical trial education and recruitment.  Over time, 
navigator services are intended to lead to change in cancer care knowledge, awareness and 
behavior among program participants and improvements in cancer care delivery systems.  Short-
term and intermediate outcomes include increasing patients’ knowledge of resources for 
overcoming barriers to care and increasing the health care centers’ knowledge of patient barriers 
to cancer care and cancer clinical trial participation.  Ultimately, the achievement of short-term 
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and intermediate outcomes is expected to lead to the elimination of barriers to cancer care and 
increased survivorship for the program’s target patient population, as well as increased African 
American representation in cancer clinical trials across participating health care centers.  MOPP 
experiences in achievements in working toward these important long-term outcomes will also 
help improve public health researchers and practitioners’ knowledge about improving CCT 
participation and reducing disparities among minority cancer patients.     
5.4.2 Data collection and intervention efforts 
Since its initiation in March 2006 through April 2008—the planned data collection end 
date for the dissertation research—a total of 249 patients have been referred, or recruited through 
case finding, to the Minority Outreach Pilot Program.  Based on program staff’s monthly 
comparisons of MOPP enrollment and UPMC new patient summaries, which are derived from 
billing data to provide the most accurate data possible; the program reports having contact with 
about 85% of all newly diagnosed African American patients receiving care at the four 
participating program sites.  Of the 249 patients the program has made contact with and/or 
served, 75 have accepted and utilized the program’s patient navigator services and 27 have 
enrolled in cancer clinical trials.  It is standard program practice to conduct cancer care barrier 
assessments with all program participants and to inform all program participants about cancer 
clinical trials.  Fidelity to this practice standard is evidenced by the documented CCT enrollment 
status and reasons for non-enrollment for each participant.      
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5.5 RESULTS 
The following tables present descriptive statistical summaries of data from the MOPP data base 
for the period of March 2006-April 2006.  The proportion of total program participants (n=249) 
enrolled in CCTs is shown in Table 9, and the reasons for non-enrollment for the 222 MOPP 
participants who were not enrolled in trials at the time of this analysis are summarized in Table 
10.   
Table 9. CCT Enrollment Status Among MOPP Participants (n=249) 
CCT Status Count Percent 
Enrolled 
Not Enrolled 
Total 
27
222
249
10.8
89.2
100
 
Table 10. Reasons for Not Enrolling in CCTs Among MOPP Participants (n=222) 
Reason Count Percent 
Already on Treatment 
Lost to Follow-up 
MD Chose Other Treatment 
Medically Ineligible 
No Clinical Research Coverage 
No HIPPA Consent 
No Trial Available 
Non-Cancer 
Pending 
Poor Performance Status 
Prior Cancer 
Refused 
Requires More Surgery 
Second Primary (Cancer) 
Total 
37
15
53
52
2
2
3
30
2
13
1
6
4
2
222
16.7 
6.8 
23.9 
23.4 
.9 
.9 
1.4 
13.5 
.9 
5.9 
.5 
2.7 
1.8 
.9 
100 
 
Qualitative data collection activities, particularly meeting observation, revealed the need 
to quantify reasons for non-enrollment, as well as CCT eligibility among program participants.  
 117 
Cancer clinical trial participation rates are one of the program highlights shared at the African 
American Cancer Care Partnership meetings and in presentations to UPMC Cancer Centers’ 
administration and funders.  Discussion of the near 11% CCT enrollment rate at program 
meetings virtually always included an acknowledgement that many patients were ineligible for 
CCT for medical reasons, including comorbidities and late stage cancer diagnosis.  However, the 
quantifiable effect that ineligibility had on the CCT enrollment rate had not been calculated.  
This is primarily attributed to the limitations of the program database interface, which did not 
allow program staff to easily calculate and track the percentage of MOPP participants who were 
ineligible for CCTs.  
The MOPP database is not designed to provide program staff with access to aggregate 
raw data or create data reports.  All program data reports are requested from a database 
administrator who is otherwise unaffiliated with the program and rather unfamiliar with MOPP 
activities.  Hence, reports generally consist of simple frequencies without adjustment for factors 
that may affect their value.  Considering this context, the evaluator worked with the program 
staff and database administrator to obtain a de-identified, raw data file for all variables in the 
database.  The data was used to calculate an adjusted enrollment rate and to develop a more 
detailed description of those program participants who enroll in CCTs. 
The number of participants eligible for CCTs (n=167) was defined as those patients who 
were not documented as medically ineligible (n=52) or non-cancer (n=30).  Calculating the CCT 
participation rate as the proportion of program participants enrolled in cancer clinical trials 
among those who are eligible, MOPP has a 16.2% CCT enrollment rate.  Table 11 presents this 
adjusted CCT enrollment rate by program year.      
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Table 11. CCT Enrollment Rate by Program Year, Excluding Medically Ineligible and Non-
Cancer Participants 
Program 
Year 
Total #of Program 
Participants* 
Number 
Enrolled in CCT 
Percent Enrolled 
in CCT 
2006 75 14 18.7 
2007 62 9 14.5 
2008 19 4 21.1 
unknown 11 0 0 
Total 167 27 16.2 
  * excluding medically ineligible and non-cancer participants 
 
Table 12 presents selected demographics for the group of program participants MOPP 
has successfully enrolled in trials during the period covered by this evaluation (March 2006-
April 2008).  Of MOPP participants enrolled in CCTs (n=27), 48.1% are male and 51.9 % are 
female. Most (59.3%) program participants enrolled in trials are between 50 and 64 years of age.  
Breast and colon cancer are the most common cancer diagnoses among CCT enrolled program 
participants, and about half of the participants have a stage IV diagnosis.   
  
Table 12. Characteristics for Program Participants Enrolled in Cancer Clinical Trials (n=27) 
Characteristic Count Percent 
Age Group 
<20 
20-49 
50-64 
65-74 
75+ 
Total 
0
6
16
4
1
 27
0
22.2
59.3
14.8
3.7
100
Gender 
Female 
Male 
Total 
13
14
27
48.1
51.9
100
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Characteristic Count Percent 
Cancer Stage 
I 
II 
III 
IV 
Unable to Stage 
Total 
1
2
9
14
1
27
3.7
7.4
33.3
51.9
3.7
100
Cancer Diagnosis 
Brain Tumor, Cerebral  
Breast Cancer 
Colon Cancer 
Head and Neck Cancer 
Leukemia, Chronic Myelogenous 
Lung Cancer, Non-Small Cell 
Pancreatic Cancer 
Prostate Cancer 
Rectal Cancer 
Total 
 
1
8
6
5
1
1
3
1
1
27
3.7
29.6
22.2
18.5
3.7
3.7
11.1
3.7
3.7
100
 
A little over half (51.5%) of the program participants enrolled in trials have between 0-2 
co-morbidities.  Among CCT participants, 44.4% accepted patient navigators.  A chi-square test 
was conducted to check for any relationship between the acceptance of navigators and CCT 
enrollment; no indication of a relationship between the two variables was found:   χ2 (1, N=167) 
= .871, p=.35.  However, this result is not unexpected considering the fact that program 
participants do not have to accept a patient navigator to receive services (e.g., transportation or 
insurance enrollment assistance) through the program.  So, if necessary data were readily 
available from the larger UPMC patient population, it may be more appropriate to test for 
association between program participation and CCT enrollment.   
It is important to note that shortly after reviewing the evaluation findings presented above 
from the descriptive statistical analysis of CCT data, program staff worked to further investigate 
the issue of CCT eligibility among their participants.  Based on eligibility criteria for current 
Table 12 Continued
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UPMC trials, staff reviewed program and patient medical records to determine whether each 
patient in the database (n=250 at the time of this additional assessment) was eligible to 
participate in a CCT.  Sixty (24%) of the 250 MOPP participants met eligibility criteria for 
available trials.  Among the 60 participants who were eligible, 31 were enrolled in a trial.  The 
program’s additional assessment of CCT eligibility indicates that, when excluding ineligible 
patients, there is a 51.6% CCT participation rate among MOPP participants.  As presented in 
Table 13, reasons for non-enrollment recorded for the remaining 29 patients who were 
potentially eligible to participate in a CCT, but did not enroll include:  patient refusal, patient 
refusal of cancer treatment in general, patient loss to follow-up, and the absence of 
documentation regarding the medical doctor’s attempt to  discuss CCT participation with the 
patient.  Through this additional assessment, the program has also identified the need to improve 
physician documentation related to efforts to inform patients and recruit them to trials.      
Table 13. Additional Program Assessment—Reasons for Non Enrollment Among MOPP 
Participants Who Are Potentially Eligible for CCTs (n=29) 
Reason Count Percent 
Refused CCT 
Refused Treatment  
Lost to Follow-up 
No Documentation of MD  
     Discussing CCT 
Total 
8
1
1
19
29
27.6 
3.4 
3.4 
 
65.6 
100 
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5.6 DISCUSSION 
The value of MOPP’s CCT education and recruitment efforts is best described by the 
staff, as they are responsible for utilizing service and evaluation data for program improvement:    
 
“…what it [MOPP] is doing for the first time is clearly demonstrating what 
are the barriers as to why they don’t enter trials, which is totally different than 
what people were sort of guessing because everyone, at least here, was saying 
it was money, or it’s Tuskegee.  That’s not what we’re finding, we’re finding 
the number of comorbidities, the number of other chronic diseases, the late 
stage diagnoses is what is inhibiting them [large proportion of newly 
diagnosed African American patients receiving cancer care at participating 
UPMC sites] from entry on the trial, which allows us to make some decisions 
internally:  Do we write trials that can address patients that have comorbidities 
of three or better?  Do we, you know, really maybe do some further research 
into does it really make a difference if you have certain comorbidities in 
regard to trials already here?  …it really gives us a clear picture of what the 
issues are.” 
 
The MOPP cancer patient navigation system provides myriad services to help address 
participants’ cancer care barriers while collecting data that informs decision-makers about the 
actual challenges and barriers to CCT participation minority and disadvantaged patients face.  In 
addition, MOPP supports efforts to improve clinical research across the UPMC system.  While 
additional study is required to test association between program participation and CCT 
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enrollment, data from initial evaluation efforts indicate that the program plays a very valuable 
role in documenting reasons for disparities in CCT participation among participating UPMC 
program sites, which is a vital first step to developing appropriate strategies for reducing these 
inequities.  
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6.1 ABSTRACT 
Context:  The large gap between public health research and public health practice is widely 
recognized and disconcerting.  Research translation, which is defined as the process of moving 
from research (i.e., tools, information, and strategies developed and ascertained through 
research) to the actual application of research findings in day-to-day public health practice, is 
fundamental for improving the public’s health.  Multiple factors—historical, political, social, 
economic, scientific (i.e., program development research, evaluation and reporting practices), 
cultural, and organizational—operate independently and interact to slow and limit translation.       
Methods:  A review and critical analysis of both scientific factors related to slow and limited 
research translation and current efforts to address these factors in the public health field was 
conducted to promote progressive thinking around enhancing translation.  The cancer patient 
navigation movement is described as a case in point for the promise of alternative approaches to 
the traditional linear and phased processes for moving between public health research and public 
health practice.   
Findings:  At least two prominent approaches were identified in the literature for ameliorating 
scientific factors that impede translation.  They were conceptualized as traditional (i.e., approach 
accepts the general tenets of traditional linear and phased translation models) and alternative 
(i.e., approach encourages a rethinking and reshaping of the traditional processes and practices 
for moving between research and practice).   
Conclusions:  The problem of limited and slow translation in the public health field calls for 
both more broad and practical conceptualizations of evidence and increased emphasis on 
contextual realities in program development research.  The cancer patient navigation movement 
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is an exemplar for the development of evidence that is more practice based, a quality that this 
critical analysis suggests is key for improving and accelerating public health research translation. 
6.2 INTRODUCTION 
The large gap between public health research and public health practice is widely recognized and 
disconcerting (Glasgow & Emmons, 2007; Schechter & Brunner, 2005).  Research translation—
the process of moving from research (i.e., tools, information, and strategies developed and 
ascertained through research) to the actual application of research findings in day-to-day public 
health practice—is fundamental for improving the public’s health (Dzewaltowski, Glasgow, 
Klesges, Estabrooks, & Brock, 2004; Schechter & Brunner, 2005; Sussman, Valente, Rohrbach, 
Skara, & Pentz, 2006).  Clearly, in order for the public to benefit from evidence-based health 
promotion and disease prevention knowledge and strategies that are identified through research, 
translation must be accelerated and improved so that research findings are applied in real-world 
public health programs (United States Department of Health and Human Services, Centers for 
Disease Control and Prevention, Office of Public Health Research [CDC], 2007).   
There are multiple factors that slow and limit translation of research findings into 
practice—historical, political, social, economic, scientific, cultural, and organizational factors 
can all operate independently or interact to threaten translation (Glasgow & Emmons, 2007).  
The study of scientific factors that impede translation, which include program development 
research, evaluation and reporting practices, is of critical importance as these factors are 
arguably most proximal to, and, therefore, most likely to be influenced by, public health 
researchers (Glasgow & Emmons).  Within the context of scientific factors that impede 
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translation, a sound and alternative approach to improving research translation is to rethink and 
enhance traditional linear processes for moving from public health research to public health 
practice—that is, to support the development of more practice-based evidence (Green & 
Glasgow, 2006).  In essence, the call for more practice-based evidence recognizes the importance 
of modifying traditional research practices and processes so that studies pay greater attention to 
real-world practice issues early on in the program development research process (Glasgow & 
Emmons, 2007; Green & Glasgow, 2006).   
6.3 A REVIEW AND CRITICAL ANALYSIS OF KEY TRANSLATION CONCEPTS 
AND MODELS 
In general terms, translation can be defined as a process of changing from one place, state, form 
or appearance to another; for example, the translation of ideas into action (Merriam-Webster, 
2007).  Translation in the health professions refers to the extended process by which research 
knowledge that is either directly or indirectly pertinent to health behavior eventually serves the 
public (Sussman, Valente, Rohrbach, Skara, & Pentz, 2006). 
6.3.1 Traditional translation models and concepts 
Although translation models have evolved over the last two decades to reflect some bidirectional 
flow, or feedback loops, between phases; all generally subscribe to a phased depiction of the 
translation process that was first introduced in the public health literature by Greenwald & 
Cullen and Flay in the 1980s (Glasgow, Lichtenstein & Marcus, 2003). Many of the models used 
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to describe translation in current health promotion and disease prevention research draw on the 
two influential works:  1) Greenwald and Cullen’s (1985) five phases of cancer control research, 
and 2) Flay’s (1986) eight-phase model for the development of health promotion programs 
(Glasgow, Lichtenstein, & Marcus, 2003).  Sussman and colleagues (2006, p.11) describe the 
five-phase translation model (i.e., hypothesis development, or basic research; methods 
development; controlled intervention trials, or efficacy trials; defined population studies, or 
effectiveness trials; and demonstration and implementation, or dissemination research) as 
“inclusive”; the authors maintain that the model reflects major efforts in many research arenas 
and go on to describe other research translation models against the backdrop of the influential 
five-phase model (2006, p. 11).  Specifically, Sussman and colleagues present additional 
research translation models and related theories as variations of the widely accepted and used 
five-phase model 
Greenwald & Cullen’s Translation Model for Cancer Control 
The original five phases of Greenwald and Cullen’s translation model are:  1) hypothesis 
development, which is referred to as the “basic research” phase in current references to the 
model; 2) methods development; 3) controlled intervention trials, more commonly referred to as 
efficacy trials; 4) defined population studies, more commonly referred to as effectiveness trials; 
and 5) demonstration and implementation, or dissemination research (Glasgow, Lichtenstein & 
Marcus, 2003; Greenwald & Cullen, 1985).  The following descriptions of the phases provide 
useful insight into Greenwald and Cullen’s conceptualization of the research translation process: 
? In general, basic research seeks to investigate new knowledge about phenomena in 
an effort to establish general principles to explain that phenomena (Potter & Quill, 
2006).   
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? Methods development refers to the specification of program development, 
measurement and analysis designs, or the specification of technology and equipment, 
required to test the intervention “objectively and accurately” in the larger, 
comparative studies that take place in subsequent translation phases (Greenwald & 
Cullen, 1985, p. 545; Sussman, Valente, Rohrbach, Skara, & Pentz, 2006).  Methods 
development studies include pilot tests to investigate feasibility, acceptability, 
potential participation, validity of data collection instruments, alternative delivery 
approaches, cost-effectiveness, and possible human subject risk of the proposed 
intervention within a specific population subgroup (Greenwald & Cullen, 1985).   
? Efficacy trials test whether an intervention does more good than harm among the 
target population in an ideal setting, such as a randomized clinical control trial or a 
community-level trial (United States Department of Health and Human Services, 
Centers for Disease Control and Prevention [CDC], 2007).    In efficacy trials, there is 
an emphasis on internal validity; the trials are generally associated with highly 
controlled conditions, such as random selection of participants or units into a trial and 
random assignment of participants or units to the intervention (Glasgow, Lichtenstein 
& Marcus, 2003; Sussman et al., 2006).   
? Effectiveness trials test whether an intervention does more good than harm for the 
target population in a real world setting (CDC, 2007).   
? In the final phase of the standard translation model, dissemination trials, there is an 
emphasis on monitoring and evaluating the conditions that hinder or facilitate 
widespread use of the intervention (CDC, 2007; Sussman et al., 2006).  Greenwald 
(1985) described Phase 5 trials as large scale demonstration projects in which 
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intervention fidelity is closely monitored.  The Centers for Disease Control and 
Prevention (2007) have adopted two definitions of intervention fidelity:  1) “the 
adherence of actual treatment delivery to the protocol originally 
developed”(Mowbray, Holter, Teague, & Bybee, 2003), and a broader definition that 
considers intervention fidelity as 2) the degree to which program developers 
implement programs, rather than just the treatment delivery component of the 
program, as intended by the developers (Sussman et al., 2006). 
Flay’s Model for the Development of Health Promotion Programs 
Greenwald & Cullen’s five phase translation model was expanded by Flay in 1986.  
Flay’s model for the development of health promotion programs consists of eight phases:  1) 
basic research, 2) hypothesis development, 3) pilot applied research, 4) prototype evaluation 
studies, 5) efficacy trials, 6) treatment effectiveness trials 7) implementation effectiveness trials, 
and 8) demonstration evaluations.  Sussman and colleagues (2006) explain the parallels and 
variations of the two early translation models:   
? In Flay’s model, the first two phases, basic research and hypothesis development, 
expand on Greenwald & Cullen’s single hypothesis development phase, although the 
graphic depiction of the Greenwald & Cullen model indicates that the hypothesis 
development phase is directly preceded and informed by basic research and 
epidemiology (see Figure I).  
? Flay expands Greenwald and Cullen’s second phase, methods development, to 
include pilot applied research (phase 3) and prototype evaluation studies (phase 4).  
Pilot applied research consists of early tests of new interventions that focus on 
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immediate outcomes, whereas prototype evaluation studies are small studies of a 
more developed intervention that focuses on longer term outcomes.   
? Finally, Flay divides Greenwald and Cullen’s fourth phase, effectiveness trials, into 
two separate effectiveness phases—phase 6, treatment effectiveness trials and phase 
7, implementation effectiveness trials.  Treatment effectiveness trials involve the 
optimized and controlled delivery of an evidence-based intervention in a real-world 
setting, compared to implementation effectiveness trials, which involve the real-
world, or natural, delivery of an evidence-based intervention in a real-world setting.   
In the final phases of both models (i.e., dissemination trials in the Greenwald and Cullen 
model and demonstration evaluations in the Flay model), trials are conducted to optimize 
widespread public use of the intervention.    
Limitations of Early Influential Models 
While the Greenwald & Cullen and Flay models imply a linear progression from research 
to practice through specified stages (Glasgow, Lichtenstein & Marcus, 2003), Sussman and 
colleagues (2006) logically assert that each of the phases of research can inform phases that 
come before or after it.  However, Glasgow, Lichtenstein and Marcus (2003) note that many 
researchers and reviewers apply the translation models in a limiting and linear “trickle down” 
fashion when designing, funding and evaluating research.  Murray’s description of the translation 
process fifteen years after it was conceptualized by Flay in 1986 reflects the pervasive linear and 
restrictive thinking about translation in the public health field: 
Efficacy trials are designed to test whether the intervention causes the 
observed effect under carefully controlled conditions in which the investigator 
has control over the assignment of study conditions, the context of the 
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intervention, the delivery of the intervention, and the conduct of the 
evaluation.  Treatment and implementation effectiveness trials are used to 
determine whether the treatment will remain effective when implemented 
under more realistic conditions.  Treatment effectiveness trials relax control 
over the context of the intervention, whereas implementation effectiveness 
trials relax control over both context and delivery of the intervention.  Finally, 
demonstration studies include only minimal evaluation activities and are 
reserved for intervention programs that have already been proven efficacious 
and effective (2001, p. 307). 
Glasgow, Lichtenstein and Marcus (2003) go on to declare that the pervasive linear 
approach to translation, particularly as it applies to the transition from efficacy to effectiveness 
trials, is one of the reasons for the “slow and incomplete translation of research findings into 
practice” (p.1261-2).  While the translation models that followed Greenwald & Cullen and Flay’s 
work do reflect some appreciation for a two-way flow of knowledge between translation phases, 
they still primarily depict the translation process as a distinct set of phases with prescribed and, 
in some cases, limited two-way flow of knowledge between phases; which supports Glasgow and 
colleagues’ (2004) notion that study design characteristics, especially the linear progression 
through the research translation process, are likely partly responsible for the gap between 
research and practice. 
Recent Translation Models from the Cancer Control Field 
As evaluation experience with innovative cancer interventions fueled this critical analysis 
of public health translation issues and strategies, it is worth noting some of the additional 
translation models that have emerged in the field of cancer control research since the Greenwald 
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& Cullen model was published in 1985, including the National Cancer Institute’s (NCI) New 
Strategy for Cancer Control Research, which is outlined in a 1999 article by Hiatt and Rimer, 
and The Research Translation Continuum presented in the 2004-2005 President’s Cancer Panel 
Annual Report.  Readers are referred to these sources for in depth descriptions of these models as 
space limitations do not allow for a detailed review of these models’ components.  The  NCI and 
President’s Cancer Panel models reflect an evolution from more linear-oriented thinking about 
the translation process to a conceptualization of translation that incorporates two-way flow, or 
feedback loops, between research phases.   
NCI’s new strategy for cancer research adopts a more interdisciplinary conceptualization 
of the research process, thus expanding on the linear interpretation of the translation process 
implied in the earlier Greenwald and Cullen and Flay models.  However, the component of the 
earlier phased models that Glasgow, Lichtenstein and Marcus (2003) find most problematic for 
the successful translation of research findings into public health practice (i.e., the “efficacy-to-
effectiveness transition”) is not entirely absent in the evolved NCI model.  In fact, in their article 
introducing the new NCI model, Hiatt and Rimer (1999) explicitly support the logical 
progression of scientific inquiry laid out by Greenwald and Cullen (1985).   
It is important to reiterate Glasgow and colleagues’ declaration that the Greenwald and 
Cullen and Flay models operate on the faulty assumption that “the best candidates for 
effectiveness studies—and later dissemination—are interventions that prove successful in certain 
types of efficacy research”, when it is indeed “highly unlikely”, according to Glasgow and 
colleagues, that interventions that prove successful in rigorously controlled efficacy trials will do 
well in effectiveness trials or in the real-world (2003, p. 1261-2).  The faulty efficacy-to-
effectiveness assumption is explicitly incorporated into the recent translation continuum 
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developed by the President’s Cancer Panel (PCP) .  However, it is important to note that the PCP 
model, similar to NCI’s New Strategy for Cancer Research, represents some re-visioning of the 
rigorous, linear approach used to describe the translation process in early models as the PCP 
model promotes a two-way flow of knowledge and influence between phases of the translation 
process. 
Other Variations in the Traditional Translation Model 
As mentioned earlier in this section, Sussman and colleagues (2006) sensibly maintain 
that variations of the five-phase translation model include theories and models that can be 
envisaged as: 1) concentrating on a subset of the standard five phases, as with diffusion models 
(see Oldenburg & Parcel, 2002, for a detailed review of Roger’s Diffusion of Innovation Model) 
or as 2) a collapse and merging of the five phases, as reflected in the National Institute’s of 
Health two-step model for the translation of biomedical research (see Westfall, Mold, & Fagnan, 
2007 for a thorough review of the NIH Two-Step Model).   
6.3.2 Translation challenges  
Despite the existence of relatively well-aligned models that describe the process of moving from 
research to practice, public health research translation is limited and slow.  Public health 
researchers, non-profit organizations and leading government agencies raise the following 
pressing questions: 
? Why is there not more translation of health promotion research to practice? (Glasgow, 
Lichtenstein & Marcus, 2003) 
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? How do we shape public health research into a usable form, translating numbers and 
theories into adaptable, effective models of social change?  (Schechter & Brunner,  
(2005) 
? What are effective methods for the broader dissemination, adoption, and 
implementation of the extensive research that has been conducted on the efficacy and 
effectiveness of health promotion and disease prevention intervention strategies? 
(CDC, 2007) 
Factors that Impede Translation 
 While a detailed review of all of the categories of factors that hinder research translation 
is outside of the focus of this critical analysis, it is worth noting the range of factors that hinder 
research translation.  The literature suggests several explanations for the slow and limited 
translation of research findings into public health practice:  “multiple interacting reasons can be 
given for the general failure of health research findings to translate into practice, including 
historical, political, social, economic, scientific, cultural, and organization factors that slow or 
impede transfer of research into practice” (Glasgow & Emmons, 2007, p. 414).  Table 14 
provides descriptions by category of factors that impede translation as identified by Sussman and 
colleagues (2006) and Glasgow & Emmons (2007). 
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Table 14.  Categories and Descriptions of Factors that Impede Translation 
Categories of Impeding Factors Descriptions 
Historical • Prevailing practices in intended target settings 
work against innovation 
Political 
• Competing demands or competing program 
alternatives exist 
• Opposing incentives or regulations hinder 
translation 
Economic • Financial instability/limited resources exist in organizations that implement public health 
programs or in programs’ intended target settings 
Scientific 
(i.e., research, program 
development, evaluation & reporting) 
• Basic research is conducted without collaboration 
protocols or attention to application pathways 
• Research studies are non-relevant or not 
representative of intervention settings, participants, 
and/or practitioners 
• Intervention cost, reach, setting adoption, 
maintenance, and sustainability are not adequately 
evaluated 
• Research findings are not interpreted or reported in 
ways amenable to dissemination 
• Interventions are not flexible 
Social/Cultural • Intervention philosophies are not aligned with those of the intervention implementers or target 
population 
Organizational • Organizational support is limited 
• Staffing to implement intervention is inadequate 
 
 Noting the multiple, interacting factors related to slow and limited research translation, 
this critical analysis focuses on “scientific” factors that impede translation.  Particular attention is 
paid to understanding how translation can be improved through expanding, enhancing, and/or 
modifying public health research and program development practices, as these scientific factors 
are arguably most proximal to public health researchers and practitioners and most likely able to 
be addressed by public health researchers and practitioners (Glasgow & Emmons, 2006).  
Notably, because many of the factors that hinder translation interact with, or can possibly 
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influence, each other; efforts to improve translation through addressing scientific barriers to 
translation can potentially, albeit indirectly, address translation issues that fall under other 
categories of impeding factors (e.g., economic barriers which includes the reality limited 
financial resources in real-world settings).   
6.4 APPROACHES FOR ADDRESSING SCIENTIFIC FACTORS THAT IMPEDE 
TRANSLATION 
There has been a great deal of scholarly study on the process of translation.  However, while 
models describing research translation have been developed and amended over the past 20 years, 
and while several key translation concepts (e.g., intervention fidelity, efficacy and effectiveness) 
have been defined and studied, public health research translation remains slow and limited.  
There is general agreement in the public health field that research translation needs to be 
improved and accelerated.  However, within the context of scientific factors that impede 
translation (i.e., those related to public health research and program development practices), 
there are at least two prominent approaches proposed in the literature for ameliorating 
translation-impeding scientific factors.  For the purposes of this critical analysis, these two 
approaches are labeled traditional and alternative and are conceptualized as follows:   
1. The traditional approach accepts the general tenets and translation process depictions 
of the standard five-phase model (or translation model versions that are, by premise, 
practically indistinguishable from the standard five-phase model) for moving from 
research to practice.  Consequently, this approach seeks a solution to improving 
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translation that does not challenge or attempt to significantly change the standard 
five-phase conceptualization of the translation process.  
2. The alternative approach encourages critical examination and rethinking of the 
standard practices for conducting research and for moving from research to practice.  
Under this approach, strategies for improving translation include modifying current 
dominant research practices in the field that are aligned with the linear-oriented, 
restrictive conceptualization of the translation process depicted in the standard five-
phase model.   
6.4.1 The traditional approach 
It is helpful to explain the concept “traditional approach” to improving translation by briefly 
reviewing a recently released Request for Applications (RFA) for translation research from the 
Centers for Disease Control and Prevention (CDC).  In an effort to achieve “new scientific 
knowledge that can accelerate the translation of research findings in to public health practice” the 
CDC announced the availability of $10 million for “translation research using an evidence-based 
intervention or policy” (CDC, 2007, p. 3).  The recently released Request for Applications 
(RFA), “Improving Public Health Practice through Translation Research (R18)”, seeks to 
improve translation through conducting research that determines how the spread and use of 
evidence-based interventions can be increased.  In other words, the CDC RFA focuses on 
improving translation by studying what occurs after an intervention has “undergone sufficient 
scientific evaluation to be proven efficacious or effective (e.g., intervention is considered valid or 
‘proven’ because it is strongly linked to desirable outcome)” (CDC, 2007, p.10).  Placing this 
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strategy within the context of the five-phase translation model, the CDC RFA focuses on 
improving translation by studying Phase V- dissemination research.   
 While its phase five context is not explicitly acknowledged in the CDC RFA, the 
announcement’s description of translation research certainly places its traditional approach to 
improving translation within the final phase of Greenwald and Cullen-aligned translation 
models:  “Translation research characterizes the sequence of events (i.e., process) in which a 
proven scientific discovery (i.e., evidence-based intervention) is successfully institutionalized 
(i.e., seamlessly integrated into established practice and policy)” (CDC, 2007, p.9).   The RFA 
goes on to specify that “translation research is comprised of dissemination research, 
implementation research and diffusion research” (CDC, 2007, p. 9).  The dissemination, 
implementation and diffusion fields of study are exactly the focus of what is commonly 
considered the final phase of the translation process as originally described by Greenwald and 
Cullen (1985) and as presented in more current literature on translation (Glasgow, Lichtenstein, 
& Marcus, 2003; Green & Glasgow, 2006; Reuben, 2005; Sussman, Valente, Rohrbach, Skara, 
& Pentz, 2006).  Worth noting are the definitions of these phase five focus areas as presented in 
the CDC RFA: 
? Dissemination research is the systematic study of how the targeted distribution of 
information and intervention materials to a specific public health audience can be 
successfully executed so that increased spread of knowledge about the evidence-
based public health interventions achieves greater use and impact of the intervention. 
? Implementation research is the systematic study of how a specific set of activities and 
designed strategies are used to successfully integrate an evidence-based public health 
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intervention within specific settings (e.g., primary care clinic, community center, 
school).  
? Diffusion research is the systematic study of the factors necessary for successful 
adoption by stakeholders and the targeted population of an evidence-based 
intervention which results in widespread use (e.g., state or national level) and 
specifically includes the uptake of new practices or the penetration of broad scale 
recommendations through dissemination and implementation efforts, marketing, laws 
and regulations, systems-research and policies (underline added) (p.9).   
The underlined passages make it clear that, what are characterized in this paper as 
traditional approaches to improving translation, focus on evidence-based interventions and, thus, 
are concerned with parts of the translation process that occur after basic research, methods 
development, efficacy and intervention trials have been conducted.  In fact, the CDC RFA 
explicitly states that “translation research does not encompass pure biomedical or formative basic 
science research….  It also does not include the conduct of an initial or replication intervention 
efficacy or effectiveness trial” (CDC, 2007, p. 9).  The RFA’s description of translation research 
and its components is based on the sensible premise that “the greatest health impact on 
individuals, the community, racial/ethnic and other population experiencing health disparities, 
and the broader population is achieved when an evidence-based intervention is optimally 
translated into public health practice and policy” (CDC, 2007, p.7).   
Interestingly, this statement regarding the high public health value of evidence-based 
interventions reflects what Glasgow and colleagues (2003) deem faulty logic in the standard five 
phase translation model—that is the belief that interventions that do well in efficacy, then 
effectiveness, studies are positioned to have successful impacts on the health of the public in 
 140 
real-world settings.  In drawing the connection between the CDC-promoted approach to 
improving translation and criticism of restricted, linear approaches to moving from research to 
practice (Glasgow, Lichtenstein & Marcus, 2003; Green & Glasgow, 2006), one could argue that 
the traditional approach to improving translation promotes the view that no change in the 
development of the “evidence base” (i.e., phases 1- 4 in the standard five phase translation 
model) need occur to improve translation.  At the very least, one could argue that the traditional 
approach to improving translation downplays the potential to improve translation by modifying 
or enhancing early translation process stages.   
Traditional Approach Trends in Current Translation Research 
Traditional thinking around public health research translation is echoed throughout public 
health literature on  dissemination, implementation and diffusion.  The literature reflects 
particular interest in identifying tools and strategies that enhance fidelity in evidence-based 
intervention dissemination and implementation while allowing for necessary community 
adaptation (Caburnay, Kreuter, & Donlin, 2001; Elliott & Mihalic, 2004; Harshbarger, Simmons, 
Coelho, Sloop, & Collins, 2006; Kelly et al., 2000; Owen, Glanz, Sallis, & Kelder, 2006; 
Paulson, Post, Herinckx, & Risser, 2002).  Beyond the fidelity-adaptation theme, there is a 
growing focus in the literature on the critical importance of implementation research for 
improving translation (Dusenbury, Brannigan, Hansen, Walsh, & Falco, 2005); and there is, 
expectedly, also general consensus in the literature that “systematic implementation practices are 
essential to any national attempt to use the products of science—such as evidence-based 
programs—to improve the lives of its citizens (Fixsen, Naoom, Blase, Friedman & Wallace, 
2005, p.vi).  
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Key Translation Research Questions 
Ultimately, the CDC RFA, which both incorporates and reflects current dissemination, 
implementation and diffusion literature, calls for proposals to address “the knowledge gap 
between evidence-based public health interventions and effective delivery” (2007, p. 8).  The 
RFA lists the following key research questions (p. 32-33): 
? Reach:  What were the key factors that determined who in the target audience were 
successfully or unsuccessfully reached? 
? Adoption:  What factors influenced organizations’ or individuals’ acceptance of the 
intervention (e.g., organizational structure, regulation, and cultural norms)? 
? Adoption:  Was cost a factor in the implementers or target population’s willingness to 
adopt the intervention?  What opportunity (non-fiscal) costs were incurred? 
? Fidelity:  How was the fidelity of the intervention or system compromised or how did 
it deviate from the original?   
? Adaptation:  What key components of the intervention or the system were modified to 
increase adoptability or use? Can the intervention vary, as needed, depending on the 
audience? 
? Adaptation and Fidelity:  Did the adaptation of the intervention to make it more 
culturally relevant result in loss of fidelity?  Did this result in decreased 
effectiveness? 
? Feasibility:  What are the realistic cost, time, facility space and human resources (e.g., 
number of staff and type of training) needed? 
? Outcomes & Impacts:  As a secondary measure, what is the effect of the intervention 
on health outcomes? 
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These key translation research questions are worth noting because they are arguably 
equally valid for each of the two approaches to improving translation ( i.e., traditional and 
alternative) presented in this paper.   
Traditional Approach Summary 
Conceptually, traditional approaches to improving translation are grounded in phase five- 
dissemination research (i.e., interventions have undergone sufficient scientific evaluation to be 
proven efficacious or effective) of the standard five-phase translation model previously 
reviewed.  On one hand, focusing the study of translation on phase five issues is reasonable 
given the fact that  
despite extensive research on the efficacy and effectiveness of health 
promotion and disease prevention intervention strategies, little is known 
regarding effective methods for the broader dissemination, adoption, and 
implementation of these interventions (CDC, 2007, p.8).     
However, a questionable premise drives the traditional approach to improving translation, 
namely that those interventions that are successful in efficacy trials, then in effectiveness trials, 
ought to produce significant public health improvements in the real world.   And yet, a focus on 
phase-five issues and a commitment to improving and accelerating the translation of the large 
number of interventions that have already proven successful in efficacy and effectiveness trials is 
critical from a resource management vantage point.  Slow and limited translation poses a very 
practical “resource wasting” concern, and distress over the wasting of significant resources that 
were committed to develop our expansive public health evidence-base is well warranted.   
Indeed, the evidence base for health promotion and disease prevention interventions is 
overwhelmingly comprehensive in some health topic areas.  The Guide to Community 
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Preventive Services, Cancer Control Planet, The National Cancer Institute’s Research- Tested 
Intervention Programs (RTIPs), the National Registry of Evidence-based Programs and Practices 
(NREPP), and The Diffusion of Effective Behavioral Interventions Project are all national level 
initiatives that provide and endorse evidence-based recommendations for programs and policies 
to promote population health.  These national repositories of evidence-based interventions cover 
a wide range of health issues, from health behaviors (e.g., tobacco use and physical activity) to 
chronic diseases (e.g., cancer) and infectious diseases (e.g., HIV) (Taskforce of Community 
Preventive Services; United States Department of Health and Human Services [US DHHS], 
American Cancer Society, and Commission on Cancer; US SHHS, National Cancer Institute; US 
DHHS, Substance Abuse and Mental Health Services Administration, 2007; Academy for 
Educational Development, Center on AIDS and Community Health, 2006).  Unfortunately, just 
as the existence of models that describe the translation process does not ensure effective 
translation from research to practice, a large body of evidence-based interventions does not 
ensure timely and effective translation of these interventions into practice.   
Unfortunately, many of public health’s evidence-based resources, such as those described 
above, go unused or take too long to be adopted and implemented.  The CDC RFA notes that, 
“although most researchers develop evidence-based intervention for public health practice, the 
rate of adoption and implementation is low due to uncharacterized impediments” (2007, p. 8).  
And so, the foremost focus in traditional efforts to improve translation is on moving the well-
developed evidence base into practice as, according this statement from the CDC RFA, the 
researchers who developed the extensive public health evidence-base intended.   But this intense 
focus on moving well-developed evidence based into practice begs the question:  To what extent 
is the development of the public health evidence-base (i.e., phases 1-4 in the standard translation 
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model) developed for real-world practice?  This is the question and concern that drives what this 
paper presents in the next section as a alternative approach to improving translation, which 
proposes that “the ‘system’ of moving from research to usual service programs, to which we 
have subscribed, may be broken and may need to be substantially modified” (Glasgow, 
Lichtenstein, & Marcus, 2003, p. 1263). 
6.4.2 The alternative approach 
As characterized in this paper, a alternative approach to improving translation involves a 
critical examination and rethinking of the standard practices for conducting and translating 
research.  The concept of a alternative approach to improving translation, viewed conversely to 
the traditional approach described in detail in the previous section, was mainly derived from 
several articles on translation and related issues by Russell E. Glasgow, Lawrence W. Green and 
colleagues (Glasgow & Emmons, 2007; Green & Glasgow, 2006; Bull, Gillette, Glasgow, & 
Estabrooks, 2003; Glasgow, 2003; Glasgow, Klesges, Dzewaltowski, Bull, & Estabrooks, 2004; 
Green, 2001).  The development of this concept was also influenced by evaluation work with a 
cancer patient navigator program, an innovative, context-driven intervention.   
As defined in this paper, the alternative approach to improving translation is grounded in 
the logic that “much research fails to translate into practice because the programs and methods 
used fail to address contextual factors,” and promotes the view that “if we want more evidence-
based practice, we need more practice-based evidence” (Glasgow & Emmons, 2007, p. 417; 
Green & Glasgow, 2006, p. 126 respectively).  In other words, in order to accelerate and improve 
translation, changes are needed in the way public health research is conducted—greater attention 
needs to be paid to the context in which programs are delivered (Bull, Gillette, Glasgow, & 
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Estabrooks, 2003; Glasgow, 2003; Glasgow, Klesges, Dzewaltowski, Bull, & Estabrooks, 2004; 
Green, 2001).  Glasgow and colleagues (2003) assert that both external validity factors and 
participatory (with potential beneficiaries, stakeholders and implementers of interventions) 
research methods “are best addressed [and evaluated in the case of external validity factors] 
during the planning phases of research…[and]…should not be left for later phases of research 
but built into efficacy studies” (p. 1264) Moreover, Glasgow and colleagues ( 2003)  promote a 
science of “larger social units that takes into account and analyzes the social context(s) in which 
experiments are conducted” (p. 1264). The researchers convincingly regard the current highly 
controlled nature and linear application of efficacy and effectiveness trials, which is promoted by 
the standard five-phase translation model and widely subscribed to in health sciences research, as 
inadequate for developing interventions that are primed for successful implementation in real-
world settings.        
Clearly, the focus of alternative efforts to improve translation is on the very “‘system’ of 
moving from research” to practice (Glasgow et al., 2003, p. 1263)—particularly phases two 
through five of the standard translation model (i.e., methods development, efficacy trials, and 
effectiveness trials).  Green and Glasgow (2006) explicitly identify the need to improve 
translation through enhancement of standard research practices and go on to suggest that such 
enhancements are worth sacrificing some of the control that is the hallmark of efficacy studies:   
If the health professions and their sponsors want more widespread and 
consistent evidence-based practice, they will need to find ways to generate 
more practice-based evidence that explicitly addresses external validity and 
local realities.  Practice-based research would produce evidence that more 
accurately and representatively reflects the program-context interactions and 
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circumstances in which the results are expected to be applied.  It would do so, 
of course, with some trade-off of the experimental control exercised in 
academically based research (p.128). 
In keeping with the alternative premise that research translation could be accelerated and 
improved by enhancing standard research practices—namely by studying external validity and 
translation during the early stages of research—key translation issues that must be addressed and 
reported on in order to improve translation in public health include:  program reach and 
representativeness, program or policy implementation and adaptation, outcomes for decision 
making, and maintenance and institutionalization (Glasgow & Emmons, 2007, p. 420; Glasgow, 
Lichtenstein, & Marcus, 2003).   
In addition to enhancing current research practices to include a focus on these key 
translation issues, Glasgow and Emmons (2007) advocate for a community-based participatory 
approach to public health research as a “means of enhancing the relevance and effectiveness of 
public health interventions” (p. 417).  Community-based participatory research (CBPR) is a 
collaborative research process that views the community as an active and equal partner in all 
phases of the research process (Goodman, 2001; Israel, Schulz, Parker, & Becker, 1998; 
Scutchfield & Keck, 2003).  This community-centered approach is particularly well-aligned with 
alternative thinking around improving research translation by enhancing research methods to 
reflect more of the content and complexity of the real world.  Glasgow and Emmons (2007) also 
suggest that CBPR facilitates translation because “effective CBPR partnerships build expertise 
and capacity in the community for research and prevention, and thus have significant potential to 
make a lasting impact, even beyond the particular program at hand” (p.417).  So, insofar as slow 
and limited translation is due to a community’s limited resources and capacity to implement 
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evidence based interventions, community participatory approaches to public health research and 
intervention development can help address both scientific and non-scientific (e.g., social/cultural 
and organizational) barriers to translation (Goodman et al., 1998; Yoo et al., 2004).    
Research Development & Practices 
Glasgow and colleagues go beyond describing key translation issues and recommending 
community-based participatory research principles for the improvement of research translation to 
present the concept of practical trials—a model for developing and evaluating programs with 
greater attention to context and external validity (Glasgow, 2003; Glasgow & Emmons, 2007; 
Glasgow, Klesges, Dzewaltowski, Bull, & Estabrooks, 2004).  Glasgow and Emmons (2007) 
explain that the purpose of practical trials is “to provide information that will make health 
information more relevant and to aid decision makers at multiple levels to evaluate the 
applicability and generalizability of research”, and they present the following scope of study for 
practical trials:  
1. Practical trials answer questions of key stakeholders (e.g., decision makers, policy 
makers & clinicians). 
2. Practical trials assess multiple and relevant outcomes, including cost, generalization, 
and quality of life. 
3. In practical trials, diverse, heterogeneous samples are recruited and robustness across 
key subgroups is evaluated. 
4. Practical trials compare clinically meaningful treatment alternatives using research 
designs matched to state of knowledge. 
5. Practical trials include multiple, representative settings and interventionists. 
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6. Issues of particular importance in practical behavioral and public health trials include:  
the level of training & expertise required, and amount of training provided, for 
implementation; patient or client preferences; and algorithms for intervention 
tailoring, or intervention manuals (p. 421). 
It is important to note that Glasgow and colleagues’ writing on practical trials focuses 
primarily on practical behavioral trials to advance evidence-based behavioral medicine 
(Glasgow, Davidson, Dobkin, Ockene, & Spring, 2006).  However, this paper proposes that the 
general concept of practical trials, as outlined in the scope of study presented above, could also 
be applied to, and beneficial for, advancing evidence-based public health—or, rather, practice-
based evidence in public health.  Because practical trials better reflect the content and 
complexity of the real world compared to traditional, more controlled efficacy studies (Glasgow 
& Emmons, 2007; Green & Glasgow, 2006), moving toward more practical trials in health 
promotion and disease prevention research seems a promising strategy for improving and 
accelerating public health research translation.   
Evaluation and Reporting 
In addition to calling for enhancements to standard research practices, Glasgow and 
Emmons (2007) alternative approach to accelerating and improving translation calls for change 
in public health evaluation and reporting practices.  Accordingly, Glasgow and Emmons (2007) 
maintain that “a defining feature of the practical trial [an exemplar for developing programs with 
greater attention to key translation issues] is assessment of multiple and relevant outcomes”, and 
the researchers recommend conducting broader evaluations that include multiple outcomes, 
address generalizability, and report on contextual factors to help enhance integration of research 
and practice (p. 421).  In efforts to conduct broader evaluations, Glasgow and Emmons argue 
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that program developers should collect more process data.  Indeed, process evaluation data are 
valuable for addressing several key translation questions, including those related to intervention 
adoption, adaptation, fidelity, and impact.  Specifically, data from process evaluations: 
? can provide indicators for the impact of an intervention at different levels of program 
implementation (Glasgow & Emmons, 2007).  
? are useful for developing recommendations related to program modifications and 
adaptation at the community level (Forsetlund, Talseth, Bradley, Nordheim, & 
Bjorndal, 2003; Glasgow & Emmons, 2007). 
?  Allow for assessment of community participation, as well as examination of the 
intermediary role community participation plays in health and related social change 
outcomes (Butterfoss, 2006). 
? aid in understanding relationships between specific program elements and program 
outcomes (Saunders, Evans, & Joshi, 2005).  
RE-AIM 
Within the discussion of improving translation through changes to standard public health 
evaluation and reporting practices, it is important to acknowledge RE-AIM (reach, 
efficacy/effectiveness, adoption, implementation and maintenance), an evaluation framework 
recommended throughout the translation literature presented in this paper (i.e., literature relevant 
to both traditional and alternative approaches to improving translation).  Importantly, RE-AIM 
provides a framework for conducting broader evaluations with significant attention to process 
data called.  RE-AIM (www.re-aim.org) was developed to expand assessment of interventions 
beyond efficacy to multiple criteria that can help better identify the translatability and public 
health impact of health promotion interventions (R.E. Glasgow, 2002; R. E. Glasgow, Vogt, & 
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Boles, 1999).  Ultimately, RE-AIM can be used to guide evaluation, as well as planning, 
conduct, and reporting of studies for researchers and practitioners whose goal is to translate 
research into practice (Dzewaltowski, Estabrooks, & Glasgow, 2004; Dzewaltowski, Glasgow, 
Klesges, Estabrooks, & Brock, 2004; Klesges, Estabrooks, Dzewaltowski, Bull, & Glasgow, 
2005; Sussman, Valente, Rohrbach, Skara, & Pentz, 2006).    
Noticeably, the dimensions of RE-AIM are well aligned with the key translation 
questions presented in the CDC RFA (see Traditional Approach section of this paper).  This 
alignment is not surprising as the CDC RFA actually encourages funding applicants to use the 
RE-AIM framework as a guide for evaluating “key variables for translation research…[and] 
relevant and comprehensive criteria to accurately measure and document the desired outcome” 
(2007, p. 32).  The similarity between RE-AIM dimensions (presented within the context of 
Glasgow, Green and colleagues alternative approach to improving translation) and key 
translation questions presented in literature that promotes what this paper has established as a 
traditional approach to improving translation is also expected because:  1) both approaches 
(traditional and alternative) draw on the key translation models and concepts presented earlier in 
this paper (e.g., standard five-phase translation model and diffusion of innovations theory) 
(Glasgow, 2002; CDC), and 2) as maintained in the Comparison of Approaches section of this 
paper, key translation questions transcend approaches (traditional versus alternative) for 
addressing scientific barriers to translation.     
Practice-Based Research 
The field of practice-based research is generally aligned with the progressive assertions 
of Glasgow, Green and colleagues (i.e., in order to improve translation, changes in standard 
research, evaluation and reporting practices must occur) (Bull, Gillette, Glasgow, & Estabrooks, 
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2003; Glasgow, 2003; Glasgow, Klesges, Dzewaltowski, Bull, & Estabrooks, 2004; Green, 
2001), but arguably broader in concept and application than the practical trials and RE-AIM 
framework developed and promoted in papers by Glasgow, Green and colleagues. Recall Green 
and Glasgow’s (2006) declaration that “practice-based research would produce evidence that 
more accurately and representatively reflects the ‘program-context interactions’ and 
circumstances in which the results of the research are expected to be applied” (p. 128).   
A recent landmark report on practice-based research from the Association of Schools of 
Public Health (Potter & Quill, 2006) is briefly reviewed to:  1) present the purpose and scope of 
practice-based research as defined by a leading public health organization, and 2) to highlight 
progressive thinking in the public health field around improving translation through research 
systems change beyond the work of Glasgow, Green and colleagues (Glasgow & Emmons, 2007; 
Green & Glasgow, 2006; Bull, Gillette, Glasgow, & Estabrooks, 2003; Glasgow, 2003; Glasgow, 
Klesges, Dzewaltowski, Bull, & Estabrooks, 2004; Green, 2001), although their work certainly 
seems to represent the most extensive study of the topic in the current literature. 
The Association of Schools of Public Health (ASPH), Council of Public Health Practice 
Coordinators defines practice-based research as “systematic inquiry into the systems, methods, 
policies, and programmatic application of public health practice [which]… includes science-
based inquiry that occurs in practice settings such as field epidemiology, systematic reflection on 
the practice experience, and laboratory analysis—to the extent that such inquiry produces 
generalizable knowledge to improve the outcomes of practice or to inform policy making” 
(Potter & Quill, 2006, p. 3).  The stated goal of practice-based research clearly explains how the 
field relates to research translation:  “The goal of practice-based research is to move the 
knowledge derived from research to creation, through dissemination, and to application to assure 
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the translation and uptake of relevant science into evidence-based practices” (ibid).  According to 
the ASPH report, in practice-based research, public health research is linked directly to public 
health practice through a cycle in which:  1) feedback from application, or practice, informs the 
development of theory, and 2) policies and practices are informed by the re-uptake of knowledge 
from research. 
Practice-based research is described as a flexible process that allows for  
constant adjustments in response to the evolving interests and needs from the 
community.  Thus, approaches, methods, and tools are adapted to the research 
process by:  1) integrating existing methods with new applications; 2) 
adapting methods and tools for new applications; 3) translating methods to 
adapt to emerging and time-sensitive research goals; and 4) developing new 
and innovative approaches, models, methods, and tools to address current and 
future research questions (Potter & Quill, 2006, p. 7).   
According to the ASPH report, community involvement is key for assuring that research is 
contextually and socially appropriate and, consequently, translatable.  This collaborative and 
participatory nature of the practice-based research process calls to mind the critical role that 
community-based participatory principles play in Glasgow, Green and colleagues’ alternative 
approach to improving translation, as well as the researchers’ insistence that research be 
conducted to enhance its relevance to program implementers, key stakeholders and 
policymakers.  Indeed, the ASPH report explains that “practice-based research in public health 
focuses on important practical issues, engages the experience of practitioners in the advancement 
of theory, and informs both practice and public policy with scientifically derived evidence to 
improve community health” (Potter & Quill, 2006, p.17). 
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While practice-based research is a proponent of scientific rigor, it also promotes 
innovation and supports, as do Green, Glasgow and colleagues, moving beyond traditional 
research approaches to develop practical answers to complex public health problems:   
The development, advancement, and dissemination of practice-based research 
all rely on the rigorous scientific evidence combined with research integrity.  
Practice-based research goes beyond traditional research approaches and seeks 
greater innovation in analyzing the socioeconomic and cultural factors that 
influence population health.  Implicit in these innovative approaches is the 
recognition of new challenges to research integrity (Potter & Quill, 2006, 
p.18).   
In expanding on the recognition of challenges to research integrity, the ASPH report 
notes that “significant tension exists between the imperatives of the university-based research 
enterprise and the obligations of agencies and organizations responsible for addressing the health 
needs of populations” (Potter & Quill, 2006, p. 14).  The ASPH report goes on to point out that, 
in the public health field, there is insufficient funding support for, and a general limited 
recognition and understanding of, the conduct of practice-based research (Potter & Quill, 2006). 
As suggested by Green & Glasgow (2006), practice-base research requires some trade-off 
with the experimental control traditionally exercised in academically-based research as:  1) the 
engagement of the community, key partners and stakeholders in practice-based research requires 
a level of relation-building, information-sharing, and time demands that is not as essential to 
other, more traditional research-driven, forms of research—thus, practice-based research 
processes must be flexible; and  2) the effort to solve complex public health programs within the 
context of real-world settings and academic-practice-community partnerships requires a 
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comprehensive, multi-method, multi-layered research strategy that goes beyond the types of 
evidence and methods typically used in tightly controlled efficacy trials (Green & Glasgow, 
2006; Potter & Quill, 2006).  However, this is not intended to suggest that practice-based 
research is not subject to standards of rigor and peer-evaluation—the ASPH report clearly states 
that practice-based research is scholarly and rigorous, in addition to practical—but rather 
suggests that there are many types of evidence that can inform and support the development and 
evaluation of public health research and interventions (Green & Glasgow, 2006; Potter & Quill, 
2006).  Further exploration of this issue of evidence as it relates to the two approaches for 
addressing scientific barriers that challenge translation follow. 
Defining Evidence 
As established in previous sections, the alternative approach to improving and 
accelerating translation calls for changes in standard public health research, program 
development, evaluation and reporting practices to better address real-world contextual factors.  
But a critical examination of standard research practices—particularly finding fault in the 
efficacy-to-effectiveness transition in the early phases of the standard translation model—
challenges not only standard intervention development practices, but also calls into question the 
very notion of what constitutes evidence in the public health field.  So Glasgow and Emmons 
(2007) note that, in addition to a failure to address contextual factors, much research is not 
translated into practice because it “employs a limited and researcher-centric perspective as to 
what constitutes evidence” (p. 417 ).  Green (2001) poses a critical question:  “Where did the 
field get the idea that evidence of an intervention’s efficacy from carefully controlled trials could 
be generalized as the best practice for widely varied populations and settings?” (p. 167).  Related 
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to Green’s question, Peter Briss (2005) of the Centers for Disease Control and Prevention’s 
Community Guide Branch warns that  
many evidence gaps remain and the gaps are not random.  There are still 
cultural, geographical, economic, and methodological biases in determining 
what is studied and how.  The availability of high-quality evidence often 
seems to favor clinical treatment over prevention, and interventions that 
are…simple over those that are more complex, those with shorter-term 
objectives over those that are longer-term….  Much more work is needed to 
fill these gaps and to shine the light where it is currently dark (p. 829). 
While Glasgow and colleagues recognize the value of evidence from tightly controlled 
efficacy trials, they argue that the field’s conceptualization of evidence needs to broaden 
significantly to include additional evidence types (R. E. Glasgow & Emmons, 2007; R. E. 
Glasgow, Lichtenstein, & Marcus, 2003; Green & Glasgow, 2006).  Glasgow and Emmons 
(2007) suggest that, for many public health problems, intervention strategies should be 
recommended based on the best available evidence instead of waiting for the best possible 
evidence.  According to the researchers, there are several types of evidence that can be drawn 
upon in public health program development and evaluation, including theoretical or mechanism 
data, feasibility/implementation evidence, contextual information (e.g., constraints, history, 
resource availability), intended primary outcome evidence, unintended or unanticipated outcome 
results, process results, outcome or clinical data, quality improvement data, cost and economic 
data, qualitative data, local data, internal validity evidence, and external validity evidence.   
Unfortunately, as noted by Glasgow and Emmons (2007), to date, discussions around 
different types of methods and the utilization of mixed methods to integrate various types of 
 156 
evidence have led to unproductive “my evidence is superior to your evidence” debates (p. 418).  
Furthermore, the authors maintain that there are no set answers to the question of what 
constitutes evidence, nor are there simple answers to the question of when do researchers have 
enough evidence to translation research into practice.  However, Briss’(2005) warning suggests 
that, while there are no set answers regarding what constitutes evidence, the public health field 
clearly favors certain types of evidence.  Where Glasgow, Green and colleagues (R. E. Glasgow 
& Emmons, 2007; R. E. Glasgow, Lichtenstein, & Marcus, 2003; Green & Glasgow, 2006) 
alternative approach to improving translation suggests the value of various types of evidence in 
developing and testing interventions, then moving them into practice; the traditional approach to 
improving translation explored earlier in this paper seems to subscribe to a more narrow view of 
what constitutes evidence.  Conceptualization of evidence is one of the main ways that 
alternative and traditional approaches to improving translation, as they are characterized in the 
paper, differ.  The following Comparison of Approaches section expands on the differences and 
similarities between the traditional and alternative approaches for addressing scientific barriers to 
translation 
6.4.3 Comparison of approaches 
This paper has used the terms traditional and alternative to describe two dominant approaches 
presented in the literature for improving and accelerating translation—particularly as this task is 
related to overcoming scientific barriers to translation.  Similarities and differences between the 
two approaches have been noted throughout this paper and are summarized in Figure 3.  Given 
significant similarities between the two approaches (i.e., agreement on key research questions 
and promotion of comprehensive, multi-method evaluation frameworks and broad stakeholder 
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involvement), it is the position of this paper that the traditional and alternative approaches are 
equally valid for addressing translation issues, and that lessons learned from traditional efforts to 
improve translation can both inform and benefit from alternative approaches to enhancing 
translation.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.  Comparison of Traditional and Alternative Approaches to  
Improving Translation 
Arguably the most critical differences between the two approaches to improving 
translation is their view of standard research and program development practices, as they are 
depicted in the five phase translation model, and their conceptualization of evidence.  
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& Risser, 2002).  Thus, the traditional approach does not view standard research and intervention 
development practices as targets for change in efforts to improve and accelerate translation. 
Rather the traditional approach implicitly promotes the standard, linearly-applied and highly 
controlled system of moving from basic research to practice through efficacy then effectiveness 
trials.  So, the question of focus in the traditional approach to improving translation is:  how do 
we move evidence-based interventions into practice?  (Schechter & Brunner, 2005).  Evidence-
based within this context means “that the proposed intervention has undergone sufficient 
scientific evaluation to be proven efficacious or effective”, where scientific evaluation primarily 
refers to peer-reviewed publications of quantitative or qualitative research, evaluation reports, 
meta-analyses, or descriptive or survey research (CDC, 2006, p.31).  There is particular interest 
in enhancing translation for the large public health evidence base recorded in national guides and 
clearinghouses, including The Guide to Community Services and the National Guideline 
Clearinghouse (CDC, 2006).  While at first glance the CDC RFA description of sufficient 
scientific evaluation seems reasonably flexible, it is important to note the preferred requirement 
of peer-reviewed publication, which Briss (2005) maintains is still very much biased toward 
more traditional views of what is published as evidence (i.e., tightly controlled trials and simple 
interventions). 
In contrast to traditional approaches, the alternative approach promotes focusing on 
translation issues in the early phases of research development (Glasgow & Emmons, 2007; 
Green & Glasgow, 2006).  Thus, the alternative approach asserts that standard research and 
intervention development practices must be modified and enhanced in order to improve and 
accelerate translation. Moreover, the alternative approach explicitly criticizes the standard 
linearly applied and highly controlled system of moving from basic research to practice through 
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efficacy then effectiveness trials (Glasgow, Lichtenstein, & Marcus, 2003).  Consequently, the 
key question of focus in the alternative approach to improving translation is:  how do we change 
our current system of research, program development and evaluation to develop more practice-
based evidence?  While evidence within the context of the alternative approach includes results 
of highly controlled trials, it is expanded to also include types of evidence that are featured less 
prominently in the public health literature, including cost and economic data and local historical 
and contextual data (Glasgow & Emmons, 2007). 
As a huge investment has been made in the development of the current public health 
evidence base; it is certainly worthwhile to explore tools and strategies for moving this evidence 
base into practice (Schechter & Brunner, 2005; Sussman, Valente, Rohrbach, Skara, & Pentz, 
2006), which is established in this paper as a major focus of the traditional approach to 
improving translation.  However, developing evidence with more attention to real-world issues 
and context is definitely a promising strategy for improving translation, one that this paper 
argues should be widely supported and adopted in the public health field.  Perhaps the alternative 
approach to improving translation is particularly useful for public health issues, like reducing 
racial/ethnic disparities in cancer care, for which a limited number of effective health 
intervention and education strategies exists.  In these cases, studies more aligned with the 
description of practice-based research presented in this paper are arguably the best way to 
proceed as the flexible, alternative approach will support the development of evidence or 
interventions that are primed for implementation in real-world settings (Potter & Quill, 2006).  
Admittedly, the notion of the alternative approach to improving research translation is largely 
conceptually based.  However, the momentum of the cancer patient navigation movement in this 
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country suggests that this conceptually-derived approach holds some value for enhancing public 
health translation. 
6.5 THE PROMISE OF THE ALTERNATIVE APPROACH—INSIGHTS FROM 
THE CANCER PATIENT NAVIGATION MOVEMENT 
Patient navigation for cancer care “refers to support and guidance offered to persons with 
abnormal findings in accessing the cancer care system and overcoming barriers to quality, 
standard care.  Navigation spans the period from abnormal finding from cancer detection 
procedure through necessary cancer diagnostic tests to completion of cancer treatment” (United 
States Department of Health and Human Services, National Institutes of Health, National Cancer 
Institute [NCI], 2004, p. 2).  There is general consensus throughout the public health field that 
patient navigation programs “provide a very promising approach to reducing disparities for 
cancer and other diseases” (Institute for Alternative Futures, 2007, p. 3).   
Hundreds of patient navigator programs have already been established throughout the 
country as part of local cancer control efforts by cancer centers, community-based clinics and 
philanthropy (Dohan & Schrag, 2005; Hede, 2006).  Although, interestingly, “studies to date 
have not employed sufficiently rigorous research designs to allow any conclusions about the true 
effects of navigation programs”, and “published evidence from randomized trials demonstrating 
that navigation is effective in reducing health disparities does not exist”(Dohan & Schrag, 2005, 
p. 853).  What then accounts for the intervention model’s widespread adoption—an adoption that 
has gained such widespread momentum, in fact, that it has recently received over $19 million 
worth of attention from NCI in the form of the Patient Navigator Research Program (PNRP), 
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which was jointly launched by NCI and the American Cancer Society in 2005.  The purpose of 
the PNRP is the development of innovative patient navigator interventions to reduce cancer 
health disparities and testing their efficacy and cost-effectiveness (NCI, 2005). 
It is the authors’ opinion that those characteristics of the original patient navigator model 
that are consistent with principles and values representative of alternative approaches to 
translation (Figure 1) contributed to the model’s popularity and widespread adoption.  In keeping 
with this reasoning, the development of cancer patient navigation was grounded in contextual 
realities.  In a more global sense, the intervention emerged within the context of both a national 
cancer care system that experiences significant disparities in disease morbidity and mortality and 
a public health evidence base void of effective intervention for reducing cancer care disparities.  
Vargas and colleagues (2008) share that the original patient navigator program model was also 
established partly in response to analysis of mortality data for the Harlem community that 
revealed racial and ethnic disparities in excess mortality from cancer and other treatable 
diseases—that is, it was developed partly in response to local contextual realities.  Additionally, 
at its most basic level, cancer patient navigation can be described as a context-driven 
intervention as the services navigators provide are specific to the needs of their patients and the 
barriers they identify (C-Change, 2005).     
Applying a broad conceptualization of evidence, another feature this paper attributes to 
the alternative approach to translation, Dr. Freeman developed the first patient navigation 
program based on local disease burden data; key findings from the American Cancer Society’s 
1989 hearings on cancer in poor populations, in which testimony was heard from poor cancer 
patients, their medical care providers and other cancer experts (Freeman, Muth, & Kerner, 1995; 
Vargas, Ryan, Jackson, Rodriguez, & Freeman, 2008); and his “personal experience in providing 
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cancer care to poor black patients in Harlem (Freeman, 2006, p. 139).  After publication and 
promotions of initial positive findings from the early navigator model, findings that included no 
evidence of causal association, the model was widely adapted and replicated across the country 
(Vargas et. al, 2008).   
It is also worth noting that the seminal article (Freeman, Muth, & Kerner, 1995) on the 
development of the American Cancer Society-supported Harlem Cancer Education and 
Demonstration Project (HCEDP), the nation’s first patient navigator program, reflected a 
program development process that, consistent with the alternative approach described in this 
paper, addressed translation issues early on: 
“The model developed and tested within the HCEDP was designed 
specifically to rely on individuals with relatively low salaries whose training 
and experience would be more limited but whose presence within the system 
could prove affordable….The HCEDP model was based in on the extensive 
collaborative experience of…promoting and delivering cancer screening 
services to low-income Harlem residents” (p.21). 
In a sense, the cancer patient navigation model represents a complete rearrangement of 
the standard five phase translation model.  The recently launched national rigorous, expensive 
and relatively controlled efficacy and effectiveness studies have followed more practice based 
research, that was grounded largely in experiential evidence, and widespread implementation.  
The cancer patient navigation movement applied an alternative approach to program 
development and translation with noteworthy success. The public health literature suggests that 
patient navigation services and programs are associated with improved rates of screening and 
follow-up, lower clinical stage of presentation, and higher patient satisfaction (Dohan & Schrag, 
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2005).  Program descriptions and process evaluations further suggest that patient navigator 
services improve clinics’ ability to engage, track, and support patients and to develop and 
enhance communication and trust between clinic staff and patients from disadvantaged groups 
(Dohan & Schrag, 2005).    
6.6 CONCLUSION 
The cancer patient navigation movement is described as a case in point for the promise of 
alternative approaches to the traditional linear and phased processes for moving between public 
health research and public health practice.  The problem of limited and slow translation in the 
public health field calls for both more broad and practical conceptualizations of evidence and an 
increased emphasis on contextual realities and public health practice in program development 
research.  The development of the cancer patient navigator model was informed by qualitative 
data related to the myriad cancer care barriers poor and minority patients face, the real world 
practice experience of health care professionals, and local health statistics.  Thus, the 
intervention model is characterized as practice based evidence, the development of which is a 
promising approach for improving public health translation.  Cancer patient navigation was 
developed within the context of real world public health practice rather than through highly 
controlled research studies, as is the prevailing method of intervention development in public 
health.  Consequently, the original model introduced by Dr. Freeman (1995) was well-suited for 
implementation in real world practice environments and has been adopted and adapted by 
hundreds of community and health care settings across the country (Dohan & Schrag 2005).  
Figure 4 illustrates this non-traditional process of public health program development. 
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Figure 4.  Alternative Approach to Public Health Research Translation 
 
As presented in Figure 4, the alternative approach to moving from public health research 
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experimental studies are added to the intervention’s evidence base and can then inform 
enhancements to the intervention model.  Those who adopt and adapt the original intervention 
model, whether before or after causal evidence on the intervention’s effects is available, can also 
conduct systematic evaluations.  These systematic evaluations will also produce valuable 
evidence that can be used to inform enhancements to the original model, adopted programs, or 
experimental studies.   
The alternative approach values a broad and practical conceptualization of evidence and 
places appropriate emphasis on real world contexts.  These principles are key for addressing the 
problem of limited and slow public health research translation.  The non-traditional development 
process of the cancer patient navigation model, and resulting widespread adoption of the model, 
suggests that the alternative approach to moving between public health research and practice is a 
valuable method for developing interventions that work in real world settings to effectively 
address complex public health problems, such as cancer care disparities.   
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7.0  GENERAL DISCUSSION AND CONCLUSIONS 
The MOPP evaluation provided valuable qualitative and quantitative data related to program 
implementation achievements and challenges.  Moreover, the evaluation produced useful 
products (e.g., logic model and data reporting templates) and sparked immediate small-scale 
enhancements (e.g., database modifications).  The evaluation also called attention to key issues 
that should be monitored closely within the MOPP program, and, perhaps, within the larger 
public health movement.   These key concerns include effectively navigating patients with 
substance abuse and minimizing the emotional burden work has on patient navigators.  There 
may be some value in longitudinally studying the issue of the emotional burden patient 
navigation work places on navigators to determine if and how this staff-reported burden changes 
over time.   
While the evaluation collected rich data from staff and participant interviews, the absence 
of input from other stakeholders (e.g., referring physicians and representatives of UPMC 
administration) is a study limitation.  However, evaluation findings will be shared with 
stakeholders and it is recommended that, as resources allow, they be included in future 
evaluations.  Saturation was not reached in the patient interviews, and this is another study 
limitation.  As presented in the results section, all interviewees described social support services 
they received through MOPP.  However, information shared during one of the final interviews 
suggests that it may be valuable to further explore patients’ level of understanding about the 
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various services MOPP offers.  As resources and patients’ health conditions allow, future 
evaluations of the Minority Outreach Pilot Program, and evaluations of cancer patient navigator 
programs in general, should collect qualitative from larger numbers of patients to help ensure 
that saturation is reached.   
 Quantitative data analysis in the evaluation is limited to descriptive statistical analysis, 
which produces useful information, but cannot provide causal information related to the impact 
of program activities.  The evaluation could have been enhanced through medical chart review to 
assess relationship between program services provided and objective measures of treatment 
compliance or completion.  Although, this would have required a great deal of time and staff 
resources, as well as additional precautions for human subjects and health care information 
protection.    
Fleisher rightly insists that “as the practice of patient navigation expands, there is a great 
deal to be learned about the process, political climate, and day-to-day challenges in planning and 
implementing a navigation program” (2008, p.2).  Ultimately, the MOPP evaluation may prove 
valuable as a model for conducting program evaluation for cancer patient navigation that 
enhances local program practice; respects real-world time, funding, and ethical constraints; and 
systematically collects and disseminates valuable information on program context, 
implementation, and early outcomes.  In turn, the MOPP program can continue to enhance and 
expand evaluation efforts by incorporating, as appropriate for program resources and stakeholder 
priorities,  data collection and analysis methods found to be practical and informative in other 
existing cancer patient navigator program.   
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7.1 RECOMMENDATIONS FOR PROGRAM IMPROVEMENT AND FUTURE 
EVALUATION & STUDY 
The following recommendations were either directly and frequently offered, or informed by 
ideas shared, in evaluation interviews or observed program meetings.  They are summarized and 
organized in Appendix E according to the levels of the social ecological framework.  They are 
highlighted in this manner to assist program staff, stakeholders and other public health 
practitioners who have, or are interested in developing cancer patient navigator programs, with 
targeting program efforts and prioritizing activities for program maintenance and expansion.  
Additionally, many of these recommendations also represent opportunities for future study 
within the cancer care and patient navigation field: 
? Present detailed participant data, such as those tables and graphs presented in this dissertation,  
related to ineligibility for CCTs and diagnosis stage to UPMC policymakers and 
administration to advocate for:  1) an assessment of , and if deemed appropriate, 
modifications to the types of clinical trials offered and CCT eligibility criteria, 2) continued 
and enhanced efforts to identify cancer patients early, particularly among minority, 
disadvantaged, and other populations disproportionately affected by the cancer burden.  This 
may include requests to use program gap funds to cover diagnostic work-ups for patients who 
are referred through the Prevention and Early Detection Clinic and other UPMC and 
community screening and early detection efforts.  This data should also be shared with 
national partner cancer organizations to support efforts to reduce disparities in CCT 
participation and with other stakeholders, including community partners and insurers, to 
encourage continued and expanded efforts (e.g., patient screening reminders and incentives) 
for reaching cancer patients earlier. 
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? Implement regular data quality assurance checks to facilitate improvements to program data 
collection and the program database.  This may include a monthly or quarterly review of the 
raw data from the program database. As, the current interface presents data under various 
tabs/screens and only allows users to view data from one patient at a time, it is not conducive 
to checking for missing or incomplete data, overlap in variables or variable codes, and related 
issues that can be more easily checked through basic descriptive statistical analysis of the raw 
program data.  If HIPAA or other restrictions prevent the regular review and descriptive 
statistical analysis of raw program data, it may also be possible to perform data quality checks 
by requesting more detailed and extensive data tables and reports from the program 
administrator.  Specifically, data reports and tables should account for missing data so the 
program can easily identify and investigate any errors or challenges in data collection and 
entry.  Additionally, denominators should be noted when reporting percentages to ensure 
accurate interpretation of program numbers and to facilitate comparisons between subgroups 
of participants and over time.  Lastly, related to CCT enrollment, it is recommended that the 
program present enrollment among eligible patients to more accurately reflect progress on 
increasing CCT participation.  Perhaps the tables presented in this dissertation could be used 
by the database administrator as templates for data reporting.   
? Present data and concerns around patients with substance abuse and addiction problems to 
administration and national partner organizations to identify, and potentially advocate for 
increasing, resources and services to help minimize the negative effects these problems may 
have on patients’ cancer care.   This issue does not appear in the patient navigation literature, 
and may be an important one to explore across the field as these health concerns will likely 
require significant attention and resources where they exist in patient navigator programs.   
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? Explore resources and options for assisting staff, particularly those who have regular direct 
contact with patients, in coping with the emotional impact related to program work.  These 
may include the establishment of employee support groups, or building connections with 
existing groups. Options could also be explored for adjusting caseload or work responsibilities 
during periods of high emotional stress.  If additional navigators are hired, particularly if lay 
navigators are hired, training should include a discussion, complete with examples and a 
quantitative description of participant characteristics, to help, to the extent possible, prepare 
navigators for coping with sharp health decline and death among their patients.     
? Review program theory (i.e., logic model) and summary data related to patients barriers, 
needs and program services to inform staff discussion and planning around the potential costs, 
benefits, and options for adding a member with clinical expertise to the staff.  While health 
care professional navigators may be very effective at explaining treatment options and 
medical findings to patients, it is not necessarily essential or cost-effective to assign health 
care professionals to patient navigator programs (Freeman, 2007).  Based on patient 
interviews, participants most highly value the program for the assistance they receive in 
overcoming logistical and access barriers to cancer care.  In addition, a great deal of 
appreciation was expressed for the emotional support provided by patient navigators.  The 
literature does not currently include studies that clearly demonstrate whether trained lay 
navigators versus health care professional navigators are a better approach within various 
contexts (Freeman, 2007).  However, Dr. Freeman, who is credited with creating and 
implementing the country’s first patient navigator program, maintains:  “The decision whether 
to use lay versus professionally trained navigators (or preferably both) should ultimately be 
based on the unique needs, structure, and patient population of each organization.” (2007, p.2) 
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? If an expansion is approved, consider phasing in additional program target populations so the 
expansion can be carefully monitored and necessary adjustments can be made to program 
resources to ensure all participants continue to receive high quality program services.  To the 
extent possible, improvements to the database should precede program expansion as current 
database challenges are likely to be exacerbated by rapid increases in the program population.  
Removal of unused or overlapping fields, and perhaps the addition of new or refined fields 
should help facilitate efficient, complete and accurate data entry to better support service 
provision and program monitoring as the intervention continues to grow. 
? Review findings from this program evaluation and the program logic model to identify 
questions for future evaluations and to assess and plan for the availability of data, both 
quantitative and qualitative, to support ongoing program evaluation, including outcome 
evaluation as the program matures.   
7.2 PUBLIC HEALTH SIGNIFICANCE 
Findings from the MOPP evaluation can be used to guide program improvement efforts 
and to facilitate advocacy for ongoing funding and organizational support, expansion, and, 
possibly, replication.  In supporting MOPP implementation, enhancement, and growth, the 
proposed evaluation potentially contributes to the reduction of cancer care disparities in 
Pittsburgh communities served by participating UPMC sites.  In addition, this dissertation 
addresses the need to develop the literature on patient navigation (Dohan & Schrag, 2005).  
Dohan and Schrag note that “systematic evaluations of navigation only recently have begun and 
have yet to appear in the literature…many navigation programs have been oriented toward local 
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quality-improvement initiatives rather than scientific research, evaluation, and publication (2005, 
p. 849).   
In a recent report on published cancer patient navigator information, C-Change noted that 
few comprehensive cancer centers appear to have discrete cancer patient navigation programs, 
and that is rare to find targeted patient navigation efforts for cancers other than breast cancer 
(date).  The unique nature of the Minority Outreach Pilot Program (i.e., it is a discrete and multi-
site navigator program housed within a comprehensive cancer center and it serves patients with 
all cancer diagnoses) suggests that evaluation findings represent a particularly original and 
valuable contribution to the patient navigation literature.   
Fleisher rightly insists that “as the practice of patient navigation expands, there is a great 
deal to be learned about the process, political climate, and day-to-day challenges in planning and 
implementing a navigation program” (2008, p.2).  It is expected that the MOPP evaluation will 
serve as a model for conducting navigator program evaluation that enhances local program 
practice; respects real-world time, funding, and ethical constraints; and systematically collects 
and analyzes valuable information on program context, implementation, and early outcomes to 
make meaningful contributions to the patient navigation literature.     
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APPENDIX A 
MINORITY OUTREACH PILOT PROGRAM LOGIC MODEL 
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APPENDIX B 
VARIABLES INCLUDED IN DESCRIPTIVE STATISICAL ANALYSIS OF THE 
MINORITY OUTREACH PILOT PROGRAM DATABASE 
Name Label Values Measurement Level 
Patient_ID program assigned 
ID # 
N/A nominal 
Age patient age N/A interval 
Age_Range patient age range 1 <20 
2 20-49 
3 50-64 
4 65-74 
5 75+  
nominal 
Gender patient gender 0 Female 
1 Male  
nominal 
Race patient race   0     African American 
  1     Other 
nominal 
Date_Referral date of patient’s 
referral to 
program 
N/A interval 
Program_Year year patient 
entered program 
 1      2006 
 2      2007 
 3      2008 
interval 
ReferredBy referral source 1 Case finding- MOPP SW 
2 CIRS   
3 Clinical Research Coord 
4 Collaorative Practice Nurse 
5 Community Agency  
6 Oncologist  
nominal 
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Name Label Values Measurement Level 
7 Other   
8 Other Medical Doctor  
9 Other UPMC site  
10 Primary Care Physician 
11 
Prevention Early Detection 
Center 
12 Self-family-friend  
13 Social worker  
14 Surgeon    
CT_Screen_Only patient only 
screened by 
program for CCT 
participation 
 
0 No 
1 Yes  
nominal 
NavigatorAccepted patient accepted 
navigator 
0 No 
1 Yes  
nominal 
Site_Attending patient’s cancer 
care site 
 
1 Beaver 
2 Hillman 
3 Jefferson 
4 Magee 
5 McKessport 
6 Mercy 
7 Moon Med 
8 Murtha 
9 Natrona 
10 New Castle 
11 Passavant 
12 Shadyside 
13 St. Margaret  
nominal 
Diagnosis patient’s cancer 
diagnosis 
1 No cancer diagnosis 
2 Not yet diagnosed 
3 
Acute Lymphoblastic Leukemia,  
Adult 
4 Acute Myeloid Leukemia, Adult 
5 Bile Duct Cancer, Extrahepatic 
6 Bladder Cancer 
7 Brain Tumor, Adult 
8 
Brain Tumor, Cerebral 
Astrocytoma/Malignant Glioma 
nominal 
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Name Label Values Measurement Level 
9 Brain Tumor, Childhood (Other) 
10 Breast Cancer 
11 Cervical Cancer 
12 Chronic Myelogenous Leukemia 
13 Colon Cancer 
14 Esophageal Cancer 
15 Head and Neck Cancer 
16 Hodgkin's Lymphoma, Adult 
17 Kaposi's Sarcoma 
18 Laryngeal Cancer 
19 Lung Cancer, Non-Small Cell 
20 Lung Cancer, Small Cell 
21 
Lymphoma, Non-Hodgkin’s  
Adult 
22 Melanoma 
23 Mesothelioma, Adult 
24 
Multiple Myeloma/Plasma Cell 
Neoplasm 
25 Myelodysplastic Syndromes 
26 
Non-malignant Hematologic  
Disorder 
27 
Osteosarcoma/Malignant Fibrous 
Histiocytoma 
28 Ovarian Epithelial Cancer 
29 Pancreatic Cancer 
30 Prostate Cancer 
31 Rectal Cancer 
32 Renal Cell (Kidney) 
33 
Renal Pelvis and Ureter,  
Transitional Cell Cancer 
34 Sarcoma, Soft Tissue 
35 Stomach (Gastric) Cancer 
36 
Thymoma and Thymic  
Carcinoma 
37 Unknown Primary Site  
D_Stage stage of patient’s 
cancer 
0 Screening or unable to stage 
1 I 
2 II 
3 III 
ordinal 
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Name Label Values Measurement Level 
4 IV  
CT_Enrolled patient’s CCT 
enrollment status 
0 No 
1 Yes  
nominal 
ReasonNotEnrolled reason patient is 
not enrolled in 
CCT 
0 Enrolled  
1 Already on rx 
2 Lost to follow-up 
3 
MD chose other 
treatment 
4 Medically ineligible 
5 No crc covereage 
6 No hipaa consent 
7 No trial available 
8 Non-cancer  
9 Pending  
10 Poor ps  
11 Prior cancer  
12 Refused  
13 Requires more surgery 
14 Secondary primary  
nominal 
Marital_Status patient’s marital 
status 
0 Single 
1 Married 
2 Divorced 
3 Other 
4 Unknown 
5 Widowed  
nominal 
LA_Alone patient’s living 
arrangement 
(alone) 
0 No 
1 Yes  
nominal 
Insurance patient’s 
insurance 
provider 
1 Commercial Indemnity Insurance 
2 
Commercial Managed Care 
(HMO/PPO/POS) 
3 
Medicaid Managed Care  
(HMO/PPO/POS) 
4 Medicaid/Public Assistance 
5 Medicare   
6 
Medicare Managed Care  
(HMO/PPO/POS) 
7 Military (DOD,CHAMPUS,VA) 
8 Other Public Coverage  
9 Self Pay or No Insurance  
nominal 
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Name Label Values Measurement Level 
Barriers 
B_CoMorbids 
B_Elder_Care 
B_Financial 
B_Health_Beliefs 
B_Housing 
B_Insurance 
B_Job_Resp 
B_Other 
B_Poor_Support 
B_Spritual_Relig 
B_Transportation 
B_None_ID 
patient-identified 
barriers to cancer 
care: 
cormobidities, 
elder care, health 
beliefs, housing, 
insurance, job 
responsibilities, 
poor support, 
spiritual/religious, 
transportation, 
none identified 
0 No 
1 Yes  
nominal 
PN Services 
Nav1_ES 
Nav2_Trans 
Nav3_Check 
Nav4_AR 
Nav5_Info_Ed 
Nav6_Other 
NavServ_None 
services 
navigators 
provide patient:  
emotional 
support, 
transportation, 
check-in with 
patient via phone 
or in person, 
appointment 
reminder, 
informational or 
educational call 
or visit, 
other (call backs, 
efforts to reach by 
phone, brief intros
no PN services 
recorded) 
0 No 
1 Yes  
nominal 
Comorbidities 
 
C1_Addiction 
C2_Arthritis 
C3_Asthma 
C4_CAD 
C5_Cancer_other 
C6_COPD 
C7_Dementia 
C8_Diabetes 
patient’s 
medically 
documented 
comorbidities 
0 No 
1 Yes  
nominal 
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Name Label Values Measurement Level 
C9_GERD 
C10_GI_condition 
C11_Gout 
C12_Hearing 
C13_Hypercholeserolemia 
C14_Hyperlipidemia 
C15_Hypertension 
C16_Kidney_Disease 
C17_Liver_Disease 
C18_Other 
C19_Psychiatric 
C20_Pulmonary_19 
C21_Stroke 
C22_Thyroid_Disease 
C23_Vision 
Total_CM patient’s total 
number of 
comorbidities 
N/A interval 
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APPENDIX C 
STAFF AND PARTICIPANT INTERVIEW SCHEDULES 
C.1 STAFF INTERVIEW QUESTIONS BY EVALUATION FOCUS 
Evaluation Focus Staff Interview Questions & Probes 
? How many participants does the 
program serve, and what are the 
characteristics of the program 
participants? 
1. How would you describe the group of patients you serve 
through the Minority Outreach Pilot Program? 
? What is the program’s reach into 
the target population?  
2. Would you say that the program is serving the intended 
population?  Why or why not? 
? To what extent is the program 
being implemented as planned? 
3. In what ways are program activities being implemented as 
planned?  In what ways are they not being implemented 
as planned?  Why do you think that is? 
? Is the program making progress 
toward the achievement of short-
term outcomes? 
4. Would you say that the program is making progress 
toward achieving desired outcomes in patients?  Why or 
why not?  In the participating UPMC sites?  Why or why 
not? 
5. What kind of changes, if any, do you think should be 
made to improve the program?  For the participants?  For 
the participating UPMC sites?  For staff?  For the 
community? 
7. How would you summarize the program’s current impact 
on:  patients enrolled in the program?  On the UPMC sites 
that participate in the program?  On the surrounding 
community?  On you as [staff position]? 
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Evaluation Focus Staff Interview Questions & Probes 
? Are there unintended or 
unexpected program outcomes? 
6. Based on your experience, has MOPP had any impact, or 
have the navigation services led to any outcomes, that 
were unplanned?  These can be positive or negative 
unexpected outcomes.  Please explain. 
C.2 PARTICIPANT INTERVIEW QUESTIONS 
1. How did you first meet [name of PN]?  
2. How do you two typically meet, over the phone, in person? 
probe: How often do you meet? 
3. Has [name of PN] helped you in any way? How? 
4. Are there any things you needed help with that [name of PN] didn’t help enough with? Please 
tell me about that. 
5. What do you like most about working with [name of PN]? Why?  
6. Is there anything that you don’t like about working with [name of PN]? Why? 
7. How would you change what [name of PN] does? Why? 
8. Do you know any of the people [name of PN] works with? [Name of 2nd PN]? [Name of 
Social Worker]? If yes,  
follow-up: Please tell me a little bit about how you know them and how they’ve worked with 
you? 
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Participants who initially refused, but eventually accepted, patient navigator services were also 
asked the following questions in addition to those listed above: 
9. Why did you decide not to work with [name of PN] at first? 
probe: What made you change your mind? 
Participants who declined patient navigator services outright were asked the following question: 
Please tell me why you decided not to accept [name of PN]’s services to help with your care.  
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APPENDIX D 
CHARACTERISTICS OF PROGRAM PARTICIPANTS BY PROGRAM YEAR 
The following table presents program participant characteristics by program year.  The time 
periods assigned to each program period (i.e., March 2006-December 2006; January 2007-
Decemember 2007; and January 2008 to present, which in the case of this evaluation was April 
2008) are aligned with MOPP program monitoring and reporting practices to facilitate use of 
data for ongoing program planning, evaluation and improvement.  Program year data was not 
recorded for 15 participants, so those participants were not included in this analysis. 
Percent 
Characteristic 2006 
(n=91) 
2007 
(n=106) 
2008 
(n=37) 
Age Group 
<20 
20-49 
50-64 
65-74 
75+ 
Unknown 
Total 
 
0 
30.8 
40.7 
20.9 
7.7 
0 
100 
.9
27.4
44.3
14.2
11.3
1.9
100
0
29.7
40.5
18.9
10.8
0
100
Gender 
Female 
Male 
Missing 
Total 
 
57.1 
42.9 
0 
100 
66.0
34.0
0
100
51.4
45.9
2.7
100
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Percent 
Characteristic 2006 
(n=91) 
2007 
(n=106) 
2008 
(n=37) 
Referral Source 
Case Finding (MOPP Social Worker) 
CIRS 
Clinical Research Coordinator 
Collaborative Practice Nurse 
Community Agency 
Oncologist 
Other 
Other Medical Doctor 
Other UPMC Site 
Primary Care Physician 
PEDC 
Self/Family/Friend 
Social Worker 
Surgeon 
Missing 
Total 
 
24.2 
16.5 
12.1 
6.6 
0 
3.3 
1.1 
0 
2.2 
1.1 
3.3 
2.2 
23.1 
4.4 
0 
100 
25.5
13.2
6.6
4.7
6.6
3.8
0
.9
1.9
.9
6.6
3.8
17.0
8.5
0
100
37.8
24.3
5.4
2.7
2.7
0
0
0
0
2.7
2.7
0
18.9
2.7
0
100
Patient Navigator 
No 
Yes 
Total 
 
62.6 
37.4 
100 
63.2
36.8
100
94.6
5.4
100
Cancer Stage 
I 
II 
III 
IV 
Screening 
Unable to Stage 
Missing 
Total 
 
9.9 
9.9 
26.4 
40.7 
5.5 
7.7 
0 
100 
3.8
12.3
22.6
38.7
12.3
10.4
0
100
5.4
2.7
10.8
40.5
5.4
29.7
5.4
100
Cancer Diagnosis 
no cancer diagnosis 
not yet diagnosed 
Acute Lymphoblastic Leukemia, Adult 
Acute Myeloid Leukemia, Adult 
Bile Duct Cancer, Extrahepatic 
Bladder Cancer 
Brain Tumor, Adult 
Brain Tumor, Cerebral Astrocytoma/Malignant Glioma 
Brain Tumor, Childhood (Other) 
Breast Cancer 
 
4.4 
2.2 
1.1 
0 
0 
1.1 
1.1 
1.1 
0 
20.9 
7.5
9.4
0
1.9
0
0
2.8
0
.9
17.9
5.4
2.7
0
2.7
0
0
2.7
5.4
0
13.5
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Percent 
Characteristic 2006 
(n=91) 
2007 
(n=106) 
2008 
(n=37) 
Cervical Cancer 
Chronic Myelogenous Leukemia 
Colon Cancer 
Esophageal Cancer 
Head and Neck Cancer 
Hodgkin's Lymphoma, Adult 
Kaposi's Sarcoma 
Laryngeal Cancer 
Lung Cancer, Non-Small Cell 
Lung Cancer, Small Cell 
Lymphoma, Non-Hodgkin’s Adult 
Melanoma 
Mesothelioma, Adult 
Multiple Myeloma/Plasma Cell Neoplasm 
Myelodysplastic Syndromes 
Non-malignant Hematologic Disorder 
Osteosarcoma/Malignant Fibrous Histiocytoma 
Ovarian Epithelial Cancer 
Pancreatic Cancer 
Prostate Cancer 
Rectal Cancer 
Renal Cell (Kidney) 
Renal Pelvis and Ureter, Transitional Cell Cancer 
Sarcoma, Soft Tissue 
Stomach (Gastric) Cancer 
Thymoma and Thymic Carcinoma 
Unknown Primary Site 
Missing 
Total 
0 
0 
9.9 
2.2 
4.4 
2.2 
0 
1.1 
16.5 
2.2 
1.1 
1.1 
1.1 
3.3 
0 
0 
0 
1.1 
4.4 
8.8 
3.3 
2.2 
0 
1.1 
0 
0 
2.2 
0 
100 
.9
1.9
4.7
0
9.4
1.9
.9
0
11.3
1.9
2.8
1.9
0
2.8
.9
0
.9
0
5.7
4.7
.9
1.9
.9
1.9
.9
0
0
0
100
0
2.7
10.8
2.7
5.4
0
0
2.7
24.3
0
5.4
0
0
0
2.7
0
0
0
2.7
2.7
2.7
0
0
0
2.7
0
0
0
100
Cancer Care Site 
Beaver Med Oncology 
Hillman 
Jefferson Med Oncology 
Magee 
McKeesport 
Mercy 
Moon Med Oncology 
Murtha Radiology Oncology 
Natrona Med Oncology 
New Castle 
Passavant 
Shadyside Hospital or Radiology Oncology 
 
0 
84.6 
0 
2.2 
2.2 
0 
0 
0 
0 
0 
0 
2.2 
0
76.4
0
2.8
2.8
.9
0
0
.9
0
.9
.9
0
67.6
0
5.4
8.1
0
2.7
0
0
0
0
5.4
 186 
Percent 
Characteristic 2006 
(n=91) 
2007 
(n=106) 
2008 
(n=37) 
St. Margaret Med Oncology 
Missing 
Total 
0 
8.8 
100 
.9
12.3
100
0
10.8
100
Insurance 
Commercial Indemnity Insurance 
Commercial Managed Care (HMO/PPO/POS) 
Medicaid Managed Care (HMO/PPO/POS) 
Medicaid/Public Assistance 
Medicare 
Medicare Managed Care (HMO/PPO/POS) 
Military (DOD,CHAMPUS,VA) 
Other Public Coverage 
Self Pay or No Insurance 
Missing 
Total 
 
0 
25.3 
28.6 
1.1 
1.1 
27.5 
1.1 
0 
15.4 
0 
100 
.9
17.9
21.7
3.8
4.7
27.4
0
0
20.8
2.8
100
0
16.2
16.2
2.7
2.7
37.8
0
8.1
13.5
2.7
100
 
APPENDIX E 
KEY THEMES AND ISSUES IDENTIFIED THROUGH MOPP EVALUATION  
 
 
DR= document review, MO= meeting observations, PI= patient interviews, 
SI= staff interviews 
Social Structure, Policy & Systems 
? Exclusionary and rigid cancer clinical trial (CCT) criteria present challenges for CCT 
recruitment (MO, SI). 
? Early detection is a critical factor for improving CCT participation- we have to reach 
patients earlier & healthier (MO, SI).  
Community 
? A strong referral base, particularly in the community, is important for achieving 
MOPP goals and outcomes (SI). 
? Community partnerships are valuable assets for program promotion, recruitment & 
referrals, and for the reduction of patient-identified barriers to care (MO, SI). 
? It takes time to build strong community partnerships and to overcome challenges with 
data reporting and information exchange, such as those currently experienced within 
the African American Cancer Care Partnership (SI).   
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Institutional/Organizational 
? MOPP is a patient navigation system that includes case finding and referral protocols; barriers 
assessment; individualized solutions planning and services, which may include navigators; 
and CCT education and recruitment (DR, SI). 
? Sound data collection practices and systems are vital for program monitoring, quality 
program delivery, accurate reporting, and effective evaluation (MO, SI).   
? Program database development and improvement has required much more time than 
anticipated (MO, SI). 
? Strong interest (at program and UPMC-level) in the cost of the program (MO, SI). 
? The provision of program services has cost much less than anticipated.  Gap funds have been 
used minimally (DR, MO, SI).   
? Strong interest in expanding the program to include:  1) other minority and other populations 
disproportionately affected by the cancer burden, such as elderly patients, and 2) discretionary 
use of gap funds for diagnostic services (MO, SI).    
Interpersonal 
? The Patient-Navigator relationship, while valued highly among staff and participants poses 
an emotional dilemma and burden for navigators over time as many navigated participants die 
or experience a significant decline in health from cancer (PI, SI).    
? Developing and nurturing strong patient-navigator relationships require time, trust, and 
compassion (PI, SI). 
? Given the late stage diagnosis of many MOPP patients and program focus on CCT 
enrollment, it may be necessary to add a staff member with clinical training to the program 
team to expand the level of support offered to patients (MO, SI).   
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Individual 
? Although all are African- American, there is great diversity among MOPP participants with 
regard to backgrounds, degrees of support, and health concerns, and service needs and 
utilization (MO, SI).   
? Substance abuse and addiction among participants is a concern as these conditions can hinder 
compliance with treatment, as well as treatment options and success, and often require 
significant program resources to address (MO, SI).   
? Large number of comorbidities and late stage presentation of cancer among participants 
represent cancer care shortcomings and major CCT recruitment challenges (MO, SI).   
 
 190 
BIBLIOGRAPHY 
Academy for Educational Development, Center on AIDS and Community Health. (2006).  
Diffusion of Effective Behavioral Interventions Project Factsheet.  Retrieved March 16, 
2007, from http://www.effectiveinterventions.org/files/DEBI.pdf 
 
Aiello Bowles, E. J., Tuzzio, L., Wiese, C. J., Kirlin, B., Greene, S. M., Clauser, S. B., et al. 
(2008). Understanding high-quality cancer care: a summary of expert perspectives. 
Cancer, 112(4), 934-942. 
 
American Cancer Society.  Cancer Facts & Figures for African Americans 2005-2006.  Atlanta:  
American Cancer Society, 2005. 
 
American Cancer Society. Cancer Facts and Figures 2007. Atlanta: American Cancer Society; 
2007. 
 
American Cancer Society.  Cancer Facts and Figures for African Americans 2007-2008.  
Atlanta:  American Cancer Society, 2008. 
 
Anderson, A., & Turner, A. (2007). Patient navigation:  Existing programs, current practices, 
and guidelines for success. Seattle: The Cross Cultural Health Care Program. 
 
Baquet, C. R., Commiskey, P., Daniel Mullins, C., & Mishra, S. I. (2006). Recruitment and 
participation in clinical trials: socio-demographic, rural/urban, and health care access 
predictors. Cancer Detect Prev, 30(1), 24-33. 
 
Battaglia, T. A., Roloff, K., Posner, M. A., & Freund, K. M. (2007). Improving follow-up to 
abnormal breast cancer screening in an urban population. A patient navigation 
intervention. Cancer, 109(2 Suppl), 359-367. 
 
BC Cancer Agency. (2005). Patient navigation in cancer care. Vancouver: Sociobehavioural 
Research Center. 
 
Besculides, M., Zaveri, H., Farris, R., & Will, J. (2006). Identifying best practices for 
WISEWOMAN programs using a mixed-methods evaluation. Prev Chronic Dis, 3(1), 
A07. 
 
 191 
Bolen, S., Tilburt, J., Baffi, C., Gary, T. L., Powe, N., Howerton, M., et al. (2006). Defining 
"success" in recruitment of underrepresented populations to cancer clinical trials: moving 
toward a more consistent approach. Cancer, 106(6), 1197-1204. 
 
Brawley, O. W. (2004). The study of accrual to clinical trials: can we learn from studying who 
enters our studies? J Clin Oncol, 22(11), 2039-2040. 
 
Briss, P. A. (2005). Evidence-based: US road and public-health side of the street. Lancet, 
365(9462), 828-830. 
 
Bruner, D. W., Jones, M., Buchanan, D., & Russo, J. (2006). Reducing cancer disparities for 
minorities: a multidisciplinary research agenda to improve patient access to health 
systems, clinical trials, and effective cancer therapy. J Clin Oncol, 24(14), 2209-2215. 
 
Bull, S. S., Gillette, C., Glasgow, R. E., & Estabrooks, P. (2003). Work site health promotion 
research: to what extent can we generalize the results and what is needed to translate 
research to practice? Health Educ Behav, 30(5), 537-549. 
 
Butterfoss, F. D. (2006). Process evaluation for community participation. Annu Rev Public 
Health, 27, 323-340. 
 
Caburnay, C. A., Kreuter, M. W., & Donlin, M. J. (2001). Disseminating effective health 
promotion programs from prevention research to community organizations. J Public 
Health Manag Pract, 7(2), 81-89. 
 
C-Change. (n.d.). Cancer patient navigation:  Published information.   Retrieved May 5. 2008, 
from hyyp://www.c-change.org 
 
C-Change. (n.d.).  Clinical Trials.  Retrieved March 1, 2007 from http://www.c-
changetogether.org/clinical_trials/default.asp 
 
Christian, M. C., & Trimble, E. L. (2003). Increasing participation of physicians and patients 
from underrepresented racial and ethnic groups in National Cancer Institute-sponsored 
clinical trials. Cancer Epidemiol Biomarkers Prev, 12(3), 277s-283s. 
 
Comis, R. L., Miller, J. D., Aldige, C. R., Krebs, L., & Stoval, E. (2003). Public attitudes toward 
participation in cancer clinical trials. J Clin Oncol, 21(5), 830-835. 
 
Corporate Research Associates. (2004). Cancer patient navigation evaluation: final report. Nova 
Scotia: CRA. 
 
Dohan, D., & Schrag, D. (2005). Using navigators to improve care of underserved patients: 
current practices and approaches. Cancer, 104(4), 848-855. 
 
 192 
Dusenbury, L., Brannigan, R., Hansen, W. B., Walsh, J., & Falco, M. (2005). Quality of 
implementation: developing measures crucial to understanding the diffusion of 
preventive interventions. Health Educ Res, 20(3), 308-313. 
 
Dzewaltowski, D. A., Estabrooks, P. A., & Glasgow, R. E. (2004). The future of physical 
activity behavior change research: what is needed to improve translation of research into 
health promotion practice? Exerc Sport Sci Rev, 32(2), 57-63. 
 
Dzewaltowski, D. A., Glasgow, R. E., Klesges, L. M., Estabrooks, P. A., & Brock, E. (2004). 
RE-AIM: evidence-based standards and a Web resource to improve translation of 
research into practice. Ann Behav Med, 28(2), 75-80. 
 
Eliminating Disparities in Clinical Trials Project (EDICT). (2008). Major Deficiencies in the 
Design and Funding of Clinical Trials: A Report to the Nation Improving on How Human 
Studies Are Conducted.   Retrieved June 6, 2008, from 
http://www.bcm.edu/edict/home.html 
 
Elliott, D. S., & Mihalic, S. (2004). Issues in disseminating and replicating effective prevention 
programs. Prev Sci, 5(1), 47-53. 
 
Flay, B. R. (1986). Efficacy and effectiveness trials (and other phases of research) in the 
development of health promotion programs. Prev Med, 15(5), 451-474. 
 
Fleisher, L. (2008). One size does not fit all.   Retrieved June 3, 2008, from 
http://patientnavigation.com 
 
Fixsen, D. L., Naoom, S. F., Blase, K. A., Friedman, R. M. & Wallace, F. (2005).  
Implementation Research: A Synthesis of the Literature. Tampa, FL: University of South 
Florida, Louis de la Parte Florida Mental Health Institute, The National Implementation 
Research Network (FMHI Publication #231). 
 
Forsetlund, L., Talseth, K. O., Bradley, P., Nordheim, L., & Bjorndal, A. (2003). Many a slip 
between cup and lip. Process evaluation of a program to promote and support evidence-
based public health practice. Eval Rev, 27(2), 179-209. 
 
Fowler, T., Steakley, C., Garcia, A. R., Kwok, J., & Bennett, L. M. (2006). Reducing disparities 
in the burden of cancer: the role of patient navigators. PLoS Med, 3(7), e193. 
 
Ford JG, Howerton MW, Bolen S, Gary TL, Lai GY, Tilburt J, Gibbons MC, Baffi C, Wilson  
Feuerstein RF, CJ, Tanpitukpongse P, Powe NR, Bass EB. Knowledge and Access to 
 Information on Recruitment of Underrepresented Populations to Cancer Clinical Trials. 
 Evidence Report/Technology Assessment No. 122 (Prepared by the Johns Hopkins  
 University Evidencebased Practice Center under Contract No. 290-02-0018.) AHRQ  
 Publication No. 05-E019-2. Rockville, MD. Agency for Healthcare Research and  
 Quality. June 2005. 
 
 193 
Freeman, H. P. (2004). A model patient navigation program. Oncology 
Issues(September/October), 44-46. 
 
Freeman, H. P. (2006). Patient navigation: a community based strategy to reduce cancer 
disparities. J Urban Health, 83(2), 139-141. 
 
Freeman, H.P. (2007). Expert commentary from Dr. Harold Freeman.   Retrieved January 3, 
2008, from http://www.patientnavigation.com 
 
Freeman, H. P., Muth, B. J., & Kerner, J. F. (1995). Expanding access to cancer screening and 
clinical follow-up among the medically underserved. Cancer Pract, 3(1), 19-30. 
 
Garcia, R. (2005). Cancer Patient Navigator Program. Paper presented at The 12th Maryland 
State Council on Cancer Control Conference. 
 
Glasgow, R. E. (2002). Evaluation of theory-based interventions:  The RE-AIM model. In K. 
Glanz, F. M. Lewis & B. K. Rimer (Eds.), Health Behavior and Health Education (3rd 
ed., pp. 531-544). San Francisco: Jossey-Bass. 
 
Glasgow, R. E. (2003). Translating research to practice: lessons learned, areas for improvement, 
and future directions. Diabetes Care, 26(8), 2451-2456. 
 
Glasgow, R. E., Davidson, K. W., Dobkin, P. L., Ockene, J., & Spring, B. (2006). Practical 
behavioral trials to advance evidence-based behavioral medicine. Ann Behav Med, 31(1), 
5-13. 
 
Glasgow, R. E., & Emmons, K. M. (2007). How can we increase translation of research into 
practice? Types of evidence needed. Annu Rev Public Health, 28, 413-433. 
 
Glasgow, R. E., Klesges, L. M., Dzewaltowski, D. A., Bull, S. S., & Estabrooks, P. (2004). The 
future of health behavior change research: What is needed to improve translation of 
research into health promotion practice? Ann Behav Med, 27(1), 3-12. 
 
Glasgow, R. E., Klesges, L. M., Dzewaltowski, D. A., Estabrooks, P. A., Vogt, T. M.. (2006).  
Evaluating the impact of health promotion programs:  using the RE-AIM framework to 
form summary measures for decision making involving complex issues. Health 
Education Research, 21, 688-694.  
 
Glasgow, R. E., Lichtenstein, E., & Marcus, A. C. (2003). Why don't we see more translation of 
health promotion research to practice? Rethinking the efficacy-to-effectiveness transition. 
Am J Public Health, 93(8), 1261-1267. 
 
Glasgow, R. E., Vogt, T. M., & Boles, S. M. (1999). Evaluating the public health impact of 
health promotion interventions: the RE-AIM framework. Am J Public Health, 89(9), 
1322-1327. 
 
 194 
Goodman, R. M. (2001). Community-based participatory research: questions and challenges to 
an essential approach. J Public Health Manag Pract, 7(5), v-vi. 
 
Goodman, R. M. (2001). Evaluation of community-based health programs: An alternate 
perspective. In N. Schneiderman, M. A. Speers, J. M. Silva, H. Tomes & J. H. Gentry 
(Eds.), Integrating behavioral and social sciences with public health. Washington D.C.: 
American Psychological Association. 
 
Goodman, R. M., Speers, M. A., McLeroy, K., Fawcett, S., Kegler, M., Parker, E., et al. (1998). 
Identifying and defining the dimensions of community capacity to provide a basis for 
measurement. Health Educ Behav, 25(3), 258-278. 
 
 
Green, L. W. (2001). From research to "best practices" in other settings and populations. Am J 
Health Behav, 25(3), 165-178. 
 
Green, L. W., & Glasgow, R. E. (2006). Evaluating the relevance, generalization, and 
applicability of research: issues in external validation and translation methodology. Eval 
Health Prof, 29(1), 126-153. 
 
Greene, A., Young, P., Taylor, E., Chu, K., & Garcia, R. (2007). Patient navigation research 
program evaluation design and implementation. Paper presented at the American Public 
Health Association Annual Meeting, Washington, D.C. 
 
Greenwald, P., & Cullen, J. W. (1985). The new emphasis in cancer control. J Natl Cancer Inst, 
74(3), 543-551. 
 
Guba, E. G., & Lincoln, Y. S. (2005). Paradigmatic controversies, contradiction, and emerging 
confluences. In N. K. Denzin & Y. S. Lincoln (Eds.), The handbook of qualitative 
research (3rd ed.). Thousand Oaks: Sage Publications. 
 
Harshbarger, C., Simmons, G., Coelho, H., Sloop, K., & Collins, C. (2006). An empirical 
assessment of implementation, adaptation, and tailoring: the evaluation of CDC's 
National Diffusion of VOICES/VOCES. AIDS Educ Prev, 18(4 Suppl A), 184-197. 
 
Heaney, C.A., & Israel, B.A. (2002). Social Networks and Social Support.  In K. Glanz, B. K. 
Rimer & F. M. Lewis (Eds.), Health behavior and health education theory, research, and 
practice (3rd ed.). San Francisco: Jossey-Bass. 
 
Hede, K. (2006). Agencies look to patient navigators to reduce cancer care disparities. J Natl 
Cancer Inst, 98(3), 157-159. 
 
Hiatt, R. A., & Rimer, B. K. (1999). A new strategy for cancer control research. Cancer 
Epidemiol Biomarkers Prev, 8(11), 957-964. 
 
 195 
Institute for Alternative Futures. Patient Navigator Program Overview. Alexandria, VA:  
Institute for Alternative Futures, 2007. 
 
Israel, B. A., Schulz, A. J., Parker, E. A., & Becker, A. B. (1998). Review of community-based 
research: assessing partnership approaches to improve public health. Annu Rev Public 
Health, 19, 173-202. 
 
Jack, L., Jr., Liburd, L., Spencer, T., & Airhihenbuwa, C. O. (2004). Understanding the 
environmental issues in diabetes self-management education research: a reexamination of 
8 studies in community-based settings. Ann Intern Med, 140(11), 964-971. 
 
 
Kee, J.E.. (2004). Cost-Effectiveness and Cost-Benefit Analysis. In J. S. Wholey, H. P. Hatry & 
K. E. Newcomer (Eds.), Handbook of Practical Program Evaluation (2 ed.). San 
Francisco: Josey-Bass. 
 
Kelly, J. A., Heckman, T. G., Stevenson, L. Y., Williams, P. N., Ertl, T., Hays, R. B., et al. 
(2000). Transfer of research-based HIV prevention interventions to community service 
providers: fidelity and adaptation. AIDS Educ Prev, 12(5 Suppl), 87-98. 
 
Kemm, J. (2006). The limitations of 'evidence-based' public health. J Eval Clin Pract, 12(3), 
319-324. 
 
Klamen DL & Miller NS.  (1997). Integration in education for addiction medicine. J  
Psychoactive Drugs, 29.  263-268.  
 
Klesges, L. M., Estabrooks, P. A., Dzewaltowski, D. A., Bull, S. S., & Glasgow, R. E. (2005). 
Beginning with the application in mind: designing and planning health behavior change 
interventions to enhance dissemination. Ann Behav Med, 29 Suppl, 66-75. 
 
Kluhsman, B. C., Bencivenga, M., Ward, A. J., Lehman, E., & Lengerich, E. J. (2006). 
Initiatives of 11 rural Appalachian cancer coalitions in Pennsylvania and New York. Prev 
Chronic Dis, 3(4), A122. 
 
Love, A. (2004). Implementation Evaluation. In J. S. Wholey, H. P. Hatry & K. E. Newcomer 
(Eds.), Handbook of Practical Program Evaluation (2 ed.). San Francisco: Josey-Bass. 
 
Merriam Webster.  (n.d.).  Merriam Webster Online Dictionary.  Retrieved April 3, 2007 from 
http://www.m-w.com/dictionary/translating 
 
McGuire, W. L. (2005). Beyond EBM:  New directions for evidence-based public health. 
Perspectives in Biology and Medicine, 48(4), 557-569. 
 
McQueen, D. V. (2001). Strengthening the evidence base for health promotion. Health 
Promotion International, 16(3), 261-268. 
 196 
 
McQueen, D. V. (2002). The evidence debate. J Epidemiol Community Health, 56(2), 83-84. 
 
Michaels, M.  (n.d.).  Current Practices in Clinical Research:  A State of Social Injustice.  
Retrieved April 3, 2007 from http://www.enacct.org 
 
Monette, D. R., Sullivan, T. J., & DeJong, C. R. (1997). Applied Social Research:  Tool for the 
Human Services (4 ed.). Orlando: Harcourt. 
 
Mowbray, C. T., Holter, M. C., Teague, G. B., & Bybee, D. (2003). Fidelity criteria: 
Development, measurement, and validation American Journal of Evaluation, 24(3), 315-
340  
 
Murray, D. M. (2001). Efficacy and effectiveness trials in health promotion and disease 
prevention:  Design and analysis of group-randomized trials. In N. Schneiderman, M. A. 
Speers, J. M. Silva, H. Tomes & J. H. Gentry (Eds.), Integrating behavioral and social 
sciences with public health. Washington D.C.: American Psychological Association. 
 
Neuman, L. W. (2002). Social research methods:  Qualitative and quantitative approaches. (5th 
ed.). Boston: Allyn and Bacon. 
 
Oldenburg, B., & Parcel, G. S. (2002). Diffusion of Innovations. In K. Glanz, B. K. Rimer & F. 
M. Lewis (Eds.), Health behavior and health education theory, research, and practice 
(3rd ed.). San Francisco: Jossey-Bass. 
 
Owen, N., Glanz, K., Sallis, J. F., & Kelder, S. H. (2006). Evidence-based approaches to 
dissemination and diffusion of physical activity interventions. Am J Prev Med, 31(4 
Suppl), S35-44. 
 
Paulson, R. I., Post, R. L., Herinckx, H. A., & Risser, P. (2002). Beyond components: using 
fidelity scales to measure and assure choice in program implementation and quality 
assurance. Community Ment Health J, 38(2), 119-128. 
 
Patton, M. Q. (1997). Utilization-focused Evaluation (3 ed.). Thousand Oaks: Sage. 
 
Patton, M. Q. (2002). Qualitative Research & Evaluation Methods (3 ed.). Thousand Oaks: Sage. 
 
Pennsylvania Department of Health, Bureau of Health Statistics and Research. (November 
2006).  Cancer Facts and Figures for African Americans, Pennsylvania, 2002.   
Retrieved August 13, 2007, from 
http://www.dsf.health.state.pa.us/health/lib/health/cff_aa/2006/cff_aa_2006.pdf 
 
Petticrew, M., & Roberts, H. (2003). Evidence, hierarchies, and typologies:  Horses for courses. 
Journal of Epidemiology in Community Health, 57, 527-529. 
 
 197 
Potter, M., & Quill, B. (2006). Demonstrating excellence in practice-based research for public 
health: Association of Schools of Public Health, Academic Public Health Practice 
Committee. 
 
Raphael, D. (2000). The question of evidence in health promotion. Health Promotion 
International, 15(4), 355-367. 
 
Reuben, S. H. (2005). Translating research into cancer care:  Delivering on the promise: The 
President's Cancer Panel. 
 
Rohrbach, L. A., Grana, R., Sussman, S., & Valente, T. W. (2006). Type II translation: 
transporting prevention interventions from research to real-world settings. Eval Health 
Prof, 29(3), 302-333. 
 
Rust, G. & Cooper, L.A. (2007). How can practice-based research contribute to the elimination 
of health disparities? J Am Board Fam Med, 20, 105-114. 
 
Rychetnik, L., Frommer, M., Hawe, P., & Shiell, A. (2002). Criteria for evaluating evidence on 
public health. Journal of Epidemiology in Community Health, 56, 119-127. 
 
Sateren, W. B., Trimble, E. L., Abrams, J., Brawley, O., Breen, N., Ford, L., et al. (2002). How 
sociodemographics, presence of oncology specialists, and hospital cancer programs affect 
accrual to cancer treatment trials. J Clin Oncol, 20(8), 2109-2117. 
 
Saunders, R. P., Evans, M. H., & Joshi, P. (2005). Developing a process-evaluation plan for 
assessing health promotion program implementation: a how-to guide. Health Promot 
Pract, 6(2), 134-147. 
 
Schechter, C., & Brunner, S. M. (2005). Bridging the gap between public health research and 
practice:  Lessons from the field: Academy for Educational Development, Center for 
Health Communication. 
Schwaderer, K. A., & Itano, J. K. (2007). Bridging the healthcare divide with patient navigation: 
development of a research program to address disparities. Clin J Oncol Nurs, 11(5), 633-
639. 
 
Scutchfield, F. D., & Keck, C. W. (Eds.). (2003). Principles of Public Health Practice: Thomson 
Delmar Learning. 
 
Sheppard, V. B., Cox, L. S., Kanamori, M. J., Canar, J., Rodriguez, Y., Goodman, M., et al. 
(2005). Brief report: if you build it, they will come: methods for recruiting Latinos into 
cancer research. J Gen Intern Med, 20(5), 444-447. 
 
Shortell, S. M., & Richardson, W. C. (1978). Health Program Evaluation. St. Louis: C.V. Mosby 
Company. 
 
 198 
Stake, R. E. (2005). Qualitative case studies. In N. K. Denzin & Y. S. Lincoln (Eds.), The sage 
handbook of qualitative research (3rd ed.). Thousand Oaks: Sage Publications. 
 
Steinberg, M. L., Fremont, A., Khan, D. C., Huang, D., Knapp, H., Karaman, D., et al. (2006). 
Lay patient navigator program implementation for equal access to cancer care and 
clinical trials: essential steps and initial challenges. Cancer, 107(11), 2669-2677. 
 
Sussman, S., Valente, T. W., Rohrbach, L. A., Skara, S., & Pentz, M. A. (2006). Translation in 
the health professions: Converting science into action. Eval Health Prof, 29(1), 7-32. 
 
The Task Force on Community Preventive Services, The Guide to Community Preventive 
Services. (March 2007).  Overview.  Retrieved August 13, 2007, from 
http://www.thecommunityguide.org/about/default.htm 
 
Trauth, J.M., Jernigan, J.C., Siminoff, L.A., Musa, D., Neal-Ferguson, D., & Weissfeld, J. 
(2005).  Factors affecting older African American women’s decisions to join the PLCO 
cancer screening trial.  Journal of Clinical Oncology, 23(34), 8730-8738. 
 
United States Department of Health and Human Services, American Cancer Society, and 
Commission on Cancer. (n.d.).  Cancer Control P.L.A.N.E.T. Factsheet.  Retrieved 
March 16, 2007, from http://cancercontrolplanet.cancer.gov/factsheet.pdf 
 
United States Department of Health and Human Services, Centers for Disease Control and 
Prevention.  Framework for Program Evaluation in Public Health. MMWR 1999;48(No. 
RR-11) 
 
United States Department of Health and Human Services, Centers for Disease Control and  
Prevention.  (October 2003). Prostate cancer screening:  A decision guide for African 
Americans.  Retrieved June 15, 2008, from 
http://www.cdc.gov/cancer/prostate/prospdf/aaprosguide.pdf 
 
United States Department of Health and Human Services. Centers for Disease Control and  
Prevention.  Office of the Director, Office of Strategy and Innovation. Introduction to 
program evaluation for public health programs: A self-study guide. Atlanta, GA: Centers 
for Disease Control and Prevention, 2005.  
 
United States Department of Health and Human Services, Centers for Disease Control and 
Prevention Office of Public Health Research. (2006/2007). 2006/2007 Cancer 
Survivorship Fact sheet.  Retrieved August 13, 2007, from 
http://www.cdc.gov/cancer/survivorship/pdf/0607_survivorship_fs.pdf 
 
United States Department of Health and Human Services, Centers for Disease Control and 
Prevention Office of Public Health Research. (2007). Improving public health practice 
through translation research (R18).   Retrieved February 27, 2007, from 
http://www.grants.gov 
 
 199 
United States Department of Health and Human Services, National Center for Health Statistics 
(February 2007).  Cancer FASTATS.  Retrieved April 3, 2007, from 
http://www.cdc.gov/nchs/fastats/cancer.htm 
United States Department of Health and Human Services, National Institutes of Health. (August 
2006).  NIH Roadmap for medical research fact sheet.  Retrieved March 16, 2007, from 
http://opasi.nih.gov/documents/NIHRoadmap_FactSheet_Aug06.pdf 
 
 
United States Department of Health and Human Services, National Institutes of Health, National 
Cancer Institute.  (n.d.).  What are Patient Navigators and Research Questions.  Retrieved 
August 13, 2007, from http://crchd.cancer.gov/pnp/pnrp-questions.html 
 
United States Department of Health and Human Services, National Institutes of Health, National 
Cancer Institute.  (August 2004).  Patient navigator research program (U01).  Retrieved 
August 10, 2007, from http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-05-019.html 
 
United States Department of Health and Human Services, National Institutes of Health, National 
Cancer Institute.  (November 2005).  Cancer Health Disparities [factsheet].  Retrieved 
March 4, 2008, from http://www.cancer.gov/newscenter/benchmarks-vol5-issue6/page2 
 
United States Department of Health and Human Services, National Institutes of Health, National 
Cancer Institute.  (March 2006).  The Patient Navigator Research Program [brochure].   
Retrieved August 13, 2007, from http://crchd.cancer.gov/attachments/pnrp_brochure.pdf 
 
United States Department of Health and Human Services, Substance Abuse and Mental Health 
Services Administration. (2007). About NREPP.  Retrieved March 16, 2007, from 
http://nrepp.samhsa.gov/about.htm 
 
United States Department of Health and Human Services, The Office of Minority Health. (2005).  
Cancer 101.  Retrieved August 10, 2007, from 
http://www.omhrc.gov/templates/content.aspx?ID=2829 
 
Vargas, R. B., Ryan, G. W., Jackson, C. A., Rodriguez, R., & Freeman, H. P. (2008). 
Characteristics of the original patient navigation programs to reduce disparities in the 
diagnosis and treatment of breast cancer. Cancer. 
 
Weiss, K. B., & Wagner, R. (2000). Performance measurement through audit, feedback, and 
profiling as tools for improving clinical care. Chest, 118(2 Suppl), 53S-58S. 
 
Westfall, J. M., Mold, J., & Fagnan, L. (2007). Practice-based research--"Blue Highways" on the 
NIH roadmap. Jama, 297(4), 403-406. 
 
Workgroup to Evaluate and Enhance the Reach and Dissemination of Health Promotion 
Interventions. (July 2004).  Frequently asked questions about RE-AIM:  The basics and 
Definitions of the Elements.  Retrieved August 13, 2007, from http://re-
aim.org/2003/FAQs_basic.html  
